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Abstract
Common therapy for diabetes mellitus is subcutaneous administration of insulin that
is subject to serious disadvantages, such as patient noncompliance and occasional hy-
poglycemia. Hence, oral administration of insulin could be more convenient and
serve as a desired route. However, oral administration of insulin is severely limited
by the low bioavailability of insulin through the gastrointestinal tract. In this study,
a semi-interpenetrating network gelatin fiber scaffold (sIPN GF) was fabricated for
oral mucosal delivery of insulin as an alternative route. This sIPN GF was engi-
neered from an electrospun gelatin fiber scaffold (GF), which was further crosslinked
with polyethylene glycol diacrylate (PEG-DA) to enhance its stability. Within the
crosslinking process, eosin Y served as a photoinitiator, and the ratio of PEG-DA to
eosin Y was optimized with respect to cytocompatibility and degradation rate. The
results showed that the fabricated scaffold morphology, mechanical properties, and
degradation rate were significantly enhanced after the crosslinking process. This op-
timized formulation was used to fabricate sIPN gelatin-co-insulin fiber scaffold (sIPN
GIF). Enzyme-linked immunosorbent assay (ELISA) was used to monitor the insulin
releasing kinetics of sIPN GIF. Western blot analysis showed that sIPN GIF acti-
vated intracellular AKT phosphorylation in a releasing time-dependant manner. Oil
red O staining confirmed the released insulin was able to induce 3T3-L1 preadipocyte
differentiation. The permeability of insulin from sIPN GIF was determined on the
xiii
order of 10−7 cm/s using a vertical Franz diffusion cell system mounted with porcine
buccal mucosa. These findings suggest that sIPN GIF holds a great potential for oral
mucosal delivery of insulin.
xiv
Chapter 1
Introduction
1.1 Background
Diabetes mellitus, or simply diabetes, is defined as a group of metabolic diseases
characterized by hyperglycemia that results from lack of insulin production or insulin
response [28]. Diabetes is a major cause of heart disease and stroke, and it can also
lead to vision loss, kidney failure, and amputations of legs and feet. It is reported
as the seventh leading cause of death in the U.S. according to the National Diabetes
Fact Sheet 2011 and Diabetes Report Card 2012 from the Centers for Disease Control
and Prevention (CDC) (http://www.cdc.gov/diabetes/pubs/reportcard.htm). The
reports show that about 8.3% of the U.S. population, including children and adults,
has diabetes. The prevalence of diabetes is projected that one of three U.S. adults
could have diabetes by 2050 if the current trend continues.
Generally, there are three common types of diabetes, referred to as type 1
diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM) and gestational diabetes.
T1DM accounts for about 5% of all diagnosed cases of diabetes in the U.S., and it
is commonly diagnosed in children and young adults. T1DM is characterized by the
destruction of the pancreatic beta cells and insulin deficiency. The risk factors of
T1DM can be autoimmune, genetic or environmental. To date, there is no therapy
available to prevent T1DM. T1DM patients require daily insulin administration from
an injection or a pump in order to survive. T2DM accounts for about 95% of all
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diagnosed cases of diabetes in the U.S. T2DM is characterized by insulin resistance
and impaired insulin secretion by the beta cells in the pancreas. As T2DM progresses,
patients require more insulin, which leads to the pancreas eventually to lose its ability
to produce insulin. Current reports indicate that healthy diet, regular exercise and
prescribed medication can help to prevent, control health complications, and delay
the onset of T2DM. Last, gestational diabetes is diagnosed as a result of pregnancy
in 2-10% of pregnant women. Gestation diabetes can cause health problems for both
mother and child. Women who have gestational diabetes may have a higher risk of
developing T2DM in the future; while their children may have an increased risk of
developing T2DM and obesity [28].
Insulin is a peptide hormone that is the key to regulate carbohydrate and fat
metabolism in the body. Proinsulin is a prohormone and the precursor of insulin
that is produced by beta cells of the islets of Langerhans. Proinsulin is synthesized
and folded in the endoplasmic reticulum (ER) where its disulfide bonds are oxidized.
After it is transported to the Golgi apparatus and packaged into secretory vesicles, it
undergoes a series of digestion by proteases to form mature insulin. As an illustration
shown in Figure 1.1, mature insulin (insulin) has 35 fewer amino acids, in which 4
amino acids are cleaved altogether and the remaining 31 amino acids form the C-
peptide. After abstraction of C-peptide from the center of the proinsulin, insulin
becomes a dimer of an A-chain (30 amino acids) and a B-chain (21 amino acids)
connected by disulfide bonds.
Under physiological circumstances, when blood glucose concentration is below
90 mg/dl, it does not cause any insulin release. When carbohydrates are consumed,
carbohydrates are digested and broken down to glucose molecules in the gut. These
glucose molecules are subsequently absorbed into the bloodstream and elevate blood
glucose concentration. The pancreas senses the rise of blood glucose concentration
and in turn stimulates the secretion of insulin from the beta cells. Insulin is required
for most cells to be able to uptake of glucose from the blood stream. The excess
glucose can be stored in the liver in the form of glycogen for future use. The liver is
2
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Figure 1.1: Structures of proinsulin and insulin [74].
able to convert glucose from fatty acids and amino acids to fat and protein respectively
via gluconeogenesis. As a result, the increased secretion of insulin from the pancreas
lowers blood glucose level, which in turn decreases insulin secretion.
Under pathophysiological circumstances, the insulin production and secretion
are altered, which results the blood glucose uptake also changes. The limitation of
the insulin production causes the decrease of glucose uptake by the cells, resulting
in hyperglycemia. Because the pancreas cannot produce insulin in T1DM patients,
glucose cannot enter cells, and it remains in the bloodstream. Subsequently, the fat
is broken down to glycerol and free fatty acids via lipolysis in order to provide energy.
Glycerol is converted to glucose as the energy source; while fatty acids are converted
to ketone bodies. The elevated ketone bodies in body fluids cause a decrease of
pH and loss of electrolytes, resulting diabetic ketoacidosis. The untreated diabetic
ketoacidosis will cause coma or death. In T2DM, it is characterized by three disorders
as peripheral insulin resistance, especially in muscle cells, increased glucose production
from the liver, and eventually impaired insulin secretion pancreas.
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The insulin signaling pathway plays an important role in homeostasis at the
cellular level. This signaling pathway is regulated by feeding/fasting states, stress
levels, and a variety of other hormones. Insulin does not directly enter the cell in its
original form, but follows a sequential process as shown in Figure 1.2.
In detail, (1) Insulin binds to the extracellular portion of the α subunits of
the insulin receptor. (2) It causes a conformational change in the insulin receptor
that activates the kinase domain in the intracellular portion of the β subunits. (3)
The activated kinase domain in turn autophosphorylates tyrosine residues on the
C-terminus of the receptor and tyrosine residues in the insulin receptor substrate-1
(IRS-1) protein. (4) The phosphorylated IRS-1 binds and activates phosphoinositol
3 kinase (PI3K). (5) The activated PI3K catalyzes the reaction of PIP2 + ATP →
PIP3 + ADP. (6) PIP3 phosphorylates and activates protein kinase B, also as known
as AKT. (7) The phosphorylated AKT (p-AKT) further phosphorylates and inacti-
vates glycogen synthase kinase (GSK). (8) The phosphorylated GSK in turn cannot
phosphorylate glycogen synthase (GS). (9) The unphosphorylated GS becomes active
form and produce glycogen. (10) The p-AKT can also facilitate glucose transporter
type 4 into the plasma membrane.
Insulin serves as a common protein therapy to diabetes mellitus, and it is
conventionally administered to patients via subcutaneous injection. Two common
subcutaneous injection methods are recommended in order to mimic physiological
release of insulin. One is multiple daily injections via a syringe or a pen; the other
one is an external continuous subcutaneous insulin infusion via a pump [28, 17].
However, these subcutaneous injection methods have serious disadvantages, includ-
ing patient noncompliance and occasional hypoglycemia. Thus, oral administration
of insulin becomes a more convenient and desired route if available [17, 71]. Nonethe-
less, oral administration of insulin is severely limited by the low bioavailability of
insulin, including inherent instability and low permeability across biological mem-
branes through the gastrointestinal tract [71]. A variety of formulations for oral
insulin delivery have been developed in the last decade. Nanoparticle-based insulin
4
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[78].
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delivery systems were reported to be able to overcome these barriers, and these sys-
tems have been received considerable attention. The nanoparticles can be made from
natural or synthetic polymers. Natural polymers are shown great interest due to
their high biocompatibility and biodegradability. Chitosan and its derivatives, as one
family of these natural polymers, have been widely explored for oral insulin deliv-
ery owing to their excellent mucoadhesive properties and permeability [54, 76, 39].
Synthetic polymers are attracting growing attention due to the high possibility of
new dosage formulations and the potential applications in cell-specific drug targeting
[3]. Poly(lactide-co-glycolide) (PLGA) [19, 20], poly(lactide) (PLA) [86], and poly(ε-
caprolactone) (PCL) [21] have been used to fabricate nanoparticles for oral insulin
delivery owing to their well-established safety records. As the summary shown in Ta-
ble 1.1, the maximum bioavailability of insulin through oral administration is around
30% among these nanoparticle-based delivery systems. At this point, maximization
of the absorptive cellular intestinal uptake and stabilization of insulin within the
gastrointestinal tract remains as a challenge for nanoparticle oral delivery of insulin.
Efficacy and economic reasons will impact a market launch for these nanoparticles as
well.
1.2 Hypothesis and research goals
A gelatin-based electrospun fiber scaffold was developed to locally deliver nystatin for
candidiasis [2]. Electrospun gelatin fiber scaffolds (GFs) possess high biocompatibility
and mucoadhesive property that allow local sustained release of drug at the absorption
site [2, 7]. GF can be stabilized using a crosslinker of photocurable polyethylene glycol
diacrylate (PEG-DA) and form a semi-interpenetrating network fiber scaffold (sIPN).
The fiber morphology, mechanical and physical properties as well as drug release
kinetics can be controlled by modulating the concentration of crosslinker [2]. In this
work, a semi-interpenetrating network gelatin-co-insulin fiber scaffold (sIPN GIF)
was hypothesized for transbuccal mucosal delivery of insulin. The cytocompatibility
6
Table 1.1: Summary of in vivo bioavailability of insulin-loaded nanoparti-
cles on oral administration [17, 12].
NP systems BA References
Chitosan NPs 14.9% [57]
Chitosan-polyglutamic acid NPs 15.1% [51]
Dextran sulfate-chitosan NPs 5.6% [62]
VB12-dextran sulfate-chitosan NPs 26.5% [14]
Alginate crosslinked dextran 13.0% [83]
Aminoalkyl Vitamin B12 dextran sulfate chitosan 29.4% [15]
Chitosan-TBA 1.7% [38]
PLGA-Hp55 NPs 6.3% [19]
Insulin-phospholipid complex loaded NPs 7.7% [20]
Aspart-insulin loaded CS/γ-PGA NPs 15.0% [69]
Abbreviations: PLGA, poly(lactide-co-glycolide); Hp55, hypromellose phtha-
late, HPMCP-55; VB12, vitamin B12; SLNs, solid lipid nanoparticles; γ-PGA,
poly(g-glutamic acid); TBA, thiobutylamidine; NPs, nanoparticles; BA, rel-
ative bioavailability; Bioavailability of insulin systems was determined based
on the serum insulin level relative to that achieved with subcutaneous insulin
injection.
of each components of sIPN GF was evaluated, and the formulation of sIPN GF
was optimized in respect to cytocompatibility and degradation rate. This optimized
formulation was used to fabricate sIPN GIF. Enzyme-linked immunosorbent assay
(ELISA) was used to monitor the insulin release kinetics of sIPN GIF. Western blot
analysis and 3T3-L1 preadipocyte differentiation analysis were used to determine the
bioactivity of insulin released from sIPN GIF. The permeability of the insulin released
from sIPN GIF was evaluated through a porcine buccal mucosal membrane, which
possesses analogous thickness, structure, morphology, and composition to normal
human buccal epithelium [91].
1.3 Thesis structure
The goal of this work is to explore the potential of sIPN GF in transbuccal mu-
cosal delivery of insulin. Photopolymerization was used to crosslink gelatin fiber in
7
order to modulate the scaffold stability and insulin release kinetics. Chapter 2 in-
vestigates the cytocompatibility of different photoinitiator systems, including eosin Y,
dimethoxyphenyl acetophenone (DMPA) and 2-hydroxy-1-[4-(hydroxyethoxy)phenyl]-
2methyl-1-propanone (Irgacure 2959) systems. This chapter illustrates the correlation
of intracellular AKT signaling transduction to cytocompatibility of photoinitiator sys-
tems and their free radicals on HN4 cells. Chapter 3 investigates sIPN GF as the
primary material platform for transbuccal mucosal delivery of insulin. This chap-
ter provides insights into: (1) the optimization of sIPN GF formulation in respect
to cytocompatibility and degradation rate; (2) the structure stability and mechanical
properties of sIPN GF; (3) the release kinetics and the bioactivity of insulin from sIPN
GIF; and (4) the permeability of insulin released from sIPN GIF through a porcine
buccal mucosal membrane. Chapter 4 summarizes the conclusions drawn from the
presented investigations and proposes possible future research directions based on the
results of this work.
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Chapter 2
Correlating intracellular AKT
signaling transduction to
cytocompatibility of
photoinitiators
2.1 Introduction
Photopolymerization has the ability to initiate rapid formation of a polymer network
from a liquid monomer or macromer under physiological conditions [9]. It has been
shown in great advantages of well spatial and temporal control of reaction kinet-
ics, minimal heat production, ability to uniformly encapsulate cells, and significant
adaptability for in situ polymerization by adapting light sources to fit biomedical
applications [81]. Photopolymerizations have been used in a broad range of biological
applications, such as dentistry [8], optical materials [72], encapsulating pancreatic
islet cells [42], blood vessel adhesives [46], controlled release applications [13], drug
delivery [29], and bone restorations [22]. For instance, a novel photopolymerized den-
drimer hydrogel was reported for delivery of two antiglaucoma drugs, brimonidine
and timolol maleate [29]. This dendrimer hydrogel was mucoadhesive to mucin par-
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ticles and nontoxic to human corneal epithelial cells. Subsequently, this dendrimer
hydrogel could increase the solubility of brimonidine and sustain the in vitro release
of both drugs over 56-72 hours. This dendrimer hydrogel was also shown a significant
increase of bovine corneal transport and human corneal epithelial cell uptake for both
drugs compared to PBS-based eye drop formulations [29].
The mechanism for photopolymerization is to dissociate initiator molecules into
radicals by exposure to specific wavelengths of light [9]. During irradiation, a photon
from a light source excites and dissociates the photoinitiator molecule into a high-
energy radical that can induce the polymerization of a macromer solution [81]. To
date, a number of photoinitiators have been developed with their unique absorption
spectrum. For instance, dimethoxyphenyl acetophone (DMPA) has a peak maximum
wavelength of 310 nm [44], eosin Y has a peak maximum wavelength of 510 nm [6], 1-
Hydroxy-cyclohexyl-phenyl-ketone (Irgacure 184) has a peak maximum wavelength of
244 [48], 2-Methyl-1-[4-(methylthio)phenyl]-2-(4-morpholinyl)-1-propanone (Irgacure
907) has a peak maximum peak wavelength of 309 nm [48], and 2-Hydroxy-1-[4-
(2-hydroxyethoxy)phenyl]-2-methyl-1-propanone Irgacure 2959 has a peak maximum
wavelength of 276 nm [48]. Despite their unique absorption spectrums, these pho-
toinitiators could be dissociated into free redicals at the wavelength of 365 nm and
convert liquid monomers or macromers into hydrogels [9, 29].
The major limitation of photopolymerization techniques for tissue engineered
scaffolds or hydrogels is that the high-energy free radicals can create the potential
for oxidative damage to the photoencapsulated cell populations [9]. Unlike surgical
adhesives and adhesion barriers, many photopolymerization applications involve cell
encapsulation that leads direct contact between cells and free radicals. Free radicals
can directly react with different cellular macromolecules (cell membranes, proteins
and DNA) or indirectly induce formation of reactive oxygen species (ROS), thereby
causing unwanted cellular damage [72]. Although the use of antioxidant reagents such
as uric acid and melatonin could help prevent oxidative damage and quench intra-
cellular ROS, exposure to ultraviolet A radiation can still induce ROS production,
potentially leading to malignant transformation of photo-exposed cells [72]. Such
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free radical-induced oxidative stress or UV-induced lesions may cause mutagenicity,
but relatively few studies have investigated intracellular signaling transduction on
photo-exposed cells.
Cells utilize numbers of signaling pathways to regulate their biological activi-
ties and transmit information from environment. AKT, also known as protein kinase
B, is a serine/threonine-specific protein kinase that regulates cell proliferation, sur-
vival and oncogenesis [4]. It has been well documented that AKT plays a central
role in promoting downstream of activated growth factor receptor signaling [47]. In
cell survival signaling pathways, AKT enhances cell survival by blocking the function
and processes of proapoptotic proteins. AKT suppresses the function and expression
of several B-cell lymphoma 2 (Bcl-2) homology domains-only proteins, which binds
and inactivates prosurvival Bcl-2 family members [47, 23]. AKT activates nuclear
factor kappa-light-chain-enhancer of activated B cells (NFB) survival signaling or
inhibits c-Jun N-terminal kinase/mitogen-activated protein kinase (JNK/p38) apop-
totic signaling under certain circumstances [47, 37]. In cell growth signaling pathways,
AKT promotes cell growth by activating mammalian target of rapamycin complex 1
(mTORC1) that is a critical regulator of translation initiation and ribosome biogene-
sis [47, 85]. In cell proliferation signaling pathways, AKT stimulates cell proliferation
through multiple downstream targets regulating cell cycling such as glycogen synthase
kinase 3 (GSK3), tuberous sclerosis 2 (TSC2) and proline-rich AKT substrate of 40
kDa (PRAS40) [47]. GSK3 plays central role in the G1 to S phase cell cycling tran-
sition [90]; while TSC2 and PRAS40 promotes cell growth by activating mTORC1
[66]. In angiogenesis signaling pathways, vascular endothelial growth factor (VEGF)
robustly activates AKT in endothelial cells and subsequently promotes endothelial
cell survival, growth, proliferation and migration [47, 56]. Understanding the funda-
mentals above, it is of interest to determine intracellular AKT signaling transduction
in photo-exposed cells during photopolymerization process.
In this chapter, the intracellular AKT signaling and the cell viability were eval-
uated in response to the photoinitiators. HN4 cells were treated with DMPA, eosin Y
and Irgacure 2959 in a broad range of concentrations with and without UV radiation.
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The intracellular AKT activity were determined by Western blot analysis, and the
cell viability was measured using WST-1 assay. The stability of free radicals induced
by UV irradiation was also evaluated in HN4 cells in respect to the intracellular AKT
activity and the cell viability.
2.2 Materials and Methods
2.2.1 Materials
1-vinyl-2 pyrrolidinone (NVP), dimethoxyphenyl acetophone (DMPA), dimethyl sul-
foxide (DMSO), eosin Y, ethanol, phosphate buffer solution (PBS), and triethanolamine
(TEOA) were purchased from Sigma-Aldrich (St. Louis, MO). Irgacure 2959 was
provided by Ciba Corporation (Newport, DE). Cell proliferation reagent WST-1 was
purchased from Roche Applied Science (Indianapolis, IN). Phospho-Akt (Ser473) (p-
AKT) antibody was purchased from Cell Signaling Technology (Danvers, MA). AKT1
(559028) antibody was purchased from BD Biosciences Pharmingen (Mississauga, ON,
Canada). β-actin (ACTBD11B7) antibody was purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). Goat anti-rabbit antibody conjugated to horseradish per-
oxidase and goat anti-mouse antibody conjugated to horseradish peroxidase were
purchased from Bio-Rad (Hercules, CA).
2.2.2 Photoinitiator preparation
Three ultraviolet photoinitiating systems were examined in this work. The photoini-
tiator solutions were prepared based on weight per volume calculations per industry
standard. Briefly, 0, 25, 50, 100 and 250 mg of DMPA was dissolved in 1 ml of
ethanol, resulting 0, 25, 50, 100 and 250 mg/ml of DMPA stock solutions. 0, 50,
100, 250 and 500 mg of DMPA was dissolved in 1 ml of ethanol, resulting 0, 50, 100,
250 and 500 mg/ml of Irgacure 2959 stock solutions. Eosin Y photoinitiator stock
solution was prepared by 0.1% eosin Y, 4% NVP, and 40% TEOA in PBS according
to the previous reports [29, 24]. All resulting photoinitiator solutions were protected
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from light and stored at room temperature until use.
2.2.3 Cell culture
HN4 cells were derived from a primary SCC of the head and neck. The cells were
cultured in Dulbecco’s Modification of Eagle’s Medium (DMEM) (Life Technologies,
Grand Island, NY) supplemented with high glucose, L-glutamine, 10% (v/v) fetal
bovine serum (Fisher Scientific, Pittsburgh, PA), 100 units/ml of penicillin and 100
µg/ml of streptomycin (Thermo Fisher Scientific, Ashville, NC) at 37◦C in a humid
environment with 5% CO2 before any biocompatibility study was performed.
2.2.4 Comparison of photoinitiators
40 µl of each DMPA or Irgacure 2959 stock solution was added to 2 ml of fresh culture
media to reach a final concentration of 0, 0.5, 1, 2 and 5 mg/ml of DMPA and 0, 1,
2, 5 and 10 mg/ml of Irgacure 2959. 0, 5, 10, 20 and 50 µl of eosin Y stock solution
was added to 2 ml of fresh culture media to reach a final concentration of 0, 2.5, 5, 10
and 25 µl/ml of eosin Y. For cell viability analysis, Pre-seeded HN4 cells on a 96-well
plate were treated with above condition media for 1-4 days. The spent media were
replaced by the same fresh condition media every day during the treatments in order
to maintain a constant concentration of each photoinitiator. For protein expression
analysis, Pre-seeded HN4 cells on a 6-well plate were treated with above condition
media for 30 min, and total protein lysates were harvested by total cell lysate buffer
with protease and phosphatase inhibitors (Roche Applied Science, Indianapolis, IN).
2.2.5 Comparison of photoinitiators after UV irradiation
The fresh cell culture media were mixed with different concentrations of each pho-
toinitiator stock solution to reach a final concentration at 0, 0.5, 1 and 2 mg/ml of
DMPA and 1, 2 and 5 mg/ml of Irgacure 2959 as well as 2.5, 5, 10 µl/ml of eosin Y.
These mixtures were equally exposed to UV radiation at 365 nm with an intensity of
100 watts for 30 min in order to decompose the photoinitiator into free radicals. Pre-
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seeded HN4 cells were then subjected to the media right after UV irradiation. After 1
and 2 days treatments, the cellular proliferation rate was determined by WST-1 assay.
After 30 min treatment, total cellular p-AKT and AKT1 expression was evaluated
by Western blot analysis.
2.2.6 Cytotoxicity and cellular response of free radicals
The fresh cell culture media were mixed with the eosin Y stock solution to reach a
final concentration at 20 µl/ml of and then exposed to UV radiation at 365 nm with
an intensity of 100 watts for 30 min to decompose into free radicals. Pre-seeded HN4
cells the conditioned media in 0, 6, 24, 48 hours after UV irradiation. After 2 days
treatments, the cellular proliferation rate was determined by WST-1 assay. After 30
min treatment, total cellular p-AKT and AKT1 expression was evaluated by Western
blot analysis.
2.2.7 Cellular proliferation rate
HN4 cells were seeded on a 96-well plate with a density of 10,000 cells/well and
cultured for 2 days to allow the cells adhesion. At the end of each treatment, the
cellular proliferation rate of surviving cells was determined by addition of 10% (v/v)
of WST-1 reagent according to the manufacturers protocol. After 30 min incubation,
the absorbance of the samples was measured at 450 nm, against a background control
as a blank, and this value was then subtracted by the absorbance at 650 nm as a
reference wavelength.
2.2.8 Western blot analysis
Western blot analysis of total cellular protein was carried out by standard procedures,
as described previously [89, 88]. Briefly, total cell lysates (30 µg) were separated on
a 10% SDS-PAGE gel and transferred onto a polyvinylidene difluoride (PVDF; Bio-
Rad, Hercules, CA) membrane using Bio-Rad Mini-Blot transfer apparatus. The
membrane was blocked for 2 hours in Tris-buffered solution (TBS) containing 5%
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of non-fat dried milk. The specific proteins on the membrane were determined by
incubating with the primary antibodies overnight at 4 ◦C with shaking. The mem-
brane was washed three times and then incubated in a 1:3,000 dilution of a secondary
antibody at room temperature for 1 hour in the washing buffer (Tris-buffered so-
lution containing 0.5% Tween 20). The specific antigen-antibody interactions were
detected using enhanced chemiluminescence (Pierce ECL Western Blotting Substrate;
Thermo Scientific, Rockford, IL). The total cellular expression of β-actin was used as
the loading control.
2.2.9 Statistical analysis
All the data were expressed as means ± standard deviation (SD) and subjected to one
way analysis of variance (ANOVA) followed by Holm-Sidak method for significance
using SigmaPlot 12. A value of p < 0.05 was considered as statistically significant.
Statistical analysis data is provided in Appendix A (p85-119).
2.3 Results and discussion
2.3.1 The effect of photoinitiators on HN4 cell viability
The effects of photoinitiators including eosin Y, Irgacure 2959 and DMPA on the
viability of HN4 cells were first evaluated. As shown in Figures 2.1, 2.2 and 2.3, eosin
Y exhibited less cytotoxicity than Irgacure 2959 and DMPA, as the evidence showed
that HN4 cells were tolerant to a wider concentration range of eosin Y than Irgacure
2959 and DMPA. Up to 4-day treatment of 2.5 µl/ml of eosin Y or 1 mg/ml Irgacure
2959, HN4 cells were able to maintain nearly 100% cell viability (Figures 2.1 and
2.2). Eosin Y reduced HN4 cell viability in a concentration-dependent manner at each
time period treatment; whereas nearly no viable HN4 cell was observed after 1-day
treatment of Irgacure 2959 at the concentration greater than 2 mg/ml. In contrast,
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Figure 2.1: The effect of eosin Y on HN4 cell viability.
HN4 cells were plated at a density of 1×104 cells/well into 96-well plates and
treated with different concentrations of eosin Y as indicated for 0, 1, 2, 3 and 4
days. The cell viabilities were measured by WST-1 assay at the end of the
treatment. The bars are mean ± standard deviation.
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Figure 2.2: The effect of Irgacure 2959 on HN4 cell viability.
HN4 cells were plated at a density of 1×104 cells/well into 96-well plates and
treated with different concentrations of Irgacure 2959 as indicated for 0, 1, 2, 3 and
4 days. The cell viabilities were measured by WST-1 assay at the end of the
treatment. The bars are mean ± standard deviation.
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Figure 2.3: The effect of DMPA on HN4 cell viability.
HN4 cells were plated at a density of 1×104 cells/well into 96-well plates and
treated with different concentrations of DMPA as indicated for 0, 1, 2, 3 and 4 days.
The cell viabilities were measured by WST-1 assay at the end of the treatment. The
bars are mean ± standard deviation.
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DMPA exhibited a significant cytotoxic effect to cells, as the evidence showed that
no viable HN4 cell was observed at each concentration of DMPA in each time period
treatment (Figure 2.3).
The cytotoxicity profile of Irgacure 2959 was consistent with the previous re-
port, which showed there was nearly no cytotoxicity of Irgacure 2959 up to 1 mg/ml
in both bovine chondrocytes and human fetal osteoblasts [9, 81]. Up to date, there
is very few reports investigating a wide concentration range of photoinitators on the
cell viability. This is the first time to show that an approximate maximum concen-
tration of eosin Y and Irgacure 2959 can be used in cell culture with a desirable
cytotoxicity. However, in vivo circumstances are different as in vitro 2-dimensional
cell culture. The use of photoinitiators in in vivo biomedical application needs to be
further evaluated based on these in vitro cell culture results.
2.3.2 The effects of photoinitiators on intracellular AKT sig-
naling transduction in HN4 cells
AKT is one of the key regulators in cell proliferation and survival that transmits
information from environment and regulates cell viability. To further evaluate the
effects of photoinitiators on cellular response, the intracellular signaling transduction
was determined in response to eosin Y, Irgacure 2959 and DMPA. HN4 cells were
used as our model cell line to determine the intracellular AKT activity in acute
response to the three photoinitiators because HN4 cells keep a constitutive high AKT
activation [79]. After 30 min treatment, eosin Y had no significant effect on the
phosphorylation of AKT up to 25 µl/ml in HN4 cells as shown in Figure 2.4. In
contrast, both Irgacure 2959 and DMPA diminished the phosphorylation of AKT in
a concentration-dependent manner as shown in Figure 2.5 and Figure 2.6, respectively.
These results suggest that the inhibition of AKT activation by Irgacure 2959
and DMPA could lead to several downstream effects, including reducing cell viability
and motility, decreasing angiogenesis, and inducing apoptosis, which are consistent
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Figure 2.4: The effect of eosin Y on intracellular AKT activity in HN4
cells.
HN4 cells were HN4 cells were plated at a density of 5×104 cells/well into 6-well
plates and treated with different concentrations of eosin Y as indicated for 30 min.
At the end of treatment, the total cell lysates were harvested and the intracellular
phospho-AKT (p-AKT) and total AKT levels were analyzed by Western blot
analysis (A). Each positive band was normalized to β-actin and was quantified by
NIH ImageJ (B). The data represent typical one of three experiments. Each value
represents mean ± standard deviation.
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Figure 2.5: The effect of Irgacure 2959 on intracellular AKT activity in
HN4 cells.
HN4 cells were HN4 cells were plated at a density of 5×104 cells/well into 6-well
plates and treated with different concentrations of eosin Y as indicated for 30 min.
At the end of treatment, the total cell lysates were harvested and the intracellular
phospho-AKT (p-AKT) and total AKT levels were analyzed by Western blot
analysis (A). Each positive band was normalized to β-actin and was quantified by
NIH ImageJ (B). The data represent typical one of three experiments. Each value
represents mean ± standard deviation.
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Figure 2.6: The effect of DMPA on intracellular AKT activity in HN4
cells.
HN4 cells were HN4 cells were plated at a density of 5×104 cells/well into 6-well
plates and treated with different concentrations of eosin Y as indicated for 30 min.
At the end of treatment, the total cell lysates were harvested and the intracellular
phospho-AKT (p-AKT) and total AKT levels were analyzed by Western blot
analysis (A). Each positive band was normalized to β-actin and was quantified by
NIH ImageJ (B). The data represent typical one of three experiments. Each value
represents mean ± standard deviation.
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with the cell viabilities shown in Figures 2.1, 2.2 and 2.3. Cell invasion, migration and
proliferation as well as angiogenesis are crucial for the success of photocrosslinking
polymer scaffold in biomedical applications, especially tissue engineering. This is
the first time to show the interaction of photoinitiators on the intracellular signaling
pathway. The results suggest that eosin Y could be a much safer photoinitiator for
photopolymerization in biomedical applications than Irgacure 2959 and DMPA.
2.3.3 The effect of UV-exposed photoinitiators on viability
and intracellular AKT signaling transduction in HN4
cells
Besides the precursor of photoinitiators, the free radicals generated during the pho-
tocrosslinking process could be cytotoxic as well. As shown in Figure 2.7, eosin Y,
Irgacure 2959 and DMPA can be decomposed into high-energy radicals. The cell via-
bility and intracellular AKT activity were evaluated in HN4 cells in response to these
free radicals. Eosin Y, Irgacure 2959 and DMPA were mixed with cell culture media
first and subjected to UV irradiation for 30 min to allow free radical generation. HN4
cells were then immediately treated with these photoinitiator solutions for 1 and 2
days. HN4 cells failed to maintain 100% viability during the 2 days incubation with
2.5 µl/ml of eosin Y and 0.5 mg/ml of Irgacure 2959 after UV irradiation (Figures
2.8 and 2.9), comparing to the non-UV irradiation treatment (Figures 2.1 and 2.2).
After UV irradiation, 2.5 µl/ml of eosin Y and 0.5 mg/ml of Irgacure 2959 reduced
cell viability about 30% and 50%, respectively; while 10 µl/ml of eosin Y and 2 mg/ml
of Irgacure 2959 reduced cell viability about 70% and 95%, respectively. DMPA was
consistently cytotoxic to HN4 cells as its precursor (Figures 2.3 and 2.10), and both
precursor and free radicals could cause a significant cytotoxicity effect. These results
suggest that eosin Y is more biocompatible than Irgacure 2959 and DMPA after UV
irradiation, which is consistent with Figures 2.1, 2.2 and 2.3. It was noticed that
the free radicals generated from UV irradiation were more cytotoxic to cells than
their precursor. These results were further confirmed by intracellular AKT signaling
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Figure 2.7: A schematic diagram of photoinitiator decomposition to free
radicals [1, 52, 59].
A, eosin Y; B, Irgacure 2959; and C, DMPA.
transduction in HN4 cells in response to these free radicals. All three UV exposed
photoinitiators diminished the phosphorylation of AKT in HN4 cells as shown in
Figure 2.11.
These results only represent the worst case scenario, in which all the free rad-
icals generated from photopolymerization process have the highest likelihood to in-
teract with cells. However, these results indicate the way in which cells response to
free radicals at the early stage. The free radicals induce fast AKT dephosphorylation,
which in turn alters numerous intracellular signaling transductions, such as inhibiting
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Figure 2.8: The effect of UV-exposed eosin Y on HN4 cell viability.
The cell culture media were first mixed with different concentrations of eosin Y, and
then the mixtures were exposed to the longwave UV at 365 nm with an intensity of
100 watts for 30 min. After the UV irradiation, the mixtures were immediately to
treat HN4 cells for 0, 1 and 2 days. The cell viabilities were measured by WST-1
assay at the end of the treatment. The bars are mean ± standard deviation.
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Figure 2.9: The effect of UV-exposed Irgacure 2959 on HN4 cell viability.
The cell culture media were first mixed with different concentrations of Irgacure
2959, and then the mixtures were exposed to the longwave UV at 365 nm with an
intensity of 100 watts for 30 min. After the UV irradiation, the mixtures were
immediately to treat HN4 cells for 0, 1 and 2 days. The cell viabilities were
measured by WST-1 assay at the end of the treatment. The bars are mean ±
standard deviation.
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Figure 2.10: The effect of UV-exposed DMPA on HN4 cell viability.
The cell culture media were first mixed with different concentrations of DMPA, and
then the mixtures were exposed to the longwave UV at 365 nm with an intensity of
100 watts for 30 min. After the UV irradiation, the mixtures were immediately to
treat HN4 cells for 0, 1 and 2 days. The cell viabilities were measured by WST-1
assay at the end of the treatment. The bars are mean ± standard deviation.
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Figure 2.11: The effect of UV-exposed photoinitiators on intracellular
AKT activity in HN4 cells.
The cell culture media were first mixed with different concentrations of eosin Y,
Irgacure 2959 or DMPA, and then the mixtures were exposed to the longwave UV
at 365 nm with an intensity of 100 watts for 30 min. After the UV irradiation, the
mixtures were immediately to treat HN4 cells for 30 min and the total cell lysates
were harvested. The intracellular phospho-AKT (p-AKT) and total AKT levels
were analyzed by Western blot analysis (A). Each positive band was normalized to
β-actin and was quantified by NIH ImageJ (B). The data represent typical one of
three experiments. Each value represents mean ± standard deviation.
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mTOR signaling pathway in cell proliferation and p53 signaling pathway in cell sur-
vival, activating ROS signaling pathway in ER stress and caspase 9 signaling pathway
in cell apoptosis [64]. For the potential use of photoinitiators to crosslink polymers in
biomedical applications, it becomes crucial to optimize the concentration of photoini-
tiators and keep the minimal free radical residues after photopolymerization process.
2.3.4 The evaluation of free radicals stability on viability and
intracellular AKT signaling transduction in HN4 cells
To further evaluate the stability of free radicals, the cell viability and intracellular
AKT activity were determined in HN4 cells in response to the quenched eosin Y con-
dition media. As shown in Figure 2.12, the quenched UV-exposed eosin Y exhibited
more cytotoxicity than unquenched UV-exposed eosin Y, indicating the free radicals
generated from UV irradiation of eosin Y were not diminished up to 48 hours of
quencher. The reason is yet unclear, but it could be due to the interaction between
free radicals and cell culture media. Such reaction then affects growth factors in
the culture media which in turn inhibits cell signaling transductions. The evidence
showed that the phosphorylation of AKT was significantly diminished in the HN4
cells treated with the quenched eosin Y condition media (Figure 2.13). These results
suggest that free radicals may not only interact with cells but extracellular compo-
nents as well. The actual cell survival in the 3-dimensional polymer scaffold might
be higher than this simplistic 2-dimensional cell culture model in in vivo biomedical
applications [81]. It depends on the ability of polymer scaffold to scavenge the free
radicals generated from photopolymerization process.
Up to date, a few of papers have been published to demonstrate the biocom-
patibility of photoinitiators in different cell lines and conclude that Irgacure 2959 is
the promising photoinitiator for cytocompatibility among Irgacure 184, Irgacure 907,
Irgacure 651 and Irgacure 2959 [9, 81]. The biocompatible concentration range of
Irgacure 2959 is within 0.5% (w/w) as reported [9, 81]. This conclusion is consistent
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Figure 2.12: The effect of the free radicals stability on HN4 cell viability.
The cell culture media were first mixed with eosin Y to reach a final concentration
of 20 µl/ml, and the mixtures were exposed to the longwave UV at 365 nm with an
intensity of 100 watts for 30 min. After the UV irradiation, the mixtures were
stored in dark for 0, 6, 24 and 48 hours before the cell treatment. HN4 cells were
then treated with no addition (NA), 20 µl/ml of eosin Y without UV irradiation or
the UV exposed mixtures for 2 days. The cell viabilities were measured by WST-1
assay at the end of the treatment. The bars are mean ± standard deviation.
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Figure 2.13: The effect of the free radicals stability on intracellular AKT
activity in HN4 cells.
The preparation of the condition media was described in Figure 2.12. HN4 cells
were then treated with no addition (NA), 20 µl/ml of eosin Y without UV
irradiation or the UV exposed mixtures for 30 min and the total cell lysates were
harvested. The intracellular phospho-AKT (p-AKT) and total AKT levels were
analyzed by Western blot analysis (A). Each positive band was normalized to
β-actin and was quantified by NIH ImageJ (B). The data represent typical one of
three experiments. Each value represents mean ± standard deviation.
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with our observations (Figures 2.2 and 2.5). However, the biocompatibility also de-
pends on the materials of polymer and UV intensity during the photopolymerization
[9]. Our finding agrees well with photoinitiator system of eosin Y with TEOA has
little effect on cell viability [25]. In this work, it is the first time to illustrate the
immediate response of cells regarding to the precursor and free radicals of photoini-
tiators. It was observed that free radicals significantly inhibited intracellular AKT
signaling transduction (Figures 2.11 and 2.13), which was closely correlated to cy-
tocompatibility in HN4 cells. Inhibition of AKT signaling transduction can further
induce ROS formation and lead oxidative stress [72]. In order to diminish oxidative
stress within the cells, antioxidants are commonly introduced to quench the activa-
tion of ROS signaling during the photopolymerization process. Nonetheless, it is of
interest to test the intracellular AKT signaling transduction in the cells encapsulated
within the photoinitiated crosslinking polymers along with the antioxidants. It is of
importance to keep cells not only viable but migrating, proliferating and functioning
in the photoinitiated crosslinking polymers as a function unit.
2.4 Conclusions
In this chapter, the effects of three photoinitiators and their free radicals on cytocom-
patibility and intracellular AKT signaling transduction were determined in HN4 cells.
It was shown that the cytocompatibility of the photoinitiators was closely correlated
to intracellular AKT signaling transduction within the cells. The most promising
cytocompatible photoinitiator in this work was eosin Y at concentrations below 10
µl/ml. Eosin Y had minimal effect on intracellular AKT signaling transduction up to
25 µl/ml. Irgacure 2959 was also a promising cytocompatible photoinitiator only at
concentration below 1 mg/ml. It was also shown that free radicals had significant ef-
fects on HN4 cells, including reducing cell viability and inhibiting intracellular AKT
signaling transduction. These free radicals may interact with cell directly or indi-
rectly via interaction with cell culture media. These findings could further enhance
our understanding of the biocompatibility in the photoinitiator systems and provide
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a novel way to look into the interaction between cells and photoinitiators or their free
radicals.
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Chapter 3
Fabrication of
semi-interpenetrating network
scaffolds for transbuccal mucosal
delivery of insulin
3.1 Introduction
Insulin has been delivered to diabetic patients exclusively through the subcutaneous
route since it was discovered. Due to the relatively short duration of action of 4
to 8 hours, patients in severe diabetic condition are required to take two to four
daily injections. The stress and noncompliance of multiple daily injections attract
numerous investigations to develop a safe and effective noninvasive route for insulin
delivery. Oral administration of insulin is the first viable alternative to multiple
daily injections. Oral administration of insulin can rapidly elevate insulin level in the
portal blood, which simulates the physiological secretion pattern of the pancreas [71].
However, insulin has to travel through stomach, small intestine and the colon intact
before reaching the blood stream. Subsequently, insulin has to be protected from the
gastric enzymes, such as pepsin, trypsin and chymotrypsin in the duodenum as well as
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exopeptidases when it reaches the brush border. Nanoparticle-based insulin delivery
systems were reported to be able to overcome these barriers [71], and these systems
have been received considerable attention. To date, there are three mechanisms for
intestinal uptake of insulin encapsulated nanoparticles: (1) uptake by paracellular
pathway, (2) transcytosis or receptor-mediated transcytosis through the epithelial
cells of the intestinal mucosa, and (3) lymphatic uptake through the M cells of the
Peyers patches mostly abundant in the ileum [71].
Therefore, the properties of a successful drug carrier for insulin have been sum-
marized as follows: (1) resistant against gastrointestinal enzymes and pH gradients,
(2) stable and biocompatible to ensure that the main fraction of insulin remains bi-
ologically active from encapsulation to release, (3) highly permeable along with the
intestinal membrane, (4) absorbable through the epithelial cell layer or the mucosal
epithelium to enhance the absorption of drug, (6) fast release in the circulation to
control the glucose concentration in blood, and (7) safe after oral administration [71].
Due to the large size, hydrophilicity, susceptibility to enzymatic degradation
and poor intestinal absorption, oral delivery of free insulin has low bioavailability.
A variety of formulations for oral insulin delivery have been developed in the last
decade. Most strategies have shown promising results, such as pH sensitivity, enzy-
matic inhibition among others, but the bioavailability is still low as shown in Table
1.1.
Transbuccal mucosal administration could be a secondary alternative route to
deliver insulin. It has been reported that co-administration of soybean-lecithin could
enhance transbuccal mucosal delivery of insulin in rabbits and rats [77, 87]. In addi-
tion, poly(methacrylic acid)-grafted-poly(ethylene glycol) (P(MAA-g-EG)) hydrogel
holds a great potential for transmucosal and intracellular delivery of insulin [41]. Both
adhesion property and release kinetics can be modulated by tuning the polymer com-
position [41]. All of these interesting findings inspire our great interest to explore the
transbuccal mucosal route for insulin delivery.
The anatomical and physiological properties of the oral mucosa have been
generally reviewed as follows. The oral cavity contains lips, cheek, tongue, hard
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palate, soft palate and floor of the mouth. The lining of the oral cavity is the oral
mucosa that includes the buccal, sublingual, gingival, palatal and labial mucosa [58].
Among these mucosa, the buccal and sublingual mucosa have the largest surface area,
which accounts for about 60% of the total oral mucosal surface area. The top layer
of the oral mucosa comprises closely compacted epithelial cells, whose function is to
protect the underlying tissue against potential harmful agents in the oral environment
and from fluid loss [58]. Lamina propia and submucosa are under the epithelium,
referred to as the basement membrane.
There are some significant challenges for systemic drug delivery through the
oral cavity. (1) The drug has to be released from the carrier to the delivery site, such
as buccal or sublingual mucosa, and the drug has to pass through the mucosal layers
to enter the systemic circulation. (2) The drug has to remain bioactive in this process,
including pH, fluid volume, enzyme activity and the permeability of oral mucosa in
the oral cavity [58]. (3) The turnover of the mucosal surface is a determinant of this
delivery route. The surface area of oral cavity is estimated at about 100 cm2, with
a local pH from 5.8 to 7.6. The relative drug absorption capacity is moderate in
oral cavity comparing to stomach, small intestine, large intestine and rectum [58].
(4) The physiological environment of the oral cavity, including pH, fluid volume and
composition, is determined by the secretion of saliva. Saliva provides a water rich
environment of the oral cavity, which can be favorable for drug release from delivery
systems, especially those based on hydrophilic polymers.
Biological polymers, such as collagen, gelatin, hyaluronic acid, and thrombin
are widely employed as backbones in the construction of hydrogels or scaffolds for
various biomedical applications [73]. Gelatin, a hydrophilic protein fragment derived
from collagen, has been extensively investigated in drug delivery system, owing its
biodegradability, its low level of immunogenicity and cytotoxicity, and its FDA ap-
proval as a clotting agent and exudate-absorbing construct. Several investigations
indicate that gelatin can be chemically crosslinked with polyethylene glycol diacry-
late (PEG-DA) to form a semi-interpenetrating network (sIPN) [73, 87, 27, 92]. This
crosslinking process is driven by photopolymerization, which can physically enhance
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the entanglement of polymer chains in three-dimensional structure. The application
of photopolymerization techniques allows the ease of loading a desired drug dosage
and control over crosslinking density [73]. It has been reported that (1) the degra-
dation and drug release rate can be modulated by turning the weight percent of
PEG-DA during the photopolymerization [92]; (2) increasing the gelatin content can
significantly increase Youngs modulus [27]; (3) the gelatin sIPN exhibits stability and
adhesive strength to fresh tissue [87, 92, 10]; and (4) the adhesion values of gelatin
IPN is up to 5.7 N [92]. Indeed, gelatin sIPN displays moisture absorbance, high
tensile strength and elasticity, tissue integration and adhesion, and favorable tissue
response, which can be for transbuccal mucosal drug delivery.
Electrospinning is a materials-processing method that is used to fabricate con-
tinuous ultrafine fibers with a diameter range from 50 nm to 10 µm. Electrospin-
ning is reported to be versatile, inexpensive, scalable, and reliable. Electrospun
fibers are produced from a solution of natural or synthetic polymers, including col-
lagens, gelatin, elastin, fibrinogen, hemoglobin and myoglobin and silk fibroin, or
poly(dioxanone) (PDO), poly(ethylene oxide) (PEO), poly(ethylene terephthalate),
poly(glyconate), PLGA, PLLA, PCL, poly(styrene), poly(vinyl alcohol) (PVA), chi-
tosan, and hyaluronic acid (HA) [35, 63]. These electrospun fibers have been widely
explored in biomedical applications such as tissue engineering, wound healing, or-
thopedics, biosensors and drug delivery [35, 32, 43, 82]. Electrospun fiber scaffold
exhibits a high surface to volume ratio and direct local adhesion ability and holds a
great potential for transbuccal mucosal drug delivery.
An electrospun gelatin fiber scaffold (GF) was developed to locally deliver nys-
tatin for candidiasis [2]. GFs possess high biocompatibility and mucoadhesive prop-
erty that allow local sustained release of drug at the absorption site [2, 7]. GF can
be stabilized using a crosslinker of photocurable PEG-DA and form sIPN. The fiber
morphology, mechanical and physical properties as well as drug release kinetics can
be controlled by modulating the concentration of crosslinker [2]. However, the major
limitation of photopolymerization techniques for these sIPN scaffolds or hydrogels is
that the high-energy free radicals can create the potential of oxidative damage to the
37
photoencapsulated cell populations [9, 81]. The cytocompatibility of photoinitiators
was investigated in Chapter 2. The results suggest that eosin Y is more cytocom-
patible than Irgacure 2959 and DMPA, with minimal effect on intracellular AKT
signaling transduction in HN4 cells (Chapter 2).
In this chapter, a sIPN gelatin-co-insulin fiber scaffold (sIPN GIF) was fabri-
cated by applying an optimized formulation of sIPN GF in respect to cytocompatibil-
ity and degradation rate. Enzyme-linked immunosorbent assay (ELISA) was used to
monitor the insulin release kinetics of sIPN GIF. Western blot analysis and 3T3-L1
preadipocyte differentiation analysis were used to determine the bioactivity of insulin
from sIPN GIF. The permeability of the insulin from sIPN GIF was evaluated through
a porcine buccal mucosal membrane, which possesses analogous thickness, structure,
morphology, and composition to normal human buccal epithelium [91]. Our results
suggest that sIPN GIF holds a great potential for transbuccal mucosal delivery of
insulin.
3.2 Materials and Methods
3.2.1 Materials
1-vinyl-2 pyrrolidinone (NVP), eosin Y, ethanol, human insulin, oil red O, phos-
phate buffer solution (PBS), Polyethylene glycol diacrylate (PEG-DA575, Mn = 575
g/mol), porcine type-A gelatin, and triethanolamine (TEOA) were purchased from
Sigma-Aldrich (St. Louis, MO). 1,1,1,3,3,3-Hexafluoro-2-propanol (HFP) was pur-
chased from TCI America (Portland, OR). Cell proliferation reagent WST-1 was
purchased from Roche Applied Science (Indianapolis, IN). Insulin enzyme-linked im-
munosorbent assay (ELISA) kit was purchased from Calbiotech (Spring Valley, CA).
Phospho-Akt (Ser473) (p-AKT) antibody was purchased from Cell Signaling Tech-
nology (Danvers, MA). AKT1 (559028) antibody was purchased from BD Biosciences
Pharmingen (Mississauga, ON, Canada). β-actin (ACTBD11B7) antibody was pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA). Goat anti-rabbit antibody
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conjugated to horseradish peroxidase and goat anti-mouse antibody conjugated to
horseradish peroxidase were purchased from Bio-Rad (Hercules, CA).
3.2.2 Cell culture
3T3-L1 preadipocytes were maintained in Dulbecco’s Modification of Eagle’s Medium
(DMEM) (Life Technologies, Grand Island, NY) supplemented with high glucose, L-
glutamine, 10% (v/v) fetal bovine serum (FBS) (Fisher Scientific, Pittsburgh, PA),
100 units/ml of penicillin (Thermo Fisher Scientific, Ashville, NC) and 100 µg/ml of
streptomycin (Thermo Fisher Scientific, Ashville, NC) at 37◦C in a humid environ-
ment with 5% CO2.
3.2.3 Scaffold preparation
The preparation of gelatin fiber scaffold required two steps, referred to as electro-
spinning and cross-linking, as previously reported [2]. Briefly, 1 g of gelatin was first
added into 10 ml of HFP solution, and the mixture was shaken continuously overnight
to obtain a homogeneous transparent 10% (w/v) gelatin/HFP solution. To prepare
gelatin-co-insulin solutions, 5 mg of insulin was added to 10 ml of the gelatin/HFP
solution, and the mixture was shaken continuously overnight to obtain a homogenous
1:200 (w/w) insulin/gelatin solution.
3.2.4 Preparation of GF and GIF
To fabricate GF and GIF, a conventional electrospinning of gelatin solution was per-
formed as shown in Figure 3.1. Briefly, a syringe of the gelatin solution or gelatin-co-
insulin solution described above was placed in an electrostatic field with the applied
voltage of 25 kV to a blunt needle (18 gauge 1.5”). A grounded aluminum collecting
mandrel was placed 20 cm away from the tip of the needle; while a flat stainless steel
collecting mandrel (7.5 × 2.5 × 0.5 cm, length × width × thickness) was placed 12.5
cm away from the needle. The gelatin solution was dispensed from the syringe into
the electrostatic field at a rate of 6.37 ml/h. The electrospun fibers were accumulated
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Figure 3.1: Experimental setup to schematically illustrate the conventional
electrospinning.
on the collecting mandrel with a rotational speed of 550 rpm and a translational
speeds of 6 cm/s over 12 cm.
3.2.5 Preparation of crosslinked GF and GIF
The eosin Y photoinitiator solution was prepared by 0.1% w/w eosin Y, 40% w/w
TEOA and 4% w/w NVP in ethanol as previously reported [24, 29]. In order to
obtain the optimal ratio of PEG-DA to eosin Y solution, (1) the electrospun GFs
were cross-linked with various concentrations (0%, 1%, 2%, 5%, 10% and 20%; w/v)
of PEG-DA in the presence of 5% (v/v) eosin Y solution; (2) the electrospun GFs were
crosslinked with various concentrations (2%, 5% and 10%; v/v) of eosin Y solutions
in the presence of 1% (w/v) PEG-DA. The crosslinking solutions were prepared by
combining appropriate amounts of eosin Y solution and PEG-DA. Next, 600 µl of
crosslinking solution was poured onto a 200 mg of eletrospun gelatin fiber, followed
by a 10 min of incubation to allow equilibrium. The scaffold was held under ultraviolet
(UV) light (UVP Blak-Ray Long Wave Lamp, 100 Watts) from a 14 cm distance for
5 min on each side of the scaffold and then air-dried as previously reported [2].
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3.2.6 Cytocompatibility assay
To evaluate the cytocompatibility of PEG-DA and PEG, both polymers were dis-
solved in ethanol first. 3T3-L1 preadipocytes were treated with 0, 17.4, 87, 174, 696
and 1739 M of PEG-DA or PEG for 2 days. To evaluate the cytocompatibility of the
fabricated scaffolds, 20 mg of the fabricated scaffold was weighed and then individ-
ually immersed into a 5 ml of cell culture medium at 37◦C for 2 hours. The elution
media were collected at the end of incubation. 3T3-L1 preadipocytes were treated
with these elution media for 2 days. At the end of each treatment, the cell viability
was determined by WST-1 proliferation assay following the manufacturers protocol.
3.2.7 In vitro degradation studies
In vitro degradation of the fabricated scaffolds was evaluated in cell culture medium
and simulated saliva fluid (SSF; 12 mM KH2PO4, 40 mM NaCl, 1.5 mM CaCl2, with
NaOH adjusted to pH 6.2) at 37 ◦C as previously reported [2]. Briefly, 20 mg of the
fabricated scaffolds (n = 5) were weighed and then individually immersed in a tube
filled with 5 ml of one of the two media mentioned above. Samples were taken out at
15, 30, 60 and 120 min, and centrifuged at 5,000 rpm for 5 min. After centrifugation,
the residue was collected, freeze-dried and weighed.
3.2.8 Uniaxial tensile testing
Uniaxial tensile testing of electrospun scaffolds was performed as previously described
[2, 50]. Briefly, dog-bone-shaped samples (n = 12-18) were obtained using a punch
die (ODC Testing & Molds) with a dimension of 19.05 mm in length, 3.175 mm
at narrowest point and 6.1 mm at widest point. The thickness of the samples was
determined using a digital caliper. Mechanical properties of the samples were tested
using an MTS Bionix 200 testing system with 100 N load cell (MTS Systems, Eden
Prairie, MN). Samples were tested to failure at a 1.33 min−1 strain rate. TestWorks
version 4 was used to calculate peak load, peak stress, modulus, strain at break and
energy to break.
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3.2.9 Scanning electron microscopy (SEM)
The fabricated and degraded scaffolds were placed on a 1 cm diameter stub, and the
stub was placed on a specimen holder and prepared by gold sputtering. SEM images
were taken on a JEOL LV-5610 scanning electron microscope in the Nanomaterials
Core Characterization facility at Virginia Commonwealth University. The diameters
of fibers were analyzed by NIH ImageJ (http://rsbweb.nih.gov/ij/) from 60 randomly
chosen fibers in each SEM image as previously reported [2, 50].
3.2.10 Insulin release studies
Insulin released from the fabricated scaffolds was analyzed by ELISA and Western
blot analysis as previously reported [84, 75, 70, 55]. Briefly, 20 mg of insulin-loaded
scaffolds were immersed in 5 ml of DMEM at 37 ◦C. At the predetermined time
points of 15, 30, 60, 120 and 240 min, a 25 µl aliquot was withdrawn from the release
medium. The cumulative drug release was then determined by ELISA according to the
manufactory standard protocol. In order to evaluate the bioactivity of released insulin
in each sample, 3T3-L1 preadipocytes were used as our model. 3T3-L1 preadipocytes
were seeded onto a 6-well plate at 5 × 105 cells/well and cultured for 3 days to
allow their attachment. The 3T3-L1 preadipocytes were then treated with the insulin
released media at these predetermined time points for 10 min. The intracellular AKT
signaling transduction in response to insulin treatment was determined by Western
blot analysis.
3.2.11 Western blot analysis
Western blot analysis of total cellular protein was carried out by standard procedures,
as described previously [89, 88]. Briefly, total cell lysates (30 µg) were separated on
a 10% SDS-PAGE gel and transferred onto a polyvinylidene difluoride (PVDF; Bio-
Rad, Hercules, CA) membrane using Bio-Rad Mini-Blot transfer apparatus. The
membrane was blocked for 2 hours in Tris-buffered solution (TBS) containing 5%
of non-fat dried milk. The specific proteins on the membrane were determined by
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incubating with the primary antibodies overnight at 4 ◦C with shaking. The mem-
brane was washed three times and then incubated in a 1:3,000 dilution of a secondary
antibody at room temperature for 1 hour in the washing buffer (Tris-buffered so-
lution containing 0.5% Tween 20). The specific antigen-antibody interactions were
detected using enhanced chemiluminescence (Pierce ECL Western Blotting Substrate;
Thermo Scientific, Rockford, IL). The total cellular expression of β-actin was used as
the loading control.
3.2.12 Oil red O staining
3T3-L1 cells were seeded onto a 6-well plate at 5 × 105 cells/well cultured for 3 days
to allow their attachment. According to the standard protocol [65, 84], differentiation
was initiated by incubating preseeded cells with DMEM containing 10% FBS, 10 g/mL
of insulin, 10 g/mL of dexamethasone (DEX; Sigma-Aldrich, St. Louis, MO), and 0.5
mM of 3-isobutyl-1-methylxanthine (IBMX; Sigma-Aldrich, St. Louis, MO) or with
insulin released media containing with 10% FBS, 10 µg/mL of dexamethasone, and
0.5 mM of IBMX at Day 0. The induction media were replaced by DMEM containing
10% FBS and 10 µg/mL of insulin or insulin released media containing with 10% FBS
at Day 2. The cells were further incubated with DMEM containing with 10% FBS
at Day 4, Day 6 and Day 8. The full maturation into adipocytes was achieved at
Day 10. Differentiated adipocytes were rinsed in PBS for three times and then fixed
with 10% formaldehyde for 2 hours. The cells were washed three times and immersed
with 60% isopropanol for 2 min and then stained with 0.2% Oil Red O in 60% of
isopropanol for 10 min. The cells were washed three times and then imaged under
the microscope (Olympus, Tokyo, Japan) equipped with image recorder under × 20
lenses [88, 45].
3.2.13 In vitro permeation studies
Porcine cheek tissues were obtained from freshly sacrificed pigs (Silver Ridge Slaughter
House, Fredericksburg, VA) and transported to the lab within 2 hours. As previously
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reported [91], the mucosa tissues were excised and cut into approximately 2 cm2 and
frozen on aluminum foil at -20 ◦C. Before permeation studies, the frozen specimens
were equilibrated in PBS for 1 hour at room temperature to allow it completely
thawed. Excesses of connective and adipose tissues were trimmed off to obtain a
thickness of approximately 0.6 ± 0.1 mm. Buccal mucosa membrane was mounted
onto a vertical Franz diffusion cell (PermeGear, Hellertown, PA) with the epithelium
facing the donor chamber and the connective tissue facing the receiver chamber. The
Franz diffusion cell had a diffusion area of 0.785 cm2 with a donor chamber volume of
1 ml and a receiver chamber volume of 5 ml. The cell was placed in the water bath
at 37 ◦C.
The permeation experiments were carried out using PBS in the receiver cham-
ber and SSF in the donor chamber to mimic the in vivo physiological conditions. The
sIPN GIF was placed on top of the mucosa membrane and immersed with 1 ml of
SSF. At a given time point up to 4 hour, an aliquot of 1 ml from the receiver chamber
was collected via syringe and analyzed with ELISA. Free insulin dissolved in SSF was
used as a comparison. The permeability coefficient, P, was calculated as follows: P =
(dQ/dt)/AC, where dQ/dt is the steady-state slope of a cumulative flux curve, C is
the loading concentration of a permeant in the donor chamber, and A is the effective
cross-sectional area (0.785 cm2) available for diffusion.
3.2.14 Statistical analysis
All the data were expressed as means ± standard deviation (SD) and subjected to one
way analysis of variance (ANOVA) followed by Holm-Sidak method for significance
using SigmaPlot 12. A value of p < 0.05 was considered as statistically significant.
Statistical analysis data is provided in Appendix A (p120-141).
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3.3 Results and discussion
3.3.1 Optimization of sINP GF scaffold
In order to optimize the sIPN GF scaffold, the fabricated scaffolds were evaluated
in respect to two aspects: cytocompatibility and degradation rate. Polyethylene
glycol (PEG) is widely used in many applications from industrial manufacturing to
medicine due to its excellent biocompatible properties. PEG-DA, a derivative of
PEG, has also been widely used in biomedical applications, including hydrogels for
drug delivery, tissue engineering and wound healing due to its crosslinking property
[11, 27, 34, 40, 67]. However, a recent report indicated that the molecular weight
of PEG-DA could affect cell viability in other ways [49]. It has been shown that
PEG-DA (MW = 400) retained about 30% cell viability; while PEG-DA (MW =
3400) retained about 60% cell viability. The reason of this phenomenon could be the
different diffusion rate of PEG-DA into the cells. A higher diffusion rate can cause
more cell damage [49]. To conform these observations, the cytotoxicity of PEG-DA
and PEG was determined first on 3T3-L1 preadipocytes. As shown in Figure 3.2, PEG
monomers exhibited no or slightly cytotoxic effect on 3T3-L1 preadipocytes up to 174
µM; in contrast, PEG-DA significantly reduced the 3T3-L1 preadipocyte viability
at all the concentrations. The cytotoxic effect is most likely due to the functional
terminals of PEG-DA chain. Thus, it is important to utilize these functional groups
during the PEG-DA based photopolymerization process in order to make the material
cytocompatible.
With the understanding of cytotoxicity of PEG-DA monomers, the cytocom-
patibility of the different formulation of GF scaffolds were determined. Eosin Y is
a good photoinitiator candidate to crosslink polymers due to its excellent cytocom-
patibility as illustrated in Chapter 2. In this work, GF was crosslinked with a fixed
5% concentration of eosin Y and various concentrations from 0% to 20% of PEG-DA
to obtain different formulations of GF scaffolds. An elution method was applied to
test cytocompatibility of these fabricated GF scaffolds. As shown in Figure 3.3, GF
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Figure 3.2: Effects of PEG and PEG-DA on cell viability.
3T3-L1 preadipocytes were treated with different concentrations of PEG or
PEG-DA (0, 17.4, 87, 174, 696 and 1739 µM) for 2 days. The cell viabilities were
measured by WST-1 assay at the end of the treatment (n = 4). The bars are mean
± standard deviation.
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incubated with 5% eosin Y alone has no cytotoxic effect on 3T3-L1 preadipocytes. It
is consistent with the previous studies that eosin Y and GF are both cytocompatible
biomaterials [68, 2]. Interestingly, a significant cytotoxic effect was observed when
the concentration of PEG-DA was above 2%. It suggests that a significant propor-
tion of PEG-DA remains uncrosslinked after crosslinking process, which could be a
severely cytotoxic reagent to the cells. In respect of cytocompatilibity, the optimal
formulation of sIPN GF scaffold is GF crosslinked with 1% PEG-DA and 5% eosin Y
photoinitiator solution. The ratio of eosin Y photoinitiator solution to PEG-DA is 5:1
(v/w), and it is sufficient to crosslink PEG-DA, subsequently to reduce the cytotoxic
effect of PEG-DA monomers.
In order to determine the degradation rate, GF was crosslinked wtih a fixed
1% concentration of PEG-DA and various concentrations from 0% to 10% of eosin Y.
The scaffold degradation rate was investigated in the cell culture media. As shown in
Figure 3.4, the scaffold degradation rate was highly regulated by the concentration
of eosin Y. The detail observation is explained as follows. GF was rapidly dissolved
in the media within 30 min and totally lost its mass, and this is consistent with
our previous results [2]. As expected, 1% PEG-DA could not crosslink with itself
or GF in the absence of eosin Y in the crosslinking reaction, and GF/1% PEG-DA
had same degradation rate as GF. The result has also shown crosslinking reaction
was initiated in the presence of eosin Y and the crosslinking density was dependent
on the concentration of eosin Y. GF/1% PEG-DA with 2% eosin Y scaffold was
degraded within 60 min, but it could be potentially cytotoxic because the amount of
eosin Y might be insufficient to utilize the functional group of PEG-DA. In turn, this
scaffold could release the cytotoxic PEG-DA monomers into the cell culture media.
In contrast, GF/1% PEG-DA with 10% eosin Y could be highly cytocompatible due
to high crosslinking process and full utilization of functional groups of PEG-DA.
However, GF/1% PEG-DA with 10% eosin Y exhibited a slow degradation rate,
as the evidence showed that the mass of the scaffold was relatively stable during
120 min of incubation. This slow degradation rate could be insufficient to release
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Figure 3.3: Effects of different formulations of GF scaffolds on cell viability.
Different concentrations of PEG-DA were used to crosslink GF to achieve the
corresponding GF scaffolds. The elution method was used to test the
cytocompatibility of these scaffolds. These fabricated scaffolds were immersed into
the cell culture media for 2 hours. 3T3-L1 preadipocytes were then treated with
these individual elution media for 2 days. The cell viabilities were measured by
WST-1 assay at the end of the treatment (n = 4). The bars are mean ± standard
deviation.
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Figure 3.4: In vitro degradation of different fabricated GF scaffolds in the
cell culture media.
20 mg of each fabricated GF scaffold was immersed into 5 ml of the cell culture
media, and each sample was collected and weighed at the indicated time intervals (n
= 5). The bars are mean ± standard deviation.
insulin that is required for transbuccal mucosal delivery of insulin within the oral
cavity. The formulation of scaffold was optimized as GF crosslinked with 1% PEG-
DA and 5% eosin Y in respect to both cytocompatibility and degradation rate, and
this formulation of scaffold was referred to as sIPN GF in the rest of the work.
3.3.2 Mechanical properties of sINP GF scaffold
The mechanical properties were evaluated to confirm the crosslinking process of sIPN
GF. As shown in Figure 3.5A, the thickness of sIPN GF was significantly smaller
than the precursor GF. Most likely, the fibers fused together and crosslinked along or
between the side chains. Similar observation was obtained using DMPA photoinitiator
to crosslink GF with PEG-DA [2]. The mechanical properties, including the peak
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load, peak stress, modulus, energy at break and strain at break, were significantly
enhanced by 6.5, 7.9, 5.0, 17.1 and 2.4 fold in sIPN GF comparing with GF as shown
in Figure 3.5B-F. The results confirmed 1% PEG-DA and 5% eosin Y were able to
crosslink GF and increased its mechanical strength.
3.3.3 Morphology and fiber diameter of sIPN GF
The fiber morphology was evaluated by SEM to monitor the crosslinking process of
sIPN GF. As shown in Figure 3.6, the morphology of GF displayed a well intercon-
nective structure with fine continuous fibers and an undefined porosity, which was
consistent with our previous reports [2, 7]. Interestingly, the morphology of sIPN GF
showed that those continuous fibers of the scaffold were fused together and formed a
much smaller porosity structure. At notice, some fibers were merged as side-by-side
chains; while some fibers were crossed over the others. This observation supported
the results from the tensile study that the thickness of sIPN GF was smaller than
GF (Figure 3.5A). Such a small space between the crosslinked fibers was most likely
resulted from the short chain of PEG-DA. Consequently, a significant increase of fiber
diameter was observed in sIPN GF comparing to GF (Figure 3.7). It could also be
observed clearly that two fibers were immersed together into one in sIPN GF (Figure
3.6). These results further confirmed the successful crosslinking process of sIPN GF.
3.3.4 Structure stability of sIPN GF
The structure stability of sIPN GF was investigated based on the degradation rate
of sIPN GF in Figure 3.4, a set of SEM images of sIPN GF taken after 15, 30, 60
and 120 min of incubation in the cell culture media were compared to that of sIPN
GF itself. As shown in Figure 3.8, the pore size significantly increased along with
the incubation time. After 15 min of incubation, the fiber diameter was significantly
reduced, and many small diameter fibers were observed, comparing to sIPN GF.
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Figure 3.5: Mechanical properties of GF and sIPN GF.
The mechanical properties of GF (n = 18) and sIPN GF (n = 12) were evaluated by
a uniaxial tensile test. (A) Thickness of the scaffolds. (B) Peak load of the scaffolds.
(C) Peak stress of the scaffolds. (D) Modulus of the scaffolds. (E) Energy at break
of the scaffolds. (F) Strain at break of the scaffolds. The bars are mean ± standard
deviation.
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Figure 3.6: Morphology of GF and sIPN GF.
The scaffold morphology of (A) GF and (B) sIPN GF was observed by SEM (n =
3). Bars: 50 µm.
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Figure 3.7: Fiber diameter of GF and sIPN GF.
Fiber diameters of GF and sIPN GF (n = 60) were measured by NIH ImageJ
software from the SEM images. The bars are mean ± standard deviation.
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Figure 3.8: Morphology of sIPN GF after degradation.
20 mg of sIPN GF was immersed into 5 ml of cell culture media, and each sample
was collected at the indicated time intervals of (A) 0 min, (B) 15 min, (C) 30 min,
(D) 60 min and (E) 120 min. The remaining scaffold morphology was observed by
SEM (n = 3). Bars: 50 µm.
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After 30 min of incubation, most of the small diameter fibers were disappeared in
the scaffold structure, while the structure remained three-dimensional. Most likely,
these small diameter fibers were more easily degraded and dissolved into the media
than the large diameter fibers. After 60 min of incubation, all the small diameter
fibers were dissolved in the scaffold and the fiber diameter became larger. It was
likely caused by the fact that some of the fibers were fused together to maintain the
structure in the media. Lastly, after 120 min of incubation, the scaffold lost its defined
three-dimensional structure and became separated pieces of polymers. These results
were consistent with the degradation assay shown in Figure 3.4 that only 20% mass
remained, and the scaffold lost its whole integrity after 120 min of incubation.
3.3.5 Insulin release kinetics of sIPN GIF
The fabricated sIPN GIF using optimized formulation described earlier was assessed
to investigate the insulin release kinetics in response to the cell culture media. Cumu-
lative insulin release studies were performed using ELISA. As shown in Figure 3.9, a
fast insulin release was achieved from GIF that almost all insulin was released within
15 min. GIF, same as GF, can be instantaneously degraded and dissolved in the cell
culture media within 30 min (Figure 3.4), which interprets all the insulin fabricated
within GIF was released into the media within 30 min. The feeding ratio of insulin to
gelatin was 5:1 (mg/g) according the formulation; and the resultant ratio of insulin to
GIF was 3.25:1 (mg/g). Indeed, the loading efficiency of insulin after electrospinning
was about 65%.
In contrast, a slower insulin release was observed from sIPN GIF within a 4-
hour window of incubation in the cell culture media. These results were also consistent
with the degradation rate (Figure 3.4) and the porosity of sIPN GF (Figure 3.8)
described above. Nearly 20% of sIPN GIF mass has been degraded from the scaffold
in the initial degradation at 15 min. The increase in porosity allows water molecules
to come inside of scaffold, dissolve the gelatin fiber, and absorb insulin molecules. As
shown in Figure 3.10, an initial burst release of insulin was observed about 70% of
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Figure 3.9: In vitro insulin release kinetics.
20 mg of GIF or sIPN GIF was immersed into 5 ml of cell culture media, and 25 µl
of release media was collected at the indicated time intervals. ELISA was employed
to evaluate the insulin concentration from the release media. The bars are mean ±
standard deviation.
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Figure 3.10: In vitro insulin release kinetics of sIPN GIF.
The insulin release kinetics of sIPN GIF was normalized by taking into account of
100% of insulin released from GIF within 30 min of incubation from Figure 3.10.
The bars are mean ± standard deviation.
loading insulin from sIPN GIF within 15 min of incubation. The release rate of insulin
was then reduced until 100% loading insulin was released from sIPN GIF, i.e., about
4 hours. This formulation of sIPN GF provides a fast release at the initial stage and a
sustained slow release at the late stage, which can be benefit in oral mucosal delivery
of insulin. Generally, an increase of both PEG-DA and eosin Y concentrations during
the crosslinking process could help to enhance the scaffold stability and subsequently
modulate the drug release kinetics. It is also important to keep the same ratio of
PEG-DA to eosin Y as 1:5 (w/v) in order to maintain its biocompatibility.
3.3.6 Bioactivity of the insulin released from sIPN GIF
The bioactivity of insulin within sIPN GIF after electrospinning was examined in
this work. It has been reported that proteins can be co-electrospun with polymers
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without causing denature of the neutral protein. For instance, purified adipose tissue-
derived extracellular matrix (At-ECM) can be electrospun alone or co-electrospun
with PDO. The resultant scaffold forms a basement membrane-rich tissue engineering
matrix that is capable of supporting stem cells [26]. Insulin is known as a peptide
hormone that can bind to the extracellular portion of the alpha subunits of the
insulin receptor and in turn trigger the signaling transduction within cells. Once
the binding occurs, it causes a conformational change of the insulin receptor and
then activates the kinase domain on the intracellular portion of the beta subunits.
The activated kinase domain autophosphorylates IRS-1 protein, which subsequently
activates phosphoinositol 3 kinase (PI3K). PI3K then catalyzes the reaction of PIP2 to
PIP3, which can phosphorylate protein kinase B (PKB). PKB is also known as AKT
that plays a key role in glucose metabolism, apoptosis, cell proliferation, transcription
and cell migration [31, 80]. In this work, the phosphorylation of AKT was used
as a marker to evaluate the bioactivity of released insulin. As shown in Figure 9,
free insulin induced AKT phosphorylation as expected; while the release media from
GIF also significantly induced AKT phosphorylation. It was also noticed that no
significant change of p-AKT was observed in the release media from GF and sIPN
GF. These results suggest that the insulin remains bioactive after electrospinning.
In the next step, sIPN GIF was examined for the ability to release bioactive
insulin. As shown in Figure 3.12, phosphorylation of AKT displayed an incubation
time-dependent manner of sIPN GIF. It was noticed that sIPN GIF in 15 min of
incubation released a portion of insulin that was able to trigger AKT phosphorylation
but not as high as that of 60 min of incubation. Together with insulin release kinetics
(Figure 3.9), it supports that insulin bioactivity is close related to its release kinetics
of sIPN GIF.
The differentiation of 3T3-L1 preadipocytes was also evaluated in regard to
the insulin released from sIPN GIF. As expected, no adipocyte differentiation was
observed in sIPN GF and negative control treatment groups; whereas a significant
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Figure 3.11: Western blot analysis of intracellular AKT activity in re-
sponding to the fabricated GF scaffolds.
20 mg of each fabricated GF scaffold (GF, sIPN GF and GIF) was immersed into 5
ml of cell culture media for 30 min. 3T3-L1 preadipocytes were then treated with
these individual elution media or free insulin for 10 min. The intracellular
phospho-AKT (p-AKT) and total AKT levels were analyzed by Western blot
analysis (A). Each positive band was normalized to β-actin and was quantified by
NIH ImageJ (B). The data represents typical one of three experiments. The bars
are mean ± standard deviation.
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Figure 3.12: Western blot analysis of intracellular AKT activity in re-
sponding to sIPN GIF.
20 mg of sIPN GIF was immersed into 5 ml of cell culture media for 15 min, 30 min,
60 min and 120 min; while 20 mg of GIF was immersed into 5 ml of cell culture
media for 30 min. 3T3-L1 preadipocytes were then treated with these individual
elution media for 10 min. The intracellular phospho-AKT (p-AKT) and total AKT
levels were analyzed by Western blot analysis (A). Each positive band was
normalized to β-actin and was quantified by NIH ImageJ (B). The data represents
typical one of three experiments. The bars are mean ± standard deviation.
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Figure 3.13: Oil red O staining of 3T3-L1 preadipocytes in responding to
sIPN GIF.
20 mg of sIPN GIF or sIPN GF was immersed into 5 ml of cell culture media for
120 min. 3T3-L1 preadipocytes were then treated with these individual elution
media or free insulin along with DEX and IBMX for 2 days. After additional 8 days
incubation, the cells are fixed and total intracellular neutral lipids were stained with
Oil Red O. (A) NA, (B) sIPN GF, (C) sIPN GIF and (D) free insulin. Arrows
indicate stained lipid inclusions.
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adipocyte differentiation was achieved in sIPN GIF and free insulin groups as shown
in Figure 3.13. It confirmed from the biological aspect that the insulin can be co-
electrospun with gelatin and remain its bioactivity. The insulin release kinetics can
be modulated by applying crosslink reaction to GIF.
3.3.7 Diffusion rate of insulin from sIPN GIF across porcine
buccal mucosa
Hydrophilic molecules across buccal membrane is generally via a paracellular route
that is driven by passive diffusion. Due to its good biodegradability, moderate stiff-
ness and satisfactory tissue adhesiveness properties [73, 92], gelatin/PEG sIPN are
investigated to deliver biomacromolecules and release them in a controlled release
manner [10]. Firstly, it has been reported that mucoadhesive hydrogels can open up
the tight junctions of the epithelium by dehydrating the cells as they swell, which in
turn increases the permeability of the loaded drug [60]. Secondly, a direct contact
of gels and mucosa could give a high localization of drug onto the mucosal surface,
which in turn facilitates drug buccal transport. Based on the understanding of these
mechanisms, a gelatin/PEG sIPN was developed to enhance transbuccal delivery of
dendritic nanoparticles through an in vitro model [91]. Although PEG-only hydro-
gel has shown a slightly higher degree of enhanced transbuccal delivery of dendritic
nanoparticles, it is a lack of mucosal adhesiveness property that makes PEG-only
hydrogel unsuitable platform for buccal administration formulations [91].
In this work, the peameability of insulin from sIPN GIF was evaluated via a
vertical Franz diffusion cell with a porcine epithelium membrane. First, the degrada-
tion rate of sIPN GF was determined in SSF, which simulates oral saliva condition.
As shown in Figure 3.14, the degradation rate of sIPN GF in SSF is similar to that
in the cell culture media (Figure 3.4). However, the composition of in vivo saliva
remains different as that of in vitro SSF. The saliva contains the enzymes secreted
from the salivary glands, such as amylase and lipase. These enzymes may have the
potential to accelerate the degradation of sIPN GF. Second, the diffusion rates of in-
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Figure 3.14: In vitro degradation of sIPN GF in SSF.
20 mg of sIPN GF was immersed into 5 ml of SSF, and each sample was collected
and weighed at the indicated time intervals (n = 8). The bars are mean ± standard
deviation.
sulin from sIPN GF and free insulin were determined through porcine buccal mucosa.
As shown in Figure 3.15, the positive control benzylamine displayed a high transport
rate, consistent with the previous report [2]. As shown in Figure 3.16, the cumulative
flux curves of both sIPN GIF and free insulin exhibited in a linear range during the
first 2 hours, indicating a steady state transport of the insulin via the paracellular
route. Permeability was then calculated from the linear range of the cumulative flux
curves. The permeability of insulin from sIPN GIF was determined to be 1.00 ×
10−7 cm/s; whereas the permeability of free insulin was 7.67 × 10−8 cm/s. A 30%
enhancement of permeability was achieved by sIPN GIF.
Although the enhanced permeability of insulin from sIPN GIF has been shown,
some challenges and future directions remain as follow. (1) It would be critical if the
mucosal endothelial cells remain as intact and tight conjunct after freeze-thaw cycle.
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Figure 3.15: Transport of insulin or benzylamine across porcine buccal
mucosa.
At the indicated time intervals, the transbuccal mucosal insulin from sIPN GIF or
free insulin was determined by ELISA, and benzylamine was determined by UV-Vis
(n = 3). The bars are mean standard deviation.
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Figure 3.16: Transport of insulin across porcine buccal mucosa.
At the indicated time intervals, the transbuccal mucosal insulin from sIPN GIF or
free insulin was determined by ELISA (n = 3). The bars are mean standard
deviation.
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(2) It is of interest to investigate whether the mucosal endothelial cells can uptake
insulin during the diffusion process. (3) The continued work could be determination of
the mucosal adhesion properties of sIPN GF. (4) Future studies include optimization
of sIPN GIF loaded with permeation enhancer, such as sodium glycodeoxycholate
(NaGDC), since it has been reported that bile salts hold a great potential to enhance
transbuccal permeability of drug [91]. (5) The studies may also include the testing
of pharmacokinetics and pharmacodynamics (PK/PD) of sIPN GIF following buccal
administration in pig.
3.4 Conclusions
In this work, sIPN GF was fabricated by crosslinking GF with PEG-DA via pho-
topolymerization process. The optimal ratio of PEG-DA to eosin Y is 1:5 (w/v) with
respect to biocompatibility, degradation rate and structure stability. This formulation
of sIPN GF exhibits high biocompatibility and possesses mucoadhesion property. It
could be a good candidate for buccal mucosal delivery of insulin. The insulin release
kinetics was modulated to achieve a desired bioactivity. Based on our preliminary
in vitro investigation, sIPN GIF significantly enhanced transbuccal diffusion rate of
insulin through the porcine mucosal membrane. The in vivo mucosal administration
of insulin on sIPN GIF will be evaluated in our future studies.
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Chapter 4
General conclusions and future
directions
4.1 General conclusions
To explore the potential application of sIPN GIF in transbuccal mucosal delivery of
insulin, a general review was provided on adhesion property and release kinetics from
polymeric insulin delivery systems (Chapter 3). Several factors may impact insulin
transbuccal mucosal behaviors from polymeric matrices, including matrix factors, so-
lute factors and experimental conditions. Among these factors, material degradation
rate and insulin release kinetics and permeability are the key driving forces. With a
better understanding of buccal mucosal transport mechanism, our objective was to
optimize sIPN GF with the most appropriate biological and physical properties for
transbuccal mucosal delivery of insulin.
sIPN GF is commonly formed by crosslinking GF with PEG-DA. This crosslink-
ing process is driven by photopolymerization. Photoinitiators play an important role
within photopolymerization. Photoinitiators can be dissociated into high-energy free
radicals by exposure to specific wavelengths of light. Subsequently, these free radicals
induce the polymerization of a macromer solution. However, these high-energy free
radicals are toxic molecules that can induce oxidative stress to the cells. Chapter 2
illustrated that eosin Y was less cytotoxic than Irgacure 2959 and DMPA, and eosin Y
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possessed minimal effect on intracellular AKT signaling transduction up to 25 µl/ml.
It has been shown that the cytocompatibility of photoinitiators was closely correlated
to the intracellular AKT signaling transduction within the cells. Free radicals can
directly or indirectly interact with cells, inhibit the intracellular AKT signaling trans-
duction and decrease cell viability. In summary, eosin Y can serve as a photoinitiator
for the photopolymerization of sIPN GF, by owing its high cytocompatible property.
The amount ratio of eosin Y to GF and PEG-DA needs to be optimized in order to
minimize the cytotoxic effect induced by free radicals.
PEG-DA and PEG are widely used in biomedical applications, including drug
delivery, tissue engineering and wound healing. A smaller molecular weight of PEG-
DA has a higher diffusion rate into the cells, which can cause more damage of the cells.
It has been shown the PEG-DA enhanced cytotoxic effect to the cells comparing to
its precursor PEG (Chapter 3). This increase of toxicity is most likely caused by the
acrylate modification at the terminals of PEG monomer chains. It becomes important
to optimize the amount of both PEG-DA and eosin Y in the formulation of sIPN GF
in respect to cytocompatibility.
Another important factor for transbuccal mucosal delivery of insulin is the
degradation rate of polymeric matrices. Photopolymerization can physically enhance
the entanglement of polymer chains in a three-dimensional structure. By controlling
the crosslinking density, polymeric matrices can achieve a desired degradation rate.
In respect to both cytocompatibility and degradation rate of the scaffold, the
formulation of sIPN GF was optimized by crosslinking GF with 1% PEG-DA and
5% eosin Y (Chapter 3). The optimized sIPN GF possessed no cytotoxic effect and
exhibited a moderate degradation rate within 4-hour window (Chapter 3).
This optimized formulation was used to fabricate sIPN GIF for transbuccal
mucosal delivery of insulin. Several important factors of sIPN GIF have been deter-
mined. 1) sIPN GIF achieved a 65% loading efficiency of insulin after electrospinning
and crosslinking. 2) The insulin release kinetics was modulated after crosslinking
in sIPN GIF. 3) The insulin released from sIPN GIF remained bioactive to activate
intracellular AKT signaling transduction and differentiate 3T3-L1 preadipocytes. 4)
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The permeability of the insulin released from sIPN GIF was on the order of 10−7
cm/s using a vertical Franz diffusion cell system mounted with porcine buccal mu-
cosa (Chapter 3).
Insulin is commercially available in a concentration of 100 or 500 units/ml,
which is designated U-100 and U-500, respectively. U-500 is only used in rare cases
of insulin resistance when the patient requires extremely large doses of insulin [5].
The bolus dose for food coverage is prescribed as an insulin to carbohydrate ratio.
The insulin to carbohydrate ratio represents the amounts of carbohydrate are covered
by 1 unit of insulin. Here, 1 unit of insulin is equivalent to about 36 µg of insulin.
Generally, 1 unit of insulin will dispose of 12-15 g of carbohydrate. This range can
vary from 6-30 g or more of carbohydrate depending on the insulin sensitivity, which
can vary according to the time of day, from person to person, and is affected by
physical activity and stress. According to the formulation of sIPN GIF, 65 µg of
insulin was incorporated within 20 mg of sIPN GIF, which is equal to 1.8 units of
insulin. In order to achieve a common unit of insulin (10 units) taken each time,
about 110 mg of sIPN GIF is required. The size of 110 of sIPN GIF is within 5 cm2
range, which is a reasonable size of pill for oral mucosal administration. These results
suggest that sIPN GIF holds a great potential for transbuccal mucosal delivery of
insulin.
4.2 Future directions
The accomplishments from this work can inspire the further suggestions for continuing
this work.
4.2.1 Evaluation of sIPN GIF in in vivo model
Porcine buccal tissues were utilized for studing the permeability of insulin from sIPN
GIF in this work. Porcine buccal mucosa has been well established to be the closest
to human mucosa. In vivo evaluation of sIPN FIG in transbuccal mucosal delivery
of insulin will be conducted in pig in our future investigations. The bioavailability of
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insulin will be studied by pharmacokinetics and pharmacodynamics. This in vivo pig
study can provide direct evidence to evaluate the buccal mucosal permeability and
biocompatibility from sIPN GIF formulation.
4.2.2 Potential application of sIPN GF for wound healing
The outcome of these studies demonstrated the potential of developing such natu-
ral/synthetic hybrid materials into dermal equivalence. As a natural protein, insulin
was successfully co-electrospun with gelatin in this work. The loading efficacy of in-
sulin was about 65%, and the insulin remained bioactive after electrospinning and
crosslinking process. These results inspire our great interests to further explore sIPN
GF in the biomedical applications, such as wound healing.
Wounds can extend partially through the dermis and have capabilities to re-
generate. However, the body cannot heal deep dermal injuries adequately. In some
cases, such as full thickness burns or deep ulcers, there are no remaining sources of
cells for regeneration except peripheral cells from the wound. Therefore, it takes a
long time to complete re-epithelialization, and it is complicated by scarring of the
base [18].
Matrix metalloproteinases, referred to as MMPs, play a major role in wound
healing. MMPs can degrade all components of the extracellular matrix as well as
regulate vascularization and inflammatory response [61, 53, 30]. It has been reported
that MMP-2 regulates the formation of a glial scar and white matter sparing and/or
axonal plasticity [30]. MMP-2 in turn can facilitate wound healing and promote
functional recovery after spinal cord injury [61]. Thus, MMP-2 is exploited as a
therapeutic target in the treatment of wound healing.
Electrospun nano- or macro-fiber scaffolds hold a great potential in the treat-
ment of dermal wounds through layered application [33, 36, 18, 16]. It is of interest
to explore sIPN GF incorporating with MMP-2 (sIPN GF/MMP-2) in the treatment
of wound healing. The formulation of sIPN GF is required to be optimized in respect
to the degradation rate. In the treatment of wound healing, the ratio of PEG-DA to
eosin Y will be further modulated in order to achieve a slow degradation rate of the
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sIPN GF and a slow release kinetics of MMP-2. It is important to investigate the
efficacy of sIPN GF/MMP-2 in modulating host inflammatory response and healing
outcome in a disease-relevant animal model, such as db/db mice with full thickness
wounds.
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Appendix A
Statistical analysis of the
experimental data
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Figure 2.1 eosin Y
Failed (P < 0.050)
Passed (P = 0.094)
Group Name N Missing Mean Std Dev SEM
0d 3 0 100 6.811 3.932
NA 1d 3 0 144.147 13.87 8.008
2.5ul/ml 1d 3 0 148.997 4.013 2.317
5ul/ml 1d 3 0 128.93 3.29 1.899
10ul/ml 1d 3 0 141.472 8.704 5.025
25ul/ml 1d 3 0 72.408 10.81 6.241
NA 2d 3 0 206.02 53.979 31.165
2.5ul/ml 2d 3 0 202.174 39.727 22.937
5ul/ml 2d 3 0 139.13 18.966 10.95
10ul/ml 2d 3 0 121.906 24.643 14.228
25ul/ml 2d 3 0 18.896 2.027 1.171
NA 3d 3 0 259.532 18.813 10.862
2.5ul/ml 3d 3 0 239.632 32.436 18.727
5ul/ml 3d 3 0 187.291 20.331 11.738
10ul/ml 3d 3 0 91.806 18.724 10.81
25ul/ml 3d 3 0 4.849 1.613 0.931
NA 4d 3 0 323.077 31.883 18.408
2.5ul/ml 4d 3 0 290.468 28.254 16.313
5ul/ml 4d 3 0 143.144 18.208 10.513
10ul/ml 4d 3 0 38.127 7.287 4.207
25ul/ml 4d 3 0 5.017 0.869 0.502
Source of Variation  DF  SS  MS   F   P 
Between Groups 20 483604.7 24180.23 49.327 <0.001
Residual 42 20588.36 490.199
Total 62 504193
Comparisons for factor: 
Comparison Diff of Me t P P<0.050
Data source: Data 1 in Fig.1 eosinY
One Way Analysis of Variance
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
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NA 4d vs. 25ul/ml 3d 318.227 17.603 <0.001 Yes
NA 4d vs. 25ul/ml 4d 318.06 17.594 <0.001 Yes
NA 4d vs. 25ul/ml 2d 304.181 16.826 <0.001 Yes
2.5ul/ml 4d vs. 25ul/ml 3d 285.619 15.8 <0.001 Yes
2.5ul/ml 4d vs. 25ul/ml 4d 285.452 15.79 <0.001 Yes
NA 4d vs. 10ul/ml 4d 284.95 15.763 <0.001 Yes
2.5ul/ml 4d vs. 25ul/ml 2d 271.572 15.023 <0.001 Yes
NA 3d vs. 25ul/ml 3d 254.682 14.088 <0.001 Yes
NA 3d vs. 25ul/ml 4d 254.515 14.079 <0.001 Yes
2.5ul/ml 4d vs. 10ul/ml 4d 252.341 13.959 <0.001 Yes
NA 4d vs. 25ul/ml 1d 250.669 13.866 <0.001 Yes
NA 3d vs. 25ul/ml 2d 240.635 13.311 <0.001 Yes
2.5ul/ml 3d vs. 25ul/ml 3d 234.783 12.987 <0.001 Yes
2.5ul/ml 3d vs. 25ul/ml 4d 234.615 12.978 <0.001 Yes
NA 4d vs. 10ul/ml 3d 231.271 12.793 <0.001 Yes
NA 4d vs. 0d 223.077 12.34 <0.001 Yes
NA 3d vs. 10ul/ml 4d 221.405 12.247 <0.001 Yes
2.5ul/ml 3d vs. 25ul/ml 2d 220.736 12.21 <0.001 Yes
2.5ul/ml 4d vs. 25ul/ml 1d 218.06 12.062 <0.001 Yes
2.5ul/ml 3d vs. 10ul/ml 4d 201.505 11.147 <0.001 Yes
NA 4d vs. 10ul/ml 2d 201.171 11.128 <0.001 Yes
NA 2d vs. 25ul/ml 3d 201.171 11.128 <0.001 Yes
NA 2d vs. 25ul/ml 4d 201.003 11.119 <0.001 Yes
2.5ul/ml 4d vs. 10ul/ml 3d 198.662 10.989 <0.001 Yes
2.5ul/ml 2d vs. 25ul/ml 3d 197.324 10.915 <0.001 Yes
2.5ul/ml 2d vs. 25ul/ml 4d 197.157 10.906 <0.001 Yes
NA 4d vs. 5ul/ml 1d 194.147 10.74 <0.001 Yes
2.5ul/ml 4d vs. 0d 190.468 10.536 <0.001 Yes
NA 3d vs. 25ul/ml 1d 187.124 10.351 <0.001 Yes
NA 2d vs. 25ul/ml 2d 187.124 10.351 <0.001 Yes
NA 4d vs. 5ul/ml 2d 183.946 10.175 <0.001 Yes
2.5ul/ml 2d vs. 25ul/ml 2d 183.278 10.138 <0.001 Yes
5ul/ml 3d vs. 25ul/ml 3d 182.441 10.092 <0.001 Yes
5ul/ml 3d vs. 25ul/ml 4d 182.274 10.083 <0.001 Yes
NA 4d vs. 10ul/ml 1d 181.605 10.046 <0.001 Yes
NA 4d vs. 5ul/ml 4d 179.933 9.953 <0.001 Yes
NA 4d vs. NA 1d 178.93 9.898 <0.001 Yes
NA 4d vs. 2.5ul/ml 1d 174.08 9.63 <0.001 Yes
2.5ul/ml 4d vs. 10ul/ml 2d 168.562 9.324 <0.001 Yes
5ul/ml 3d vs. 25ul/ml 2d 168.395 9.315 <0.001 Yes
NA 2d vs. 10ul/ml 4d 167.893 9.287 <0.001 Yes
NA 3d vs. 10ul/ml 3d 167.726 9.278 <0.001 Yes
2.5ul/ml 3d vs. 25ul/ml 1d 167.224 9.25 <0.001 Yes
2.5ul/ml 2d vs. 10ul/ml 4d 164.047 9.075 <0.001 Yes
2.5ul/ml 4d vs. 5ul/ml 1d 161.538 8.936 <0.001 Yes
NA 3d vs. 0d 159.532 8.825 <0.001 Yes
2.5ul/ml 4d vs. 5ul/ml 2d 151.338 8.372 <0.001 Yes
5ul/ml 3d vs. 10ul/ml 4d 149.164 8.251 <0.001 Yes
2.5ul/ml 4d vs. 10ul/ml 1d 148.997 8.242 <0.001 Yes
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2.5ul/ml 3d vs. 10ul/ml 3d 147.826 8.177 <0.001 Yes
2.5ul/ml 4d vs. 5ul/ml 4d 147.324 8.15 <0.001 Yes
2.5ul/ml 4d vs. NA 1d 146.321 8.094 <0.001 Yes
2.5ul/ml 1d vs. 25ul/ml 3d 144.147 7.974 <0.001 Yes
2.5ul/ml 1d vs. 25ul/ml 4d 143.98 7.965 <0.001 Yes
2.5ul/ml 4d vs. 2.5ul/ml 1d 141.472 7.826 <0.001 Yes
2.5ul/ml 3d vs. 0d 139.632 7.724 <0.001 Yes
NA 1d vs. 25ul/ml 3d 139.298 7.706 <0.001 Yes
NA 1d vs. 25ul/ml 4d 139.13 7.696 <0.001 Yes
5ul/ml 4d vs. 25ul/ml 3d 138.294 7.65 <0.001 Yes
5ul/ml 4d vs. 25ul/ml 4d 138.127 7.641 <0.001 Yes
NA 3d vs. 10ul/ml 2d 137.625 7.613 <0.001 Yes
10ul/ml 1d vs. 25ul/ml 3d 136.622 7.558 <0.001 Yes
10ul/ml 1d vs. 25ul/ml 4d 136.455 7.548 <0.001 Yes
NA 4d vs. 5ul/ml 3d 135.786 7.511 <0.001 Yes
5ul/ml 2d vs. 25ul/ml 3d 134.281 7.428 <0.001 Yes
5ul/ml 2d vs. 25ul/ml 4d 134.114 7.419 <0.001 Yes
NA 2d vs. 25ul/ml 1d 133.612 7.391 <0.001 Yes
NA 3d vs. 5ul/ml 1d 130.602 7.225 <0.001 Yes
2.5ul/ml 1d vs. 25ul/ml 2d 130.1 7.197 <0.001 Yes
2.5ul/ml 2d vs. 25ul/ml 1d 129.766 7.178 <0.001 Yes
NA 1d vs. 25ul/ml 2d 125.251 6.929 <0.001 Yes
5ul/ml 4d vs. 25ul/ml 2d 124.247 6.873 <0.001 Yes
5ul/ml 1d vs. 25ul/ml 3d 124.08 6.864 <0.001 Yes
5ul/ml 1d vs. 25ul/ml 4d 123.913 6.855 <0.001 Yes
10ul/ml 1d vs. 25ul/ml 2d 122.575 6.781 <0.001 Yes
NA 4d vs. 2.5ul/ml 2d 120.903 6.688 <0.001 Yes
NA 3d vs. 5ul/ml 2d 120.401 6.66 <0.001 Yes
5ul/ml 2d vs. 25ul/ml 2d 120.234 6.651 <0.001 Yes
NA 3d vs. 10ul/ml 1d 118.06 6.531 <0.001 Yes
2.5ul/ml 3d vs. 10ul/ml 2d 117.726 6.512 <0.001 Yes
NA 4d vs. NA 2d 117.057 6.475 <0.001 Yes
10ul/ml 2d vs. 25ul/ml 3d 117.057 6.475 <0.001 Yes
10ul/ml 2d vs. 25ul/ml 4d 116.89 6.466 <0.001 Yes
NA 3d vs. 5ul/ml 4d 116.388 6.438 <0.001 Yes
NA 3d vs. NA 1d 115.385 6.383 <0.001 Yes
5ul/ml 3d vs. 25ul/ml 1d 114.883 6.355 <0.001 Yes
NA 2d vs. 10ul/ml 3d 114.214 6.318 <0.001 Yes
2.5ul/ml 1d vs. 10ul/ml 4d 110.87 6.133 <0.001 Yes
2.5ul/ml 3d vs. 5ul/ml 1d 110.702 6.124 <0.001 Yes
NA 3d vs. 2.5ul/ml 1d 110.535 6.114 <0.001 Yes
2.5ul/ml 2d vs. 10ul/ml 3d 110.368 6.105 <0.001 Yes
5ul/ml 1d vs. 25ul/ml 2d 110.033 6.087 <0.001 Yes
NA 1d vs. 10ul/ml 4d 106.02 5.865 <0.001 Yes
NA 2d vs. 0d 106.02 5.865 <0.001 Yes
5ul/ml 4d vs. 10ul/ml 4d 105.017 5.809 <0.001 Yes
10ul/ml 1d vs. 10ul/ml 4d 103.344 5.717 <0.001 Yes
2.5ul/ml 4d vs. 5ul/ml 3d 103.177 5.707 <0.001 Yes
10ul/ml 2d vs. 25ul/ml 2d 103.01 5.698 <0.001 Yes
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2.5ul/ml 2d vs. 0d 102.174 5.652 <0.001 Yes
5ul/ml 2d vs. 10ul/ml 4d 101.003 5.587 <0.001 Yes
2.5ul/ml 3d vs. 5ul/ml 2d 100.502 5.559 <0.001 Yes
2.5ul/ml 3d vs. 10ul/ml 1d 98.161 5.43 <0.001 Yes
2.5ul/ml 3d vs. 5ul/ml 4d 96.488 5.337 <0.001 Yes
5ul/ml 3d vs. 10ul/ml 3d 95.485 5.282 <0.001 Yes
2.5ul/ml 3d vs. NA 1d 95.485 5.282 <0.001 Yes
0d vs. 25ul/ml 3d 95.151 5.263 <0.001 Yes
0d vs. 25ul/ml 4d 94.983 5.254 <0.001 Yes
5ul/ml 1d vs. 10ul/ml 4d 90.803 5.023 0.001 Yes
2.5ul/ml 3d vs. 2.5ul/ml 1d 90.635 5.014 0.001 Yes
2.5ul/ml 4d vs. 2.5ul/ml 2d 88.294 4.884 0.002 Yes
5ul/ml 3d vs. 0d 87.291 4.829 0.002 Yes
10ul/ml 3d vs. 25ul/ml 3d 86.957 4.81 0.002 Yes
10ul/ml 3d vs. 25ul/ml 4d 86.789 4.801 0.002 Yes
2.5ul/ml 4d vs. NA 2d 84.448 4.671 0.003 Yes
NA 2d vs. 10ul/ml 2d 84.114 4.653 0.003 Yes
10ul/ml 2d vs. 10ul/ml 4d 83.779 4.634 0.003 Yes
NA 4d vs. 2.5ul/ml 3d 83.445 4.616 0.003 Yes
0d vs. 25ul/ml 2d 81.104 4.486 0.005 Yes
2.5ul/ml 2d vs. 10ul/ml 2d 80.268 4.44 0.006 Yes
NA 2d vs. 5ul/ml 1d 77.09 4.264 0.01 Yes
2.5ul/ml 1d vs. 25ul/ml 1d 76.589 4.237 0.011 Yes
2.5ul/ml 2d vs. 5ul/ml 1d 73.244 4.052 0.019 Yes
10ul/ml 3d vs. 25ul/ml 2d 72.91 4.033 0.02 Yes
NA 3d vs. 5ul/ml 3d 72.241 3.996 0.022 Yes
NA 1d vs. 25ul/ml 1d 71.739 3.968 0.024 Yes
5ul/ml 4d vs. 25ul/ml 1d 70.736 3.913 0.027 Yes
10ul/ml 1d vs. 25ul/ml 1d 69.064 3.82 0.036 Yes
25ul/ml 1d vs. 25ul/ml 3d 67.559 3.737 0.045 Yes
25ul/ml 1d vs. 25ul/ml 4d 67.391 3.728 0.046 Yes
NA 2d vs. 5ul/ml 2d 66.89 3.7 0.049 Yes
5ul/ml 2d vs. 25ul/ml 1d 66.722 3.691 0.05 Yes
5ul/ml 3d vs. 10ul/ml 2d 65.385 3.617 0.061 No
NA 2d vs. 10ul/ml 1d 64.548 3.571 0.068 No
NA 4d vs. NA 3d 63.545 3.515 0.079 No
2.5ul/ml 2d vs. 5ul/ml 2d 63.043 3.487 0.084 No
NA 2d vs. 5ul/ml 4d 62.876 3.478 0.085 No
NA 2d vs. NA 1d 61.873 3.423 0.098 No
0d vs. 10ul/ml 4d 61.873 3.423 0.097 No
2.5ul/ml 2d vs. 10ul/ml 1d 60.702 3.358 0.114 No
2.5ul/ml 2d vs. 5ul/ml 4d 59.03 3.265 0.144 No
5ul/ml 3d vs. 5ul/ml 1d 58.361 3.228 0.156 No
2.5ul/ml 2d vs. NA 1d 58.027 3.21 0.161 No
NA 3d vs. 2.5ul/ml 2d 57.358 3.173 0.175 No
2.5ul/ml 1d vs. 10ul/ml 3d 57.191 3.164 0.177 No
NA 2d vs. 2.5ul/ml 1d 57.023 3.154 0.178 No
5ul/ml 1d vs. 25ul/ml 1d 56.522 3.127 0.188 No
10ul/ml 3d vs. 10ul/ml 4d 53.679 2.969 0.27 No
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NA 3d vs. NA 2d 53.512 2.96 0.273 No
25ul/ml 1d vs. 25ul/ml 2d 53.512 2.96 0.269 No
2.5ul/ml 2d vs. 2.5ul/ml 1d 53.177 2.942 0.277 No
NA 1d vs. 10ul/ml 3d 52.341 2.895 0.303 No
2.5ul/ml 3d vs. 5ul/ml 3d 52.341 2.895 0.298 No
5ul/ml 4d vs. 10ul/ml 3d 51.338 2.84 0.332 No
2.5ul/ml 4d vs. 2.5ul/ml 3d 50.836 2.812 0.347 No
10ul/ml 1d vs. 10ul/ml 3d 49.666 2.747 0.391 No
10ul/ml 2d vs. 25ul/ml 1d 49.498 2.738 0.393 No
2.5ul/ml 1d vs. 0d 48.997 2.71 0.409 No
5ul/ml 3d vs. 5ul/ml 2d 48.161 2.664 0.441 No
5ul/ml 2d vs. 10ul/ml 3d 47.324 2.618 0.473 No
5ul/ml 3d vs. 10ul/ml 1d 45.819 2.535 0.539 No
5ul/ml 3d vs. 5ul/ml 4d 44.147 2.442 0.615 No
NA 1d vs. 0d 44.147 2.442 0.607 No
5ul/ml 3d vs. NA 1d 43.144 2.387 0.649 No
5ul/ml 4d vs. 0d 43.144 2.387 0.641 No
10ul/ml 1d vs. 0d 41.472 2.294 0.714 No
5ul/ml 2d vs. 0d 39.13 2.165 0.809 No
5ul/ml 3d vs. 2.5ul/ml 1d 38.294 2.118 0.835 No
2.5ul/ml 3d vs. 2.5ul/ml 2d 37.458 2.072 0.858 No
5ul/ml 1d vs. 10ul/ml 3d 37.124 2.054 0.863 No
25ul/ml 1d vs. 10ul/ml 4d 34.281 1.896 0.936 No
2.5ul/ml 3d vs. NA 2d 33.612 1.859 0.945 No
10ul/ml 4d vs. 25ul/ml 3d 33.278 1.841 0.947 No
10ul/ml 4d vs. 25ul/ml 4d 33.11 1.832 0.946 No
NA 4d vs. 2.5ul/ml 4d 32.609 1.804 0.951 No
2.5ul/ml 4d vs. NA 3d 30.936 1.711 0.972 No
10ul/ml 2d vs. 10ul/ml 3d 30.1 1.665 0.978 No
5ul/ml 1d vs. 0d 28.93 1.6 0.985 No
0d vs. 25ul/ml 1d 27.592 1.526 0.991 No
2.5ul/ml 1d vs. 10ul/ml 2d 27.09 1.499 0.992 No
NA 1d vs. 10ul/ml 2d 22.241 1.23 1 No
10ul/ml 2d vs. 0d 21.906 1.212 1 No
5ul/ml 4d vs. 10ul/ml 2d 21.237 1.175 1 No
2.5ul/ml 1d vs. 5ul/ml 1d 20.067 1.11 1 No
NA 3d vs. 2.5ul/ml 3d 19.9 1.101 1 No
10ul/ml 1d vs. 10ul/ml 2d 19.565 1.082 1 No
10ul/ml 3d vs. 25ul/ml 1d 19.398 1.073 1 No
10ul/ml 4d vs. 25ul/ml 2d 19.231 1.064 1 No
NA 2d vs. 5ul/ml 3d 18.729 1.036 1 No
5ul/ml 2d vs. 10ul/ml 2d 17.224 0.953 1 No
NA 1d vs. 5ul/ml 1d 15.217 0.842 1 No
2.5ul/ml 2d vs. 5ul/ml 3d 14.883 0.823 1 No
5ul/ml 4d vs. 5ul/ml 1d 14.214 0.786 1 No
25ul/ml 2d vs. 25ul/ml 3d 14.047 0.777 1 No
25ul/ml 2d vs. 25ul/ml 4d 13.88 0.768 1 No
10ul/ml 1d vs. 5ul/ml 1d 12.542 0.694 1 No
5ul/ml 2d vs. 5ul/ml 1d 10.201 0.564 1 No
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2.5ul/ml 1d vs. 5ul/ml 2d 9.866 0.546 1 No
0d vs. 10ul/ml 3d 8.194 0.453 1 No
2.5ul/ml 1d vs. 10ul/ml 1d 7.525 0.416 1 No
5ul/ml 1d vs. 10ul/ml 2d 7.023 0.389 1 No
2.5ul/ml 1d vs. 5ul/ml 4d 5.853 0.324 1 No
NA 1d vs. 5ul/ml 2d 5.017 0.278 1 No
2.5ul/ml 1d vs. NA 1d 4.849 0.268 1 No
5ul/ml 4d vs. 5ul/ml 2d 4.013 0.222 1 No
NA 2d vs. 2.5ul/ml 2d 3.846 0.213 1 No
NA 1d vs. 10ul/ml 1d 2.676 0.148 1 No
10ul/ml 1d vs. 5ul/ml 2d 2.341 0.13 1 No
5ul/ml 4d vs. 10ul/ml 1d 1.672 0.0925 1 No
NA 1d vs. 5ul/ml 4d 1.003 0.0555 0.998 No
25ul/ml 4d vs. 25ul/ml 3d 1.67E-01 9.25E-03 0.993 No
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Figure 2.2 Irgacure2959
Failed (P < 0.050)
Passed (P = 0.147)
Group Name N Missing Mean Std Dev SEM
0d 3 0 100 6.811 3.932
NA 1d 3 0 141.472 6.56 3.788
1mg/ml 1d 3 0 144.649 13.76 7.944
2mg/ml 1d 3 0 96.488 7.396 4.27
5mg/ml 1d 3 0 8.528 1.003 0.579
10mg/ml 1d 3 0 5.518 2.299 1.327
NA 2d 3 0 207.191 16.147 9.323
1mg/ml 2d 3 0 208.696 9.291 5.364
2mg/ml 2d 3 0 148.662 21.132 12.2
5mg/ml 2d 3 0 2.843 0.766 0.442
10mg/ml 2d 3 0 5.351 2.262 1.306
NA 3d 3 0 265.552 14.491 8.366
1mg/ml 3d 3 0 236.789 22.17 12.8
2mg/ml 3d 3 0 193.478 7.206 4.16
5mg/ml 3d 3 0 7.358 1.263 0.729
10mg/ml 3d 3 0 9.699 1.159 0.669
NA 4d 3 0 350.334 17.668 10.201
1mg/ml 4d 3 0 348.328 53.584 30.936
2mg/ml 4d 3 0 220.736 14.618 8.439
5mg/ml 4d 3 0 5.184 2.262 1.306
10mg/ml 4d 3 0 2.508 2.508 1.448
Source of Variation  DF  SS  MS   F   P 
Between Groups 20 829222.5 41461.13 164.16 <0.001
Residual 42 10607.77 252.566
Total 62 839830.3
Comparisons for factor: 
Comparison Diff of Me t P P<0.050
One Way Analysis of Variance
Data source: Data 1 in Irgacure 2959 viability
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
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NA 4d vs. 10mg/ml 4d 347.826 26.805 <0.001 Yes
NA 4d vs. 5mg/ml 2d 347.492 26.78 <0.001 Yes
1mg/ml 4d vs. 10mg/ml 4d 345.819 26.651 <0.001 Yes
1mg/ml 4d vs. 5mg/ml 2d 345.485 26.625 <0.001 Yes
NA 4d vs. 5mg/ml 4d 345.151 26.599 <0.001 Yes
NA 4d vs. 10mg/ml 2d 344.983 26.586 <0.001 Yes
NA 4d vs. 10mg/ml 1d 344.816 26.573 <0.001 Yes
1mg/ml 4d vs. 5mg/ml 4d 343.144 26.444 <0.001 Yes
NA 4d vs. 5mg/ml 3d 342.977 26.432 <0.001 Yes
1mg/ml 4d vs. 10mg/ml 2d 342.977 26.432 <0.001 Yes
1mg/ml 4d vs. 10mg/ml 1d 342.809 26.419 <0.001 Yes
NA 4d vs. 5mg/ml 1d 341.806 26.341 <0.001 Yes
1mg/ml 4d vs. 5mg/ml 3d 340.97 26.277 <0.001 Yes
NA 4d vs. 10mg/ml 3d 340.635 26.251 <0.001 Yes
1mg/ml 4d vs. 5mg/ml 1d 339.799 26.187 <0.001 Yes
1mg/ml 4d vs. 10mg/ml 3d 338.629 26.096 <0.001 Yes
NA 3d vs. 10mg/ml 4d 263.043 20.271 <0.001 Yes
NA 3d vs. 5mg/ml 2d 262.709 20.246 <0.001 Yes
NA 3d vs. 5mg/ml 4d 260.368 20.065 <0.001 Yes
NA 3d vs. 10mg/ml 2d 260.201 20.052 <0.001 Yes
NA 3d vs. 10mg/ml 1d 260.033 20.04 <0.001 Yes
NA 3d vs. 5mg/ml 3d 258.194 19.898 <0.001 Yes
NA 3d vs. 5mg/ml 1d 257.023 19.808 <0.001 Yes
NA 3d vs. 10mg/ml 3d 255.853 19.717 <0.001 Yes
NA 4d vs. 2mg/ml 1d 253.846 19.563 <0.001 Yes
1mg/ml 4d vs. 2mg/ml 1d 251.839 19.408 <0.001 Yes
NA 4d vs. 0d 250.334 19.292 <0.001 Yes
1mg/ml 4d vs. 0d 248.328 19.137 <0.001 Yes
1mg/ml 3d vs. 10mg/ml 4d 234.281 18.055 <0.001 Yes
1mg/ml 3d vs. 5mg/ml 2d 233.946 18.029 <0.001 Yes
1mg/ml 3d vs. 5mg/ml 4d 231.605 17.849 <0.001 Yes
1mg/ml 3d vs. 10mg/ml 2d 231.438 17.836 <0.001 Yes
1mg/ml 3d vs. 10mg/ml 1d 231.271 17.823 <0.001 Yes
1mg/ml 3d vs. 5mg/ml 3d 229.431 17.681 <0.001 Yes
1mg/ml 3d vs. 5mg/ml 1d 228.261 17.591 <0.001 Yes
1mg/ml 3d vs. 10mg/ml 3d 227.09 17.501 <0.001 Yes
2mg/ml 4d vs. 10mg/ml 4d 218.227 16.818 <0.001 Yes
2mg/ml 4d vs. 5mg/ml 2d 217.893 16.792 <0.001 Yes
2mg/ml 4d vs. 5mg/ml 4d 215.552 16.612 <0.001 Yes
2mg/ml 4d vs. 10mg/ml 2d 215.385 16.599 <0.001 Yes
2mg/ml 4d vs. 10mg/ml 1d 215.217 16.586 <0.001 Yes
2mg/ml 4d vs. 5mg/ml 3d 213.378 16.444 <0.001 Yes
2mg/ml 4d vs. 5mg/ml 1d 212.207 16.354 <0.001 Yes
2mg/ml 4d vs. 10mg/ml 3d 211.037 16.264 <0.001 Yes
NA 4d vs. NA 1d 208.863 16.096 <0.001 Yes
1mg/ml 4d vs. NA 1d 206.856 15.941 <0.001 Yes
1mg/ml 2d vs. 10mg/ml 4d 206.187 15.89 <0.001 Yes
1mg/ml 2d vs. 5mg/ml 2d 205.853 15.864 <0.001 Yes
NA 4d vs. 1mg/ml 1d 205.686 15.851 <0.001 Yes
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NA 2d vs. 10mg/ml 4d 204.682 15.774 <0.001 Yes
NA 2d vs. 5mg/ml 2d 204.348 15.748 <0.001 Yes
1mg/ml 4d vs. 1mg/ml 1d 203.679 15.697 <0.001 Yes
1mg/ml 2d vs. 5mg/ml 4d 203.512 15.684 <0.001 Yes
1mg/ml 2d vs. 10mg/ml 2d 203.344 15.671 <0.001 Yes
1mg/ml 2d vs. 10mg/ml 1d 203.177 15.658 <0.001 Yes
NA 2d vs. 5mg/ml 4d 202.007 15.568 <0.001 Yes
NA 2d vs. 10mg/ml 2d 201.839 15.555 <0.001 Yes
NA 4d vs. 2mg/ml 2d 201.672 15.542 <0.001 Yes
NA 2d vs. 10mg/ml 1d 201.672 15.542 <0.001 Yes
1mg/ml 2d vs. 5mg/ml 3d 201.338 15.516 <0.001 Yes
1mg/ml 2d vs. 5mg/ml 1d 200.167 15.426 <0.001 Yes
NA 2d vs. 5mg/ml 3d 199.833 15.4 <0.001 Yes
1mg/ml 4d vs. 2mg/ml 2d 199.666 15.387 <0.001 Yes
1mg/ml 2d vs. 10mg/ml 3d 198.997 15.336 <0.001 Yes
NA 2d vs. 5mg/ml 1d 198.662 15.31 <0.001 Yes
NA 2d vs. 10mg/ml 3d 197.492 15.22 <0.001 Yes
2mg/ml 3d vs. 10mg/ml 4d 190.97 14.717 <0.001 Yes
2mg/ml 3d vs. 5mg/ml 2d 190.635 14.691 <0.001 Yes
2mg/ml 3d vs. 5mg/ml 4d 188.294 14.511 <0.001 Yes
2mg/ml 3d vs. 10mg/ml 2d 188.127 14.498 <0.001 Yes
2mg/ml 3d vs. 10mg/ml 1d 187.96 14.485 <0.001 Yes
2mg/ml 3d vs. 5mg/ml 3d 186.12 14.343 <0.001 Yes
2mg/ml 3d vs. 5mg/ml 1d 184.95 14.253 <0.001 Yes
2mg/ml 3d vs. 10mg/ml 3d 183.779 14.163 <0.001 Yes
NA 3d vs. 2mg/ml 1d 169.064 13.029 <0.001 Yes
NA 3d vs. 0d 165.552 12.758 <0.001 Yes
NA 4d vs. 2mg/ml 3d 156.856 12.088 <0.001 Yes
1mg/ml 4d vs. 2mg/ml 3d 154.849 11.934 <0.001 Yes
2mg/ml 2d vs. 10mg/ml 4d 146.154 11.263 <0.001 Yes
2mg/ml 2d vs. 5mg/ml 2d 145.819 11.238 <0.001 Yes
2mg/ml 2d vs. 5mg/ml 4d 143.478 11.057 <0.001 Yes
2mg/ml 2d vs. 10mg/ml 2d 143.311 11.044 <0.001 Yes
NA 4d vs. NA 2d 143.144 11.031 <0.001 Yes
2mg/ml 2d vs. 10mg/ml 1d 143.144 11.031 <0.001 Yes
1mg/ml 1d vs. 10mg/ml 4d 142.14 10.954 <0.001 Yes
1mg/ml 1d vs. 5mg/ml 2d 141.806 10.928 <0.001 Yes
NA 4d vs. 1mg/ml 2d 141.639 10.915 <0.001 Yes
2mg/ml 2d vs. 5mg/ml 3d 141.304 10.89 <0.001 Yes
1mg/ml 4d vs. NA 2d 141.137 10.877 <0.001 Yes
1mg/ml 3d vs. 2mg/ml 1d 140.301 10.812 <0.001 Yes
2mg/ml 2d vs. 5mg/ml 1d 140.134 10.799 <0.001 Yes
1mg/ml 4d vs. 1mg/ml 2d 139.632 10.761 <0.001 Yes
1mg/ml 1d vs. 5mg/ml 4d 139.465 10.748 <0.001 Yes
1mg/ml 1d vs. 10mg/ml 2d 139.298 10.735 <0.001 Yes
1mg/ml 1d vs. 10mg/ml 1d 139.13 10.722 <0.001 Yes
NA 1d vs. 10mg/ml 4d 138.963 10.709 <0.001 Yes
2mg/ml 2d vs. 10mg/ml 3d 138.963 10.709 <0.001 Yes
NA 1d vs. 5mg/ml 2d 138.629 10.683 <0.001 Yes
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1mg/ml 1d vs. 5mg/ml 3d 137.291 10.58 <0.001 Yes
1mg/ml 3d vs. 0d 136.789 10.542 <0.001 Yes
NA 1d vs. 5mg/ml 4d 136.288 10.503 <0.001 Yes
NA 1d vs. 10mg/ml 2d 136.12 10.49 <0.001 Yes
1mg/ml 1d vs. 5mg/ml 1d 136.12 10.49 <0.001 Yes
NA 1d vs. 10mg/ml 1d 135.953 10.477 <0.001 Yes
1mg/ml 1d vs. 10mg/ml 3d 134.95 10.4 <0.001 Yes
NA 1d vs. 5mg/ml 3d 134.114 10.335 <0.001 Yes
NA 1d vs. 5mg/ml 1d 132.943 10.245 <0.001 Yes
NA 1d vs. 10mg/ml 3d 131.773 10.155 <0.001 Yes
NA 4d vs. 2mg/ml 4d 129.599 9.988 <0.001 Yes
1mg/ml 4d vs. 2mg/ml 4d 127.592 9.833 <0.001 Yes
2mg/ml 4d vs. 2mg/ml 1d 124.247 9.575 <0.001 Yes
NA 3d vs. NA 1d 124.08 9.562 <0.001 Yes
NA 3d vs. 1mg/ml 1d 120.903 9.317 <0.001 Yes
2mg/ml 4d vs. 0d 120.736 9.305 <0.001 Yes
NA 3d vs. 2mg/ml 2d 116.89 9.008 <0.001 Yes
NA 4d vs. 1mg/ml 3d 113.545 8.75 <0.001 Yes
1mg/ml 2d vs. 2mg/ml 1d 112.207 8.647 <0.001 Yes
1mg/ml 4d vs. 1mg/ml 3d 111.538 8.596 <0.001 Yes
NA 2d vs. 2mg/ml 1d 110.702 8.531 <0.001 Yes
1mg/ml 2d vs. 0d 108.696 8.377 <0.001 Yes
NA 2d vs. 0d 107.191 8.261 <0.001 Yes
0d vs. 10mg/ml 4d 97.492 7.513 <0.001 Yes
0d vs. 5mg/ml 2d 97.157 7.487 <0.001 Yes
2mg/ml 3d vs. 2mg/ml 1d 96.99 7.475 <0.001 Yes
1mg/ml 3d vs. NA 1d 95.318 7.346 <0.001 Yes
0d vs. 5mg/ml 4d 94.816 7.307 <0.001 Yes
0d vs. 10mg/ml 2d 94.649 7.294 <0.001 Yes
0d vs. 10mg/ml 1d 94.482 7.281 <0.001 Yes
2mg/ml 1d vs. 10mg/ml 4d 93.98 7.243 <0.001 Yes
2mg/ml 1d vs. 5mg/ml 2d 93.645 7.217 <0.001 Yes
2mg/ml 3d vs. 0d 93.478 7.204 <0.001 Yes
0d vs. 5mg/ml 3d 92.642 7.139 <0.001 Yes
1mg/ml 3d vs. 1mg/ml 1d 92.14 7.101 <0.001 Yes
0d vs. 5mg/ml 1d 91.472 7.049 <0.001 Yes
2mg/ml 1d vs. 5mg/ml 4d 91.304 7.036 <0.001 Yes
2mg/ml 1d vs. 10mg/ml 2d 91.137 7.024 <0.001 Yes
2mg/ml 1d vs. 10mg/ml 1d 90.97 7.011 <0.001 Yes
0d vs. 10mg/ml 3d 90.301 6.959 <0.001 Yes
2mg/ml 1d vs. 5mg/ml 3d 89.13 6.869 <0.001 Yes
1mg/ml 3d vs. 2mg/ml 2d 88.127 6.792 <0.001 Yes
2mg/ml 1d vs. 5mg/ml 1d 87.96 6.779 <0.001 Yes
2mg/ml 1d vs. 10mg/ml 3d 86.789 6.688 <0.001 Yes
NA 4d vs. NA 3d 84.783 6.534 <0.001 Yes
1mg/ml 4d vs. NA 3d 82.776 6.379 <0.001 Yes
2mg/ml 4d vs. NA 1d 79.264 6.109 <0.001 Yes
2mg/ml 4d vs. 1mg/ml 1d 76.087 5.864 <0.001 Yes
NA 3d vs. 2mg/ml 3d 72.074 5.554 <0.001 Yes
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2mg/ml 4d vs. 2mg/ml 2d 72.074 5.554 <0.001 Yes
1mg/ml 2d vs. NA 1d 67.224 5.181 <0.001 Yes
NA 2d vs. NA 1d 65.719 5.065 <0.001 Yes
1mg/ml 2d vs. 1mg/ml 1d 64.047 4.936 <0.001 Yes
NA 2d vs. 1mg/ml 1d 62.542 4.82 0.001 Yes
1mg/ml 2d vs. 2mg/ml 2d 60.033 4.626 0.002 Yes
NA 2d vs. 2mg/ml 2d 58.528 4.511 0.003 Yes
NA 3d vs. NA 2d 58.361 4.498 0.003 Yes
NA 3d vs. 1mg/ml 2d 56.856 4.382 0.004 Yes
2mg/ml 2d vs. 2mg/ml 1d 52.174 4.021 0.013 Yes
2mg/ml 3d vs. NA 1d 52.007 4.008 0.013 Yes
2mg/ml 3d vs. 1mg/ml 1d 48.829 3.763 0.026 Yes
2mg/ml 2d vs. 0d 48.662 3.75 0.027 Yes
1mg/ml 1d vs. 2mg/ml 1d 48.161 3.712 0.03 Yes
NA 1d vs. 2mg/ml 1d 44.983 3.467 0.058 No
NA 3d vs. 2mg/ml 4d 44.816 3.454 0.059 No
2mg/ml 3d vs. 2mg/ml 2d 44.816 3.454 0.058 No
1mg/ml 1d vs. 0d 44.649 3.441 0.059 No
1mg/ml 3d vs. 2mg/ml 3d 43.311 3.338 0.077 No
NA 1d vs. 0d 41.472 3.196 0.11 No
1mg/ml 3d vs. NA 2d 29.599 2.281 0.701 No
NA 3d vs. 1mg/ml 3d 28.763 2.217 0.746 No
1mg/ml 3d vs. 1mg/ml 2d 28.094 2.165 0.779 No
2mg/ml 4d vs. 2mg/ml 3d 27.258 2.101 0.818 No
1mg/ml 3d vs. 2mg/ml 4d 16.054 1.237 1 No
1mg/ml 2d vs. 2mg/ml 3d 15.217 1.173 1 No
NA 2d vs. 2mg/ml 3d 13.712 1.057 1 No
2mg/ml 4d vs. NA 2d 13.545 1.044 1 No
2mg/ml 4d vs. 1mg/ml 2d 12.04 0.928 1 No
10mg/ml 3d vs. 10mg/ml 4d 7.191 0.554 1 No
2mg/ml 2d vs. NA 1d 7.191 0.554 1 No
10mg/ml 3d vs. 5mg/ml 2d 6.856 0.528 1 No
5mg/ml 1d vs. 10mg/ml 4d 6.02 0.464 1 No
5mg/ml 1d vs. 5mg/ml 2d 5.686 0.438 1 No
5mg/ml 3d vs. 10mg/ml 4d 4.849 0.374 1 No
5mg/ml 3d vs. 5mg/ml 2d 4.515 0.348 1 No
10mg/ml 3d vs. 5mg/ml 4d 4.515 0.348 1 No
10mg/ml 3d vs. 10mg/ml 2d 4.348 0.335 1 No
10mg/ml 3d vs. 10mg/ml 1d 4.181 0.322 1 No
2mg/ml 2d vs. 1mg/ml 1d 4.013 0.309 1 No
0d vs. 2mg/ml 1d 3.512 0.271 1 No
5mg/ml 1d vs. 5mg/ml 4d 3.344 0.258 1 No
5mg/ml 1d vs. 10mg/ml 2d 3.177 0.245 1 No
1mg/ml 1d vs. NA 1d 3.177 0.245 1 No
10mg/ml 1d vs. 10mg/ml 4d 3.01 0.232 1 No
5mg/ml 1d vs. 10mg/ml 1d 3.01 0.232 1 No
10mg/ml 2d vs. 10mg/ml 4d 2.843 0.219 1 No
10mg/ml 1d vs. 5mg/ml 2d 2.676 0.206 1 No
5mg/ml 4d vs. 10mg/ml 4d 2.676 0.206 1 No
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10mg/ml 2d vs. 5mg/ml 2d 2.508 0.193 1 No
5mg/ml 4d vs. 5mg/ml 2d 2.341 0.18 1 No
10mg/ml 3d vs. 5mg/ml 3d 2.341 0.18 1 No
5mg/ml 3d vs. 5mg/ml 4d 2.174 0.168 1 No
NA 4d vs. 1mg/ml 4d 2.007 0.155 1 No
5mg/ml 3d vs. 10mg/ml 2d 2.007 0.155 1 No
5mg/ml 3d vs. 10mg/ml 1d 1.839 0.142 1 No
1mg/ml 2d vs. NA 2d 1.505 0.116 1 No
5mg/ml 1d vs. 5mg/ml 3d 1.171 0.0902 1 No
10mg/ml 3d vs. 5mg/ml 1d 1.171 0.0902 1 No
10mg/ml 1d vs. 5mg/ml 4d 0.334 0.0258 1 No
5mg/ml 2d vs. 10mg/ml 4d 0.334 0.0258 1 No
10mg/ml 1d vs. 10mg/ml 2d 0.167 0.0129 1 No
10mg/ml 2d vs. 5mg/ml 4d 1.67E-01 1.29E-02 0.99 No
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Figure 2.3 DMPA
Failed (P < 0.050)
Passed (P = 0.414)
Group Name N Missing Mean Std Dev SEM
0d 3 0 100 8.822 5.093
NA 1d 3 0 144.245 6.41 3.701
0.5mg/ml 1d 3 0 2.691 1.186 0.685
1mg/ml 1d 3 0 4.634 2.883 1.665
2mg/ml 1d 3 0 4.933 0.777 0.448
5mg/ml 1d 3 0 5.082 1.698 0.98
NA 2d 3 0 211.211 7.883 4.551
0.5mg/ml 2d 3 0 4.185 1.812 1.046
1mg/ml 2d 3 0 6.278 2.497 1.442
2mg/ml 2d 3 0 5.83 1.186 0.685
5mg/ml 2d 3 0 3.737 1.37 0.791
NA 3d 3 0 274.29 13.069 7.545
0.5mg/ml 3d 3 0 4.036 0 0
1mg/ml 3d 3 0 2.541 0.518 0.299
2mg/ml 3d 3 0 1.046 1.812 1.046
5mg/ml 3d 3 0 0.598 1.036 0.598
NA 4d 3 0 386.846 32.77 18.92
0.5mg/ml 4d 3 0 2.84 1.867 1.078
1mg/ml 4d 3 0 5.082 2.55 1.472
2mg/ml 4d 3 0 4.783 0.933 0.539
5mg/ml 4d 3 0 2.242 2.055 1.186
Source of Variation  DF  SS  MS   F   P 
Between Groups 20 703765.9 35188.29 502.197 <0.001
Residual 42 2942.884 70.069
Total 62 706708.8
Comparisons for factor: 
Comparison Diff of Me t P P<0.050
One Way Analysis of Variance
Data source: Data 1 in DMPA viability
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
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NA 4d vs. 5mg/ml 3d 386.248 56.513 <0.001 Yes
NA 4d vs. 2mg/ml 3d 385.8 56.448 <0.001 Yes
NA 4d vs. 5mg/ml 4d 384.604 56.273 <0.001 Yes
NA 4d vs. 1mg/ml 3d 384.305 56.229 <0.001 Yes
NA 4d vs. 0.5mg/ml 1d 384.155 56.207 <0.001 Yes
NA 4d vs. 0.5mg/ml 4d 384.006 56.185 <0.001 Yes
NA 4d vs. 5mg/ml 2d 383.109 56.054 <0.001 Yes
NA 4d vs. 0.5mg/ml 3d 382.81 56.01 <0.001 Yes
NA 4d vs. 0.5mg/ml 2d 382.661 55.988 <0.001 Yes
NA 4d vs. 1mg/ml 1d 382.212 55.923 <0.001 Yes
NA 4d vs. 2mg/ml 4d 382.063 55.901 <0.001 Yes
NA 4d vs. 2mg/ml 1d 381.913 55.879 <0.001 Yes
NA 4d vs. 1mg/ml 4d 381.764 55.857 <0.001 Yes
NA 4d vs. 5mg/ml 1d 381.764 55.857 <0.001 Yes
NA 4d vs. 2mg/ml 2d 381.016 55.748 <0.001 Yes
NA 4d vs. 1mg/ml 2d 380.568 55.682 <0.001 Yes
NA 4d vs. 0d 286.846 41.969 <0.001 Yes
NA 3d vs. 5mg/ml 3d 273.692 40.045 <0.001 Yes
NA 3d vs. 2mg/ml 3d 273.244 39.979 <0.001 Yes
NA 3d vs. 5mg/ml 4d 272.048 39.804 <0.001 Yes
NA 3d vs. 1mg/ml 3d 271.749 39.76 <0.001 Yes
NA 3d vs. 0.5mg/ml 1d 271.599 39.739 <0.001 Yes
NA 3d vs. 0.5mg/ml 4d 271.45 39.717 <0.001 Yes
NA 3d vs. 5mg/ml 2d 270.553 39.586 <0.001 Yes
NA 3d vs. 0.5mg/ml 3d 270.254 39.542 <0.001 Yes
NA 3d vs. 0.5mg/ml 2d 270.105 39.52 <0.001 Yes
NA 3d vs. 1mg/ml 1d 269.656 39.454 <0.001 Yes
NA 3d vs. 2mg/ml 4d 269.507 39.432 <0.001 Yes
NA 3d vs. 2mg/ml 1d 269.357 39.411 <0.001 Yes
NA 3d vs. 5mg/ml 1d 269.208 39.389 <0.001 Yes
NA 3d vs. 1mg/ml 4d 269.208 39.389 <0.001 Yes
NA 3d vs. 2mg/ml 2d 268.46 39.279 <0.001 Yes
NA 3d vs. 1mg/ml 2d 268.012 39.214 <0.001 Yes
NA 4d vs. NA 1d 242.601 35.496 <0.001 Yes
NA 2d vs. 5mg/ml 3d 210.613 30.815 <0.001 Yes
NA 2d vs. 2mg/ml 3d 210.164 30.75 <0.001 Yes
NA 2d vs. 5mg/ml 4d 208.969 30.575 <0.001 Yes
NA 2d vs. 1mg/ml 3d 208.67 30.531 <0.001 Yes
NA 2d vs. 0.5mg/ml 1d 208.52 30.509 <0.001 Yes
NA 2d vs. 0.5mg/ml 4d 208.371 30.487 <0.001 Yes
NA 2d vs. 5mg/ml 2d 207.474 30.356 <0.001 Yes
NA 2d vs. 0.5mg/ml 3d 207.175 30.312 <0.001 Yes
NA 2d vs. 0.5mg/ml 2d 207.025 30.291 <0.001 Yes
NA 2d vs. 1mg/ml 1d 206.577 30.225 <0.001 Yes
NA 2d vs. 2mg/ml 4d 206.428 30.203 <0.001 Yes
NA 2d vs. 2mg/ml 1d 206.278 30.181 <0.001 Yes
NA 2d vs. 5mg/ml 1d 206.129 30.159 <0.001 Yes
NA 2d vs. 1mg/ml 4d 206.129 30.159 <0.001 Yes
NA 2d vs. 2mg/ml 2d 205.381 30.05 <0.001 Yes
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NA 2d vs. 1mg/ml 2d 204.933 29.984 <0.001 Yes
NA 4d vs. NA 2d 175.635 25.698 <0.001 Yes
NA 3d vs. 0d 174.29 25.501 <0.001 Yes
NA 1d vs. 5mg/ml 3d 143.647 21.017 <0.001 Yes
NA 1d vs. 2mg/ml 3d 143.199 20.952 <0.001 Yes
NA 1d vs. 5mg/ml 4d 142.003 20.777 <0.001 Yes
NA 1d vs. 1mg/ml 3d 141.704 20.733 <0.001 Yes
NA 1d vs. 0.5mg/ml 1d 141.555 20.711 <0.001 Yes
NA 1d vs. 0.5mg/ml 4d 141.405 20.689 <0.001 Yes
NA 1d vs. 5mg/ml 2d 140.508 20.558 <0.001 Yes
NA 1d vs. 0.5mg/ml 3d 140.209 20.514 <0.001 Yes
NA 1d vs. 0.5mg/ml 2d 140.06 20.493 <0.001 Yes
NA 1d vs. 1mg/ml 1d 139.611 20.427 <0.001 Yes
NA 1d vs. 2mg/ml 4d 139.462 20.405 <0.001 Yes
NA 1d vs. 2mg/ml 1d 139.312 20.383 <0.001 Yes
NA 1d vs. 5mg/ml 1d 139.163 20.361 <0.001 Yes
NA 1d vs. 1mg/ml 4d 139.163 20.361 <0.001 Yes
NA 1d vs. 2mg/ml 2d 138.416 20.252 <0.001 Yes
NA 1d vs. 1mg/ml 2d 137.967 20.186 <0.001 Yes
NA 3d vs. NA 1d 130.045 19.027 <0.001 Yes
NA 4d vs. NA 3d 112.556 16.468 <0.001 Yes
NA 2d vs. 0d 111.211 16.272 <0.001 Yes
0d vs. 5mg/ml 3d 99.402 14.544 <0.001 Yes
0d vs. 2mg/ml 3d 98.954 14.478 <0.001 Yes
0d vs. 5mg/ml 4d 97.758 14.303 <0.001 Yes
0d vs. 1mg/ml 3d 97.459 14.26 <0.001 Yes
0d vs. 0.5mg/ml 1d 97.309 14.238 <0.001 Yes
0d vs. 0.5mg/ml 4d 97.16 14.216 <0.001 Yes
0d vs. 5mg/ml 2d 96.263 14.085 <0.001 Yes
0d vs. 0.5mg/ml 3d 95.964 14.041 <0.001 Yes
0d vs. 0.5mg/ml 2d 95.815 14.019 <0.001 Yes
0d vs. 1mg/ml 1d 95.366 13.953 <0.001 Yes
0d vs. 2mg/ml 4d 95.217 13.931 <0.001 Yes
0d vs. 2mg/ml 1d 95.067 13.91 <0.001 Yes
0d vs. 5mg/ml 1d 94.918 13.888 <0.001 Yes
0d vs. 1mg/ml 4d 94.918 13.888 <0.001 Yes
0d vs. 2mg/ml 2d 94.17 13.778 <0.001 Yes
0d vs. 1mg/ml 2d 93.722 13.713 <0.001 Yes
NA 2d vs. NA 1d 66.966 9.798 <0.001 Yes
NA 3d vs. NA 2d 63.079 9.229 <0.001 Yes
NA 1d vs. 0d 44.245 6.474 <0.001 Yes
1mg/ml 2d vs. 5mg/ml 3d 5.68 0.831 1 No
1mg/ml 2d vs. 2mg/ml 3d 5.232 0.765 1 No
2mg/ml 2d vs. 5mg/ml 3d 5.232 0.765 1 No
2mg/ml 2d vs. 2mg/ml 3d 4.783 0.7 1 No
1mg/ml 4d vs. 5mg/ml 3d 4.484 0.656 1 No
5mg/ml 1d vs. 5mg/ml 3d 4.484 0.656 1 No
2mg/ml 1d vs. 5mg/ml 3d 4.335 0.634 1 No
2mg/ml 4d vs. 5mg/ml 3d 4.185 0.612 1 No
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5mg/ml 1d vs. 2mg/ml 3d 4.036 0.591 1 No
1mg/ml 2d vs. 5mg/ml 4d 4.036 0.591 1 No
1mg/ml 4d vs. 2mg/ml 3d 4.036 0.591 1 No
1mg/ml 1d vs. 5mg/ml 3d 4.036 0.591 1 No
2mg/ml 1d vs. 2mg/ml 3d 3.886 0.569 1 No
2mg/ml 4d vs. 2mg/ml 3d 3.737 0.547 1 No
1mg/ml 2d vs. 1mg/ml 3d 3.737 0.547 1 No
0.5mg/ml 2d vs. 5mg/ml 3d 3.587 0.525 1 No
2mg/ml 2d vs. 5mg/ml 4d 3.587 0.525 1 No
1mg/ml 1d vs. 2mg/ml 3d 3.587 0.525 1 No
1mg/ml 2d vs. 0.5mg/ml 1d 3.587 0.525 1 No
0.5mg/ml 3d vs. 5mg/ml 3d 3.438 0.503 1 No
1mg/ml 2d vs. 0.5mg/ml 4d 3.438 0.503 1 No
2mg/ml 2d vs. 1mg/ml 3d 3.288 0.481 1 No
2mg/ml 2d vs. 0.5mg/ml 1d 3.139 0.459 1 No
0.5mg/ml 2d vs. 2mg/ml 3d 3.139 0.459 1 No
5mg/ml 2d vs. 5mg/ml 3d 3.139 0.459 1 No
2mg/ml 2d vs. 0.5mg/ml 4d 2.99 0.437 1 No
0.5mg/ml 3d vs. 2mg/ml 3d 2.99 0.437 1 No
5mg/ml 1d vs. 5mg/ml 4d 2.84 0.416 1 No
1mg/ml 4d vs. 5mg/ml 4d 2.84 0.416 1 No
2mg/ml 1d vs. 5mg/ml 4d 2.691 0.394 1 No
5mg/ml 2d vs. 2mg/ml 3d 2.691 0.394 1 No
1mg/ml 4d vs. 1mg/ml 3d 2.541 0.372 1 No
2mg/ml 4d vs. 5mg/ml 4d 2.541 0.372 1 No
1mg/ml 2d vs. 5mg/ml 2d 2.541 0.372 1 No
5mg/ml 1d vs. 1mg/ml 3d 2.541 0.372 1 No
1mg/ml 4d vs. 0.5mg/ml 1d 2.392 0.35 1 No
1mg/ml 1d vs. 5mg/ml 4d 2.392 0.35 1 No
2mg/ml 1d vs. 1mg/ml 3d 2.392 0.35 1 No
5mg/ml 1d vs. 0.5mg/ml 1d 2.392 0.35 1 No
2mg/ml 4d vs. 1mg/ml 3d 2.242 0.328 1 No
0.5mg/ml 4d vs. 5mg/ml 3d 2.242 0.328 1 No
2mg/ml 1d vs. 0.5mg/ml 1d 2.242 0.328 1 No
1mg/ml 2d vs. 0.5mg/ml 3d 2.242 0.328 1 No
1mg/ml 4d vs. 0.5mg/ml 4d 2.242 0.328 1 No
5mg/ml 1d vs. 0.5mg/ml 4d 2.242 0.328 1 No
1mg/ml 1d vs. 1mg/ml 3d 2.093 0.306 1 No
1mg/ml 2d vs. 0.5mg/ml 2d 2.093 0.306 1 No
2mg/ml 1d vs. 0.5mg/ml 4d 2.093 0.306 1 No
2mg/ml 4d vs. 0.5mg/ml 1d 2.093 0.306 1 No
2mg/ml 2d vs. 5mg/ml 2d 2.093 0.306 1 No
0.5mg/ml 1d vs. 5mg/ml 3d 2.093 0.306 1 No
0.5mg/ml 2d vs. 5mg/ml 4d 1.943 0.284 1 No
1mg/ml 1d vs. 0.5mg/ml 1d 1.943 0.284 1 No
2mg/ml 4d vs. 0.5mg/ml 4d 1.943 0.284 1 No
1mg/ml 3d vs. 5mg/ml 3d 1.943 0.284 1 No
0.5mg/ml 3d vs. 5mg/ml 4d 1.794 0.262 1 No
0.5mg/ml 4d vs. 2mg/ml 3d 1.794 0.262 1 No
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1mg/ml 1d vs. 0.5mg/ml 4d 1.794 0.262 1 No
2mg/ml 2d vs. 0.5mg/ml 3d 1.794 0.262 1 No
5mg/ml 4d vs. 5mg/ml 3d 1.644 0.241 1 No
1mg/ml 2d vs. 1mg/ml 1d 1.644 0.241 1 No
0.5mg/ml 2d vs. 1mg/ml 3d 1.644 0.241 1 No
0.5mg/ml 1d vs. 2mg/ml 3d 1.644 0.241 1 No
2mg/ml 2d vs. 0.5mg/ml 2d 1.644 0.241 1 No
0.5mg/ml 2d vs. 0.5mg/ml 1d 1.495 0.219 1 No
1mg/ml 2d vs. 2mg/ml 4d 1.495 0.219 1 No
5mg/ml 2d vs. 5mg/ml 4d 1.495 0.219 1 No
1mg/ml 3d vs. 2mg/ml 3d 1.495 0.219 1 No
0.5mg/ml 3d vs. 1mg/ml 3d 1.495 0.219 1 No
0.5mg/ml 2d vs. 0.5mg/ml 4d 1.345 0.197 1 No
1mg/ml 2d vs. 2mg/ml 1d 1.345 0.197 1 No
5mg/ml 1d vs. 5mg/ml 2d 1.345 0.197 1 No
1mg/ml 4d vs. 5mg/ml 2d 1.345 0.197 1 No
0.5mg/ml 3d vs. 0.5mg/ml 1d 1.345 0.197 1 No
5mg/ml 4d vs. 2mg/ml 3d 1.196 0.175 1 No
5mg/ml 2d vs. 1mg/ml 3d 1.196 0.175 1 No
2mg/ml 2d vs. 1mg/ml 1d 1.196 0.175 1 No
1mg/ml 2d vs. 5mg/ml 1d 1.196 0.175 1 No
0.5mg/ml 3d vs. 0.5mg/ml 4d 1.196 0.175 1 No
2mg/ml 1d vs. 5mg/ml 2d 1.196 0.175 1 No
1mg/ml 2d vs. 1mg/ml 4d 1.196 0.175 1 No
2mg/ml 2d vs. 2mg/ml 4d 1.046 0.153 1 No
2mg/ml 4d vs. 5mg/ml 2d 1.046 0.153 1 No
5mg/ml 1d vs. 0.5mg/ml 3d 1.046 0.153 1 No
5mg/ml 2d vs. 0.5mg/ml 1d 1.046 0.153 1 No
1mg/ml 4d vs. 0.5mg/ml 3d 1.046 0.153 1 No
2mg/ml 1d vs. 0.5mg/ml 3d 0.897 0.131 1 No
1mg/ml 1d vs. 5mg/ml 2d 0.897 0.131 1 No
5mg/ml 1d vs. 0.5mg/ml 2d 0.897 0.131 1 No
1mg/ml 4d vs. 0.5mg/ml 2d 0.897 0.131 1 No
5mg/ml 2d vs. 0.5mg/ml 4d 0.897 0.131 1 No
2mg/ml 2d vs. 2mg/ml 1d 0.897 0.131 1 No
2mg/ml 1d vs. 0.5mg/ml 2d 0.747 0.109 1 No
2mg/ml 2d vs. 5mg/ml 1d 0.747 0.109 1 No
2mg/ml 4d vs. 0.5mg/ml 3d 0.747 0.109 1 No
2mg/ml 2d vs. 1mg/ml 4d 0.747 0.109 1 No
0.5mg/ml 4d vs. 5mg/ml 4d 0.598 0.0875 1 No
1mg/ml 1d vs. 0.5mg/ml 3d 0.598 0.0875 1 No
2mg/ml 4d vs. 0.5mg/ml 2d 0.598 0.0875 1 No
0.5mg/ml 1d vs. 5mg/ml 4d 0.448 0.0656 1 No
1mg/ml 2d vs. 2mg/ml 2d 0.448 0.0656 1 No
2mg/ml 3d vs. 5mg/ml 3d 0.448 0.0656 1 No
1mg/ml 4d vs. 1mg/ml 1d 0.448 0.0656 1 No
1mg/ml 1d vs. 0.5mg/ml 2d 0.448 0.0656 1 No
5mg/ml 1d vs. 1mg/ml 1d 0.448 0.0656 1 No
0.5mg/ml 2d vs. 5mg/ml 2d 0.448 0.0656 1 No
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1mg/ml 4d vs. 2mg/ml 4d 0.299 0.0437 1 No
5mg/ml 1d vs. 2mg/ml 4d 0.299 0.0437 1 No
1mg/ml 3d vs. 5mg/ml 4d 0.299 0.0437 1 No
0.5mg/ml 3d vs. 5mg/ml 2d 0.299 0.0437 1 No
2mg/ml 1d vs. 1mg/ml 1d 0.299 0.0437 1 No
0.5mg/ml 4d vs. 1mg/ml 3d 0.299 0.0437 1 No
2mg/ml 1d vs. 2mg/ml 4d 0.149 0.0219 1 No
5mg/ml 1d vs. 2mg/ml 1d 0.149 0.0219 1 No
1mg/ml 4d vs. 2mg/ml 1d 0.149 0.0219 1 No
2mg/ml 4d vs. 1mg/ml 1d 0.149 0.0219 1 No
0.5mg/ml 2d vs. 0.5mg/ml 3d 0.149 0.0219 1 No
0.5mg/ml 1d vs. 1mg/ml 3d 0.149 0.0219 1 No
0.5mg/ml 4d vs. 0.5mg/ml 1d 0.149 0.0219 1 No
5mg/ml 1d vs. 1mg/ml 4d 3.55E-15 5.20E-16 1 No
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Figure 2.4 eosin Y - p-AKT
Passed (P = 0.794)
Passed (P = 0.631)
Group Name N Missing Mean Std Dev SEM
NA 3 0 1 0.0346 0.02
2.5ul/ml 3 0 0.915 0.194 0.112
5ul/ml 3 0 0.873 0.236 0.136
10ul/ml 3 0 0.836 0.1 0.058
25ul/ml 3 0 0.952 0.187 0.108
Source of Variation  DF  SS  MS   F   P 
Between Groups 4 0.0496 0.0124 0.444 0.774
Residual 10 0.279 0.0279
Total 14 0.329
Figure 2.4 eosin Y- AKT1
Passed (P = 0.472)
Passed (P = 0.708)
Group Name N Missing Mean Std Dev SEM
NA 3 0 1 0.0354 0.0204
2.5ul/ml 3 0 1.014 0.0962 0.0555
5ul/ml 3 0 1.077 0.0439 0.0254
10ul/ml 3 0 1.029 0.0569 0.0329
25ul/ml 3 0 0.936 0.0658 0.038
Source of Variation  DF  SS  MS   F   P 
Between Groups 4 0.0314 0.00785 1.963 0.176
Residual 10 0.04 0.004
One Way Analysis of Variance
Data source: Data 1 in eosin Y WB
Less than desired power indicates you are less likely to detect a difference when one actually exists. 
Negative results should be interpreted cautiously.
The power of the performed test (0.050) is below the desired power of 0.800.
Power of performed test with alpha = 0.050: 0.050
The differences in the mean values among the treatment groups are not great enough to exclude the 
possibility that the difference is due to random sampling variability; there is not a statistically 
significant difference  (P = 0.774).
Normality Test (Shapiro-Wilk)
Equal Variance Test:
Normality Test (Shapiro-Wilk)
Equal Variance Test:
103
Total 14 0.0714
The differences in the mean values among the treatment groups are not great enough to exclude the 
possibility that the difference is due to random sampling variability; there is not a statistically 
significant difference  (P = 0.176).
Power of performed test with alpha = 0.050: 0.205
The power of the performed test (0.205) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. 
Negative results should be interpreted cautiously.
104
Figure 2.5 Irgacure2959 - p-AKT
Passed (P = 0.117)
Passed (P = 0.423)
Group Name N Missing Mean Std Dev SEM
NA 3 0 1 0.0254 0.0147
0mg/ml 3 0 1.01 0.0214 0.0123
1mg/ml 3 0 0.882 0.22 0.127
2mg/ml 3 0 0.843 0.381 0.22
5mg/ml 3 0 0.481 0.261 0.151
10mg/ml 3 0 0.0884 0.0716 0.0414
Source of Variation  DF  SS  MS   F   P 
Between Groups 5 1.979 0.396 8.842 0.001
Residual 12 0.537 0.0448
Total 17 2.516
Comparisons for factor: 
Comparison Diff of Me t P P<0.050
0mg/ml vs. 10mg/ml 0.921 5.333 0.003 Yes
NA vs. 10mg/ml 0.912 5.276 0.003 Yes
1mg/ml vs. 10mg/ml 0.793 4.591 0.008 Yes
2mg/ml vs. 10mg/ml 0.754 4.367 0.011 Yes
0mg/ml vs. 5mg/ml 0.529 3.063 0.103 No
NA vs. 5mg/ml 0.519 3.007 0.104 No
1mg/ml vs. 5mg/ml 0.401 2.322 0.299 No
5mg/ml vs. 10mg/ml 0.392 2.27 0.293 No
2mg/ml vs. 5mg/ml 0.362 2.097 0.341 No
0mg/ml vs. 2mg/ml 0.167 0.966 0.927 No
NA vs. 2mg/ml 0.157 0.91 0.909 No
0mg/ml vs. 1mg/ml 0.128 0.741 0.923 No
NA vs. 1mg/ml 0.118 0.685 0.88 No
1mg/ml vs. 2mg/ml 0.0388 0.225 0.97 No
0mg/ml vs. NA 0.00971 0.0562 0.956 No
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = 0.001).
Power of performed test with alpha = 0.050: 0.985
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
One Way Analysis of Variance
Data source: Data 1 in Irgacure 2959 WB
Normality Test (Shapiro-Wilk)
Equal Variance Test:
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Figure 2.5 Iragcure2959 - AKT1
Passed (P = 0.104)
Passed (P = 0.073)
Group Name N Missing Mean Std Dev SEM
NA 3 0 1 0.0289 0.0167
0mg/ml 3 0 1.092 0.131 0.0757
1mg/ml 3 0 1.157 0.0318 0.0183
2mg/ml 3 0 1.178 0.149 0.0861
5mg/ml 3 0 1.084 0.0288 0.0166
10mg/ml 3 0 0.89 0.0418 0.0242
Source of Variation  DF  SS  MS   F   P 
Between Groups 5 0.171 0.0342 4.684 0.013
Residual 12 0.0877 0.00731
Total 17 0.259
Power of performed test with alpha = 0.050: 0.765
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Comparisons for factor: 
Comparison Diff of Me t P P<0.050
2mg/ml vs. 10mg/ml 0.288 4.121 0.021 Yes
1mg/ml vs. 10mg/ml 0.267 3.822 0.033 Yes
0mg/ml vs. 10mg/ml 0.202 2.895 0.161 No
5mg/ml vs. 10mg/ml 0.193 2.772 0.185 No
2mg/ml vs. NA 0.178 2.548 0.248 No
1mg/ml vs. NA 0.157 2.249 0.363 No
NA vs. 10mg/ml 0.11 1.573 0.747 No
2mg/ml vs. 5mg/ml 0.0942 1.35 0.836 No
0mg/ml vs. NA 0.0923 1.321 0.81 No
2mg/ml vs. 0mg/ml 0.0856 1.226 0.813 No
5mg/ml vs. NA 0.0836 1.198 0.769 No
1mg/ml vs. 5mg/ml 0.0734 1.051 0.779 No
1mg/ml vs. 0mg/ml 0.0648 0.928 0.752 No
2mg/ml vs. 1mg/ml 0.0208 0.299 0.947 No
0mg/ml vs. 5mg/ml 0.0086 0.123 0.904 No
Overall significance level = 0.05
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = 0.013).
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Figure 2.6 DMPA - p-AKT
Passed (P = 0.349)
Passed (P = 0.794)
Group Name N Missing Mean Std Dev SEM
NA 3 0 1 0.0897 0.0518
0mg/ml 3 0 0.962 0.121 0.0697
0.5mg/ml 3 0 0.959 0.275 0.159
1mg/ml 3 0 0.539 0.134 0.0772
2mg/ml 3 0 0.271 0.0474 0.0273
5mg/ml 3 0 0.213 0.0753 0.0435
Source of Variation  DF  SS  MS   F   P 
Between Groups 5 1.987 0.397 19.224 <0.001
Residual 12 0.248 0.0207
Total 17 2.235
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Comparisons for factor: 
Comparison Diff of Me t P P<0.050
NA vs. 5mg/ml 0.787 6.703 <0.001 Yes
0mg/ml vs. 5mg/ml 0.749 6.378 <0.001 Yes
0.5mg/ml vs. 5mg/ml 0.746 6.358 <0.001 Yes
NA vs. 2mg/ml 0.729 6.212 <0.001 Yes
0mg/ml vs. 2mg/ml 0.691 5.888 <0.001 Yes
0.5mg/ml vs. 2mg/ml 0.689 5.867 <0.001 Yes
NA vs. 1mg/ml 0.461 3.93 0.018 Yes
0mg/ml vs. 1mg/ml 0.423 3.605 0.029 Yes
0.5mg/ml vs. 1mg/ml 0.421 3.585 0.026 Yes
1mg/ml vs. 5mg/ml 0.326 2.773 0.097 No
1mg/ml vs. 2mg/ml 0.268 2.283 0.191 No
2mg/ml vs. 5mg/ml 0.0576 0.49 0.982 No
NA vs. 0.5mg/ml 0.0405 0.345 0.982 No
NA vs. 0mg/ml 0.0381 0.325 0.938 No
0mg/ml vs. 0.5mg/ml 0.00239 0.0203 0.984 No
Overall significance level = 0.05
One Way Analysis of Variance
Data source: Data 1 in DMPA WB
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
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Figure 2.6 DMPA - AKT1
Passed (P = 0.256)
Passed (P = 0.728)
Group Name N Missing Mean Std Dev SEM
NA 3 0 1 0.0322 0.0186
0mg/ml 3 0 1.031 0.0703 0.0406
0.5mg/ml 3 0 1.125 0.14 0.0809
1mg/ml 3 0 1.168 0.0917 0.0529
2mg/ml 3 0 1.223 0.111 0.064
5mg/ml 3 0 1.131 0.211 0.122
Source of Variation  DF  SS  MS   F   P 
Between Groups 5 0.106 0.0212 1.395 0.294
Residual 12 0.182 0.0152
Total 17 0.288
Power of performed test with alpha = 0.050: 0.115
The power of the performed test (0.115) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. 
Negative results should be interpreted cautiously.
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are not great enough to exclude the 
possibility that the difference is due to random sampling variability; there is not a statistically 
significant difference  (P = 0.294).
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Figure 2.8 eosin Y - UV
Passed (P = 0.424)
Passed (P = 0.485)
Group Name N Missing Mean Std Dev SEM
0d 3 0 99.649 12.734 7.352
NA 1d 3 0 143.86 19.702 11.375
2.5ul/ml 1d 3 0 92.982 2.191 1.265
5ul/ml 1d 3 0 69.474 14.24 8.221
10ul/ml 1d 3 0 60.702 11.643 6.722
NA 2d 3 0 187.719 16.787 9.692
2.5ul/ml 2d 3 0 67.719 5.986 3.456
5ul/ml 2d 3 0 63.86 7.468 4.312
10ul/ml 2d 3 0 49.474 5.57 3.216
Source of Variation  DF  SS  MS   F   P 
Between Groups 8 49745.6 6218.2 43.12 <0.001
Residual 18 2595.753 144.208
Total 26 52341.36
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Comparisons for factor: 
NA 2d vs. 10ul/ml 2d 138.246 14.099 <0.001 Yes
NA 2d vs. 10ul/ml 1d 127.018 12.954 <0.001 Yes
NA 2d vs. 5ul/ml 2d 123.86 12.632 <0.001 Yes
NA 2d vs. 2.5ul/ml 2d 120 12.239 <0.001 Yes
NA 2d vs. 5ul/ml 1d 118.246 12.06 <0.001 Yes
NA 2d vs. 2.5ul/ml 1d 94.737 9.662 <0.001 Yes
NA 1d vs. 10ul/ml 2d 94.386 9.626 <0.001 Yes
NA 2d vs. 0d 88.07 8.982 <0.001 Yes
NA 1d vs. 10ul/ml 1d 83.158 8.481 <0.001 Yes
NA 1d vs. 5ul/ml 2d 80 8.159 <0.001 Yes
NA 1d vs. 2.5ul/ml 2d 76.14 7.765 <0.001 Yes
NA 1d vs. 5ul/ml 1d 74.386 7.586 <0.001 Yes
Overall significance level = 0.05
Comparison
Data source: Data 1 in eosin Y UV viability
One Way Analysis of Variance
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
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NA 1d vs. 2.5ul/ml 1d 50.877 5.189 0.001 Yes
0d vs. 10ul/ml 2d 50.175 5.117 0.002 Yes
NA 1d vs. 0d 44.211 4.509 0.006 Yes
NA 2d vs. NA 1d 43.86 4.473 0.006 Yes
2.5ul/ml 1d vs. 10ul/ml 2d 43.509 4.437 0.006 Yes
0d vs. 10ul/ml 1d 38.947 3.972 0.017 Yes
0d vs. 5ul/ml 2d 35.789 3.65 0.032 Yes
2.5ul/ml 1d vs. 10ul/ml 1d 32.281 3.292 0.067 No
0d vs. 2.5ul/ml 2d 31.93 3.256 0.068 No
0d vs. 5ul/ml 1d 30.175 3.078 0.093 No
2.5ul/ml 1d vs. 5ul/ml 2d 29.123 2.97 0.109 No
2.5ul/ml 1d vs. 2.5ul/ml 2d 25.263 2.577 0.221 No
2.5ul/ml 1d vs. 5ul/ml 1d 23.509 2.398 0.285 No
5ul/ml 1d vs. 10ul/ml 2d 20 2.04 0.472 No
2.5ul/ml 2d vs. 10ul/ml 2d 18.246 1.861 0.562 No
5ul/ml 2d vs. 10ul/ml 2d 14.386 1.467 0.791 No
10ul/ml 1d vs. 10ul/ml 2d 11.228 1.145 0.917 No
5ul/ml 1d vs. 10ul/ml 1d 8.772 0.895 0.966 No
2.5ul/ml 2d vs. 10ul/ml 1d 7.018 0.716 0.981 No
0d vs. 2.5ul/ml 1d 6.667 0.68 0.97 No
5ul/ml 1d vs. 5ul/ml 2d 5.614 0.573 0.967 No
2.5ul/ml 2d vs. 5ul/ml 2d 3.86 0.394 0.973 No
5ul/ml 2d vs. 10ul/ml 1d 3.158 0.322 0.938 No
5ul/ml 1d vs. 2.5ul/ml 2d 1.754 0.179 0.86 No
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Figure 2.9 Irgacure 2959 - UV
Passed (P = 0.708)
Passed (P = 0.345)
Group Name N Missing Mean Std Dev SEM
0d 3 0 100 11.628 6.713
NA 1d 3 0 144.186 20.44 11.801
1mg/ml 1d 3 0 78.682 16.622 9.596
2mg/ml 1d 3 0 65.504 20.318 11.731
5mg/ml 1d 3 0 3.101 2.421 1.398
NA 2d 3 0 207.364 18.544 10.706
1mg/ml 2d 3 0 70.155 14.724 8.501
2mg/ml 2d 3 0 23.256 3.076 1.776
5mg/ml 2d 3 0 2.326 2.326 1.343
Source of Variation  DF  SS  MS   F   P 
Between Groups 8 108435.6 13554.45 66.899 <0.001
Residual 18 3647.016 202.612
Total 26 112082.6
Comparison Diff of Me t P P<0.050
NA 2d vs. 5mg/ml 2d 205.039 17.642 <0.001 Yes
NA 2d vs. 5mg/ml 1d 204.264 17.575 <0.001 Yes
NA 2d vs. 2mg/ml 2d 184.109 15.841 <0.001 Yes
NA 2d vs. 2mg/ml 1d 141.86 12.206 <0.001 Yes
NA 1d vs. 5mg/ml 2d 141.86 12.206 <0.001 Yes
NA 1d vs. 5mg/ml 1d 141.085 12.139 <0.001 Yes
NA 2d vs. 1mg/ml 2d 137.209 11.806 <0.001 Yes
NA 2d vs. 1mg/ml 1d 128.682 11.072 <0.001 Yes
NA 1d vs. 2mg/ml 2d 120.93 10.405 <0.001 Yes
NA 2d vs. 0d 107.364 9.238 <0.001 Yes
0d vs. 5mg/ml 2d 97.674 8.404 <0.001 Yes
0d vs. 5mg/ml 1d 96.899 8.337 <0.001 Yes
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: 
One Way Analysis of Variance
Data source: Data 1 in Irgacure 2959 UV viability
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
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NA 1d vs. 2mg/ml 1d 78.682 6.77 <0.001 Yes
0d vs. 2mg/ml 2d 76.744 6.603 <0.001 Yes
1mg/ml 1d vs. 5mg/ml 2d 76.357 6.57 <0.001 Yes
1mg/ml 1d vs. 5mg/ml 1d 75.581 6.503 <0.001 Yes
NA 1d vs. 1mg/ml 2d 74.031 6.37 <0.001 Yes
1mg/ml 2d vs. 5mg/ml 2d 67.829 5.836 <0.001 Yes
1mg/ml 2d vs. 5mg/ml 1d 67.054 5.77 <0.001 Yes
NA 1d vs. 1mg/ml 1d 65.504 5.636 <0.001 Yes
NA 2d vs. NA 1d 63.178 5.436 <0.001 Yes
2mg/ml 1d vs. 5mg/ml 2d 63.178 5.436 <0.001 Yes
2mg/ml 1d vs. 5mg/ml 1d 62.403 5.369 <0.001 Yes
1mg/ml 1d vs. 2mg/ml 2d 55.426 4.769 0.002 Yes
1mg/ml 2d vs. 2mg/ml 2d 46.899 4.035 0.009 Yes
NA 1d vs. 0d 44.186 3.802 0.014 Yes
2mg/ml 1d vs. 2mg/ml 2d 42.248 3.635 0.019 Yes
0d vs. 2mg/ml 1d 34.496 2.968 0.072 No
0d vs. 1mg/ml 2d 29.845 2.568 0.145 No
0d vs. 1mg/ml 1d 21.318 1.834 0.456 No
2mg/ml 2d vs. 5mg/ml 2d 20.93 1.801 0.426 No
2mg/ml 2d vs. 5mg/ml 1d 20.155 1.734 0.409 No
1mg/ml 1d vs. 2mg/ml 1d 13.178 1.134 0.719 No
1mg/ml 1d vs. 1mg/ml 2d 8.527 0.734 0.853 No
1mg/ml 2d vs. 2mg/ml 1d 4.651 0.4 0.906 No
5mg/ml 1d vs. 5mg/ml 2d 7.75E-01 6.67E-02 0.948 No
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Figure 2.10 DMPA - UV
Failed (P < 0.050)
Passed (P = 0.291)
Group Name N Missing Mean Std Dev SEM
0d 3 0 100 11.628 6.713
NA 1d 3 0 144.186 20.44 11.801
1mg/ml 1d 3 0 9.69 2.421 1.398
2mg/ml 1d 3 0 9.69 3.357 1.938
5mg/ml 1d 3 0 11.628 5.068 2.926
NA 2d 3 0 207.364 18.544 10.706
1mg/ml 2d 3 0 5.814 0 0
2mg/ml 2d 3 0 8.14 2.014 1.163
5mg/ml 2d 3 0 7.364 4.699 2.713
Source of Variation  DF  SS  MS   F   P 
Between Groups 8 138170.3 17271.29 160.94 <0.001
Residual 18 1931.675 107.315
Total 26 140102
Comparison Diff of Me t P P<0.050
NA 2d vs. 1mg/ml 2d 201.55 23.829 <0.001 Yes
NA 2d vs. 5mg/ml 2d 200 23.645 <0.001 Yes
NA 2d vs. 2mg/ml 2d 199.225 23.554 <0.001 Yes
NA 2d vs. 1mg/ml 1d 197.674 23.37 <0.001 Yes
NA 2d vs. 2mg/ml 1d 197.674 23.37 <0.001 Yes
NA 2d vs. 5mg/ml 1d 195.736 23.141 <0.001 Yes
NA 1d vs. 1mg/ml 2d 138.372 16.359 <0.001 Yes
NA 1d vs. 5mg/ml 2d 136.822 16.176 <0.001 Yes
NA 1d vs. 2mg/ml 2d 136.047 16.084 <0.001 Yes
NA 1d vs. 2mg/ml 1d 134.496 15.901 <0.001 Yes
NA 1d vs. 1mg/ml 1d 134.496 15.901 <0.001 Yes
NA 1d vs. 5mg/ml 1d 132.558 15.672 <0.001 Yes
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: 
One Way Analysis of Variance
Data source: Data 1 in DMPA UV viability
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
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NA 2d vs. 0d 107.364 12.693 <0.001 Yes
0d vs. 1mg/ml 2d 94.186 11.135 <0.001 Yes
0d vs. 5mg/ml 2d 92.636 10.952 <0.001 Yes
0d vs. 2mg/ml 2d 91.86 10.86 <0.001 Yes
0d vs. 2mg/ml 1d 90.31 10.677 <0.001 Yes
0d vs. 1mg/ml 1d 90.31 10.677 <0.001 Yes
0d vs. 5mg/ml 1d 88.372 10.448 <0.001 Yes
NA 2d vs. NA 1d 63.178 7.469 <0.001 Yes
NA 1d vs. 0d 44.186 5.224 <0.001 Yes
5mg/ml 1d vs. 1mg/ml 2d 5.814 0.687 1 No
5mg/ml 1d vs. 5mg/ml 2d 4.264 0.504 1 No
1mg/ml 1d vs. 1mg/ml 2d 3.876 0.458 1 No
2mg/ml 1d vs. 1mg/ml 2d 3.876 0.458 1 No
5mg/ml 1d vs. 2mg/ml 2d 3.488 0.412 1 No
1mg/ml 1d vs. 5mg/ml 2d 2.326 0.275 1 No
2mg/ml 1d vs. 5mg/ml 2d 2.326 0.275 1 No
2mg/ml 2d vs. 1mg/ml 2d 2.326 0.275 1 No
5mg/ml 1d vs. 1mg/ml 1d 1.938 0.229 1 No
5mg/ml 1d vs. 2mg/ml 1d 1.938 0.229 1 No
1mg/ml 1d vs. 2mg/ml 2d 1.55 0.183 1 No
2mg/ml 1d vs. 2mg/ml 2d 1.55 0.183 1 No
5mg/ml 2d vs. 1mg/ml 2d 1.55 0.183 0.997 No
2mg/ml 2d vs. 5mg/ml 2d 0.775 0.0916 0.995 No
1mg/ml 1d vs. 2mg/ml 1d 7.11E-15 8.40E-16 1 No
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Figure 2.11 UV- p-AKT
Passed (P = 0.213)
Passed (P = 0.902)
Group Name N Missing Mean Std Dev SEM
NA 3 0 1 0.124 0.0718
DMPA 2mg/ml 3 0 0.572 0.0776 0.0448
DMPA 5mg/ml 3 0 0.521 0.0763 0.0441
eosin Y 10ul/ml 3 0 0.622 0.0811 0.0468
eosin Y 25ul/ml 3 0 0.271 0.061 0.0352
I2959 2mg/ml 3 0 0.423 0.0602 0.0347
I2959 5mg/ml 3 0 0.197 0.0586 0.0339
Source of Variation  DF  SS  MS   F   P 
Between Groups 6 1.256 0.209 32.823 <0.001
Residual 14 0.0893 0.00638
Total 20 1.346
Comparisons for factor: 
Comparison Diff of Me t P P<0.050
NA vs. I2959 5mg/ml 0.803 12.307 <0.001 Yes
NA vs. eosin Y 25ul/ml 0.729 11.178 <0.001 Yes
NA vs. I2959 2mg/ml 0.577 8.847 <0.001 Yes
NA vs. DMPA 5mg/ml 0.479 7.352 <0.001 Yes
NA vs. DMPA 2mg/ml 0.428 6.563 <0.001 Yes
eosin Y 10ul vs. I2959 5mg/ml 0.425 6.511 <0.001 Yes
NA vs. eosin Y 10ul/ml 0.378 5.796 <0.001 Yes
DMPA 2mg/ml vs. I2959 5mg/ml 0.375 5.744 <0.001 Yes
eosin Y 10ul vs. eosin Y 25ul 0.351 5.381 0.001 Yes
DMPA 5mg/ml vs. I2959 5mg/ml 0.323 4.955 0.003 Yes
DMPA 2mg/ml vs. eosin Y 25ul 0.301 4.614 0.004 Yes
DMPA 5mg/ml vs. eosin Y 25ul 0.249 3.826 0.018 Yes
I2959 2mg/ml vs. I2959 5mg/ml 0.226 3.461 0.034 Yes
eosin Y 10ul vs. I2959 2mg/ml 0.199 3.05 0.067 No
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
One Way Analysis of Variance
Data source: Data 1 in UV photo WB
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
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I2959 2mg/ml vs. eosin Y 25ul 0.152 2.331 0.222 No
DMPA 2mg/ml vs. I2959 2mg/ml 0.149 2.283 0.21 No
eosin Y 10ul vs. DMPA 5mg/ml 0.101 1.556 0.535 No
DMPA 5mg/ml vs. I2959 2mg/ml 0.0975 1.495 0.495 No
eosin Y 25ul vs. I2959 5mg/ml 0.0737 1.13 0.623 No
DMPA 2mg/ml vs. DMPA 5mg/m 0.0514 0.789 0.69 No
eosin Y 10ul vs. DMPA 2mg/ml 0.05 0.767 0.456 No
Figure 2.11 UV- AKT1
Passed (P = 0.783)
Passed (P = 0.424)
Group Name N Missing Mean Std Dev SEM
NA 3 0 1 0.0659 0.0381
DMPA 2mg/ml 3 0 1.192 0.0955 0.0551
DMPA 5mg/ml 3 0 1.212 0.248 0.143
eosin Y 10ul/ml 3 0 1.208 0.129 0.0742
eosin Y 25ul/ml 3 0 1.307 0.133 0.0768
I2959 2mg/ml 3 0 1.168 0.167 0.0962
I2959 5mg/ml 3 0 1.349 0.206 0.119
Source of Variation  DF  SS  MS   F   P 
Between Groups 6 0.225 0.0374 1.459 0.262
Residual 14 0.359 0.0256
Total 20 0.584
Power of performed test with alpha = 0.050: 0.138
The power of the performed test (0.138) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. 
Negative results should be interpreted cautiously.
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are not great enough to exclude the 
possibility that the difference is due to random sampling variability; there is not a statistically 
significant difference  (P = 0.262).
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Figure 2.12 viability
Passed (P = 0.471)
Passed (P = 0.591)
Group Name N Missing Mean Std Dev SEM
NA 3 0 0.179 0.0119 0.00689
eosin Y 3 0 0.0983 0.00777 0.00448
0h UV eosin Y 3 0 0.0537 0.00503 0.00291
6h UV eosin Y 3 0 0.00833 0.00306 0.00176
24h UV eosin Y 3 0 0.00933 0.00321 0.00186
48h UV eosin Y 3 0 0.009 0.00265 0.00153
Source of Variation  DF  SS  MS   F   P 
Between Groups 5 0.0708 0.0142 333.427 <0.001
Residual 12 0.000509 4.24E-05
Total 17 0.0713
Comparisons for factor: 
Comparison Diff of Me t P P<0.050
NA vs. 6h UV eosin Y 0.171 32.146 <0.001 Yes
NA vs. 48h UV eosin Y 0.17 32.021 <0.001 Yes
NA vs. 24h UV eosin Y 0.17 31.958 <0.001 Yes
NA vs. 0h UV eosin Y 0.126 23.624 <0.001 Yes
eosin Y vs. 6h UV eosin Y 0.09 16.919 <0.001 Yes
eosin Y vs. 48h UV eosin Y 0.0893 16.794 <0.001 Yes
eosin Y vs. 24h UV eosin Y 0.089 16.731 <0.001 Yes
NA vs. eosin Y 0.081 15.227 <0.001 Yes
0h UV eosin  vs. 6h UV eosin 0.0453 8.522 <0.001 Yes
0h UV eosin  vs. 48h UV eosin 0.0447 8.397 <0.001 Yes
eosin Y vs. 0h UV eosin Y 0.0447 8.397 <0.001 Yes
0h UV eosin  vs. 24h UV eosin 0.0443 8.334 <0.001 Yes
24h UV eosin vs. 6h UV eosin 0.001 0.188 0.997 No
48h UV eosin vs. 6h UV eosin 0.000667 0.125 0.99 No
24h UV eosin vs. 48h UV eosin 0.000333 0.0627 0.951 No
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
One Way Analysis of Variance
Data source: Data 1 in UV time eosin Y viability
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
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Figure 2.13 UV - p-AKT
Failed (P < 0.050)
Passed (P = 0.186)
Group Name N Missing Mean Std Dev SEM
NA 3 0 1 0.0964 0.0556
eoain Y 3 0 1.043 0.115 0.0662
eosin Y UV 0h 3 0 0.0594 0.00737 0.00425
eosin Y UV 6h 3 0 0.0401 0.00549 0.00317
eosin Y UV 24h 3 0 0.015 0.00153 0.000882
eosin Y UV 48h 3 0 0.0351 0.0122 0.00704
Source of Variation  DF  SS  MS   F   P 
Between Groups 5 3.88 0.776 205.414 <0.001
Residual 12 0.0453 0.00378
Total 17 3.925
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Comparisons for factor: 
Comparison Diff of Me t P P<0.050
eoain Y vs. eosin Y UV 24h 1.028 20.485 <0.001 Yes
eoain Y vs. eosin Y UV 48h 1.008 20.085 <0.001 Yes
eoain Y vs. eosin Y UV 6h 1.003 19.986 <0.001 Yes
NA vs. eosin Y UV 24h 0.985 19.628 <0.001 Yes
eoain Y vs. eosin Y UV 0h 0.984 19.6 <0.001 Yes
NA vs. eosin Y UV 48h 0.965 19.228 <0.001 Yes
NA vs. eosin Y UV 6h 0.96 19.129 <0.001 Yes
NA vs. eosin Y UV 0h 0.941 18.744 <0.001 Yes
eosin Y UV 0 vs. eosin Y UV 2 0.0444 0.885 0.97 No
eoain Y vs. NA 0.043 0.857 0.957 No
eosin Y UV 6 vs. eosin Y UV 2 0.0251 0.5 0.993 No
eosin Y UV 0 vs. eosin Y UV 4 0.0243 0.485 0.983 No
eosin Y UV 4 vs. eosin Y UV 2 0.0201 0.4 0.972 No
eosin Y UV 0 vs. eosin Y UV 6 0.0193 0.385 0.914 No
eosin Y UV 6 vs. eosin Y UV 4 0.00501 0.0998 0.922 No
Overall significance level = 0.05
One Way Analysis of Variance
Data source: Data 1 in UV time eosin Y WB
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
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Figure 2.13 UV - AKT1
Passed (P = 0.268)
Passed (P = 0.857)
Group Name N Missing Mean Std Dev SEM
NA 3 0 1 0.0397 0.0229
eoain Y 3 0 1.116 0.0706 0.0407
eosin Y UV 0h 3 0 1.321 0.122 0.0704
eosin Y UV 6h 3 0 1.399 0.145 0.0837
eosin Y UV 24h 3 0 1.59 0.0696 0.0402
eosin Y UV 48h 3 0 1.504 0.0727 0.042
Source of Variation  DF  SS  MS   F   P 
Between Groups 5 0.772 0.154 17.62 <0.001
Residual 12 0.105 0.00876
Total 17 0.877
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Comparisons for factor: 
Comparison Diff of Me t P P<0.050
eosin Y UV 24h vs. NA 0.59 7.725 <0.001 Yes
eosin Y UV 48h vs. NA 0.504 6.595 <0.001 Yes
eosin Y UV 24h vs. eoain Y 0.475 6.211 <0.001 Yes
eosin Y UV 6h vs. NA 0.399 5.216 0.003 Yes
eosin Y UV 48h vs. eoain Y 0.388 5.082 0.003 Yes
eosin Y UV 0h vs. NA 0.321 4.195 0.012 Yes
eosin Y UV 6h vs. eoain Y 0.283 3.702 0.027 Yes
eosin Y UV 2 vs. eosin Y UV 0 0.27 3.53 0.033 Yes
eosin Y UV 0h vs. eoain Y 0.205 2.681 0.132 No
eosin Y UV 2 vs. eosin Y UV 6 0.192 2.509 0.154 No
eosin Y UV 4 vs. eosin Y UV 0 0.183 2.4 0.157 No
eoain Y vs. NA 0.116 1.514 0.493 No
eosin Y UV 4 vs. eosin Y UV 6 0.105 1.379 0.474 No
eosin Y UV 2 vs. eosin Y UV 4 0.0863 1.129 0.483 No
eosin Y UV 6 vs. eosin Y UV 0 0.078 1.021 0.327 No
Overall significance level = 0.05
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
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Figure 3.2
Failed (P < 0.050)
Failed (P < 0.050)
Group Name N Missing Mean Std Dev SEM
NA 4 0 100 3.136 1.568
PEG17.4 4 0 95.716 4.984 2.492
PEG87 4 0 83.197 3.546 1.773
PEG174 4 0 70.769 2.238 1.119
PEG696 4 0 35.156 9.383 4.691
PEG1739 4 0 8.231 0.467 0.233
PEG-DA17.4 4 0 70.358 1.605 0.803
PEG-DA87 4 0 18.78 0.589 0.295
PEG-DA174 4 0 7.979 0.61 0.305
PEG-DA696 4 0 8.214 0.759 0.38
PEG-DA1739 4 0 7.946 0.355 0.178
Source of Variation  DF  SS  MS   F   P 
Between Groups 10 58338.12 5833.812 444.062 <0.001
Residual 33 433.533 13.137
Total 43 58771.65
Comparison Diff of Me t P P<0.050
NA vs. PEG-DA1739 92.054 35.917 <0.001 Yes
NA vs. PEG-DA174 92.021 35.905 <0.001 Yes
NA vs. PEG-DA696 91.786 35.813 <0.001 Yes
NA vs. PEG1739 91.769 35.806 <0.001 Yes
PEG17.4 vs. PEG-DA1739 87.769 34.245 <0.001 Yes
PEG17.4 vs. PEG-DA174 87.737 34.233 <0.001 Yes
PEG17.4 vs. PEG-DA696 87.501 34.141 <0.001 Yes
PEG17.4 vs. PEG1739 87.485 34.135 <0.001 Yes
NA vs. PEG-DA87 81.22 31.69 <0.001 Yes
PEG17.4 vs. PEG-DA87 76.935 30.018 <0.001 Yes
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: 
Data source: Data 1 in Notebook1
One Way Analysis of Variance
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
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PEG87 vs. PEG-DA1739 75.25 29.361 <0.001 Yes
PEG87 vs. PEG-DA174 75.218 29.348 <0.001 Yes
PEG87 vs. PEG-DA696 74.982 29.256 <0.001 Yes
PEG87 vs. PEG1739 74.966 29.25 <0.001 Yes
NA vs. PEG696 64.844 25.3 <0.001 Yes
PEG87 vs. PEG-DA87 64.417 25.134 <0.001 Yes
PEG174 vs. PEG-DA1739 62.822 24.512 <0.001 Yes
PEG174 vs. PEG-DA174 62.79 24.499 <0.001 Yes
PEG174 vs. PEG-DA696 62.554 24.407 <0.001 Yes
PEG174 vs. PEG1739 62.538 24.401 <0.001 Yes
PEG-DA17.4 vs. PEG-DA1739 62.412 24.352 <0.001 Yes
PEG-DA17.4 vs. PEG-DA174 62.38 24.339 <0.001 Yes
PEG-DA17.4 vs. PEG-DA696 62.144 24.247 <0.001 Yes
PEG-DA17.4 vs. PEG1739 62.128 24.241 <0.001 Yes
PEG17.4 vs. PEG696 60.559 23.629 <0.001 Yes
PEG174 vs. PEG-DA87 51.989 20.285 <0.001 Yes
PEG-DA17.4 vs. PEG-DA87 51.578 20.125 <0.001 Yes
PEG87 vs. PEG696 48.04 18.744 <0.001 Yes
PEG174 vs. PEG696 35.612 13.895 <0.001 Yes
PEG-DA17.4 vs. PEG696 35.202 13.735 <0.001 Yes
NA vs. PEG-DA17.4 29.642 11.565 <0.001 Yes
NA vs. PEG174 29.231 11.405 <0.001 Yes
PEG696 vs. PEG-DA1739 27.21 10.617 <0.001 Yes
PEG696 vs. PEG-DA174 27.178 10.604 <0.001 Yes
PEG696 vs. PEG-DA696 26.942 10.512 <0.001 Yes
PEG696 vs. PEG1739 26.926 10.506 <0.001 Yes
PEG17.4 vs. PEG-DA17.4 25.357 9.894 <0.001 Yes
PEG17.4 vs. PEG174 24.947 9.734 <0.001 Yes
NA vs. PEG87 16.803 6.556 <0.001 Yes
PEG696 vs. PEG-DA87 16.376 6.39 <0.001 Yes
PEG87 vs. PEG-DA17.4 12.838 5.009 <0.001 Yes
PEG17.4 vs. PEG87 12.519 4.885 <0.001 Yes
PEG87 vs. PEG174 12.428 4.849 <0.001 Yes
PEG-DA87 vs. PEG-DA1739 10.834 4.227 0.002 Yes
PEG-DA87 vs. PEG-DA174 10.801 4.214 0.002 Yes
PEG-DA87 vs. PEG-DA696 10.566 4.123 0.002 Yes
PEG-DA87 vs. PEG1739 10.55 4.116 0.002 Yes
NA vs. PEG17.4 4.284 1.672 0.585 No
PEG174 vs. PEG-DA17.4 0.41 0.16 1 No
PEG1739 vs. PEG-DA1739 0.284 0.111 1 No
PEG-DA696 vs. PEG-DA1739 0.268 0.105 1 No
PEG1739 vs. PEG-DA174 0.252 0.0983 1 No
PEG-DA696 vs. PEG-DA174 0.236 0.0919 1 No
PEG-DA174 vs. PEG-DA1739 0.0323 0.0126 1 No
PEG1739 vs. PEG-DA696 0.0163 0.00635 0.995 No
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Figure  3.3
Failed (P < 0.050)
Failed (P < 0.050)
Group Name N Missing Mean Std Dev SEM
NA 4 0 99.725 6.073 3.037
GF/0PEGDA+5eY 4 0 112.4 1.146 0.573
GF/1PEGDA+5eY 4 0 106.95 3.648 1.824
GF/2PEGDA+5eY 4 0 17.336 1.563 0.781
GF/5PEGDA+5eY 4 0 2.95 0.265 0.132
GF/10PEGDA+5eY 4 0 3.325 0.222 0.111
GF/20PEGDA+5eY 4 0 3.95 0.3 0.15
Source of Variation  DF  SS  MS   F   P 
Between Groups 6 68751.17 11458.53 1481.032 <0.001
Residual 21 162.474 7.737
Total 27 68913.65
Comparison Diff of Me t P P<0.050
GF/0PEGDA+5e vs. GF/5PEGDA+5 109.45 55.648 <0.001 Yes
GF/0PEGDA+5e vs. GF/10PEGDA+ 109.075 55.457 <0.001 Yes
GF/0PEGDA+5e vs. GF/20PEGDA+ 108.45 55.139 <0.001 Yes
GF/1PEGDA+5e vs. GF/5PEGDA+5 104 52.877 <0.001 Yes
GF/1PEGDA+5e vs. GF/10PEGDA+ 103.625 52.686 <0.001 Yes
GF/1PEGDA+5e vs. GF/20PEGDA+ 103 52.368 <0.001 Yes
NA vs. GF/5PEGDA+5eY 96.775 49.204 <0.001 Yes
NA vs. GF/10PEGDA+5eY 96.4 49.013 <0.001 Yes
NA vs. GF/20PEGDA+5eY 95.775 48.695 <0.001 Yes
GF/0PEGDA+5e vs. GF/2PEGDA+5 95.064 48.333 <0.001 Yes
GF/1PEGDA+5e vs. GF/2PEGDA+5 89.614 45.562 <0.001 Yes
NA vs. GF/2PEGDA+5eY 82.389 41.889 <0.001 Yes
GF/2PEGDA+5e vs. GF/5PEGDA+5 14.386 7.315 <0.001 Yes
GF/2PEGDA+5e vs. GF/10PEGDA+ 14.011 7.124 <0.001 Yes
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: 
One Way Analysis of Variance
Data source: Data 1 in Notebook1
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected by 
chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
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GF/2PEGDA+5e vs. GF/20PEGDA+ 13.386 6.806 <0.001 Yes
GF/0PEGDA+5eY vs. NA 12.675 6.444 <0.001 Yes
GF/1PEGDA+5eY vs. NA 7.225 3.673 0.007 Yes
GF/0PEGDA+5e vs. GF/1PEGDA+5 5.45 2.771 0.045 Yes
GF/20PEGDA+5 vs. GF/5PEGDA+5 1 0.508 0.944 No
GF/20PEGDA+5 vs. GF/10PEGDA+ 0.625 0.318 0.939 No
GF/10PEGDA+5 vs. GF/5PEGDA+5 0.375 0.191 0.851 No
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Figure 3.4
Failed (P < 0.050)
Failed (P < 0.050)
Group Name N Missing Mean Std Dev SEM
0min 5 0 100 0 0
GF-15min 5 0 0.15 0.077 0.0345
GF/0eY-15min 5 0 0.124 0.063 0.0282
GF/2eY-15min 5 0 49.38 5.372 2.402
GF/5eY-15min 5 0 75.497 2.322 1.038
GF/10eY-15min 5 0 77.562 0.421 0.188
GF/2eY-30min 5 0 29.828 12.544 5.61
GF/5eY-30min 5 0 65.323 6.071 2.715
GF/10eY-30min 5 0 77.97 1.246 0.557
GF/2eY-60min 5 0 1.688 2.433 1.088
GF/5eY-60min 5 0 45.016 9.581 4.285
GF/10eY-60min 5 0 75.544 3.682 1.647
GF/2eY-120min 5 0 0 0 0
GF/5eY-120min 5 0 23.846 11.855 5.302
GF/10eY-120min 5 0 70.657 2.783 1.245
Source of Variation  DF  SS  MS   F   P 
Between Groups 14 83545.78 5967.556 182.775 <0.001
Residual 60 1958.988 32.65
Total 74 85504.77
Comparison Diff of Me t P P<0.050
0min vs. GF/2eY-120min 100 27.671 <0.001 Yes
0min vs. GF/0eY-15min 99.876 27.637 <0.001 Yes
0min vs. GF-15min 99.85 27.63 <0.001 Yes
0min vs. GF/2eY-60min 98.312 27.204 <0.001 Yes
GF/10eY-30mi vs. GF/2eY-120mi 77.97 21.575 <0.001 Yes
GF/10eY-30min vs. GF/0eY-15min 77.846 21.541 <0.001 Yes
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: 
One Way Analysis of Variance
Data source: Data 1 in Notebook1
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected by 
chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
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GF/10eY-30min vs. GF-15min 77.82 21.534 <0.001 Yes
GF/10eY-15mi vs. GF/2eY-120mi 77.562 21.462 <0.001 Yes
GF/10eY-15min vs. GF/0eY-15min 77.438 21.428 <0.001 Yes
GF/10eY-15min vs. GF-15min 77.412 21.421 <0.001 Yes
GF/10eY-30min vs. GF/2eY-60min 76.282 21.108 <0.001 Yes
0min vs. GF/5eY-120min 76.154 21.073 <0.001 Yes
GF/10eY-15min vs. GF/2eY-60min 75.874 20.995 <0.001 Yes
GF/10eY-60mi vs. GF/2eY-120mi 75.544 20.904 <0.001 Yes
GF/5eY-15min vs. GF/2eY-120min 75.497 20.891 <0.001 Yes
GF/10eY-60min vs. GF/0eY-15min 75.42 20.87 <0.001 Yes
GF/10eY-60min vs. GF-15min 75.394 20.863 <0.001 Yes
GF/5eY-15min vs. GF/0eY-15min 75.373 20.857 <0.001 Yes
GF/5eY-15min vs. GF-15min 75.347 20.85 <0.001 Yes
GF/10eY-60min vs. GF/2eY-60min 73.856 20.437 <0.001 Yes
GF/5eY-15min vs. GF/2eY-60min 73.809 20.424 <0.001 Yes
GF/10eY-120m vs. GF/2eY-120mi 70.657 19.552 <0.001 Yes
GF/10eY-120m vs. GF/0eY-15min 70.533 19.517 <0.001 Yes
GF/10eY-120min vs. GF-15min 70.507 19.51 <0.001 Yes
0min vs. GF/2eY-30min 70.172 19.417 <0.001 Yes
GF/10eY-120m vs. GF/2eY-60min 68.969 19.085 <0.001 Yes
GF/5eY-30min vs. GF/2eY-120min 65.323 18.076 <0.001 Yes
GF/5eY-30min vs. GF/0eY-15min 65.199 18.042 <0.001 Yes
GF/5eY-30min vs. GF-15min 65.174 18.034 <0.001 Yes
GF/5eY-30min vs. GF/2eY-60min 63.636 17.609 <0.001 Yes
0min vs. GF/5eY-60min 54.984 15.215 <0.001 Yes
GF/10eY-30mi vs. GF/5eY-120mi 54.123 14.977 <0.001 Yes
GF/10eY-15mi vs. GF/5eY-120mi 53.716 14.864 <0.001 Yes
GF/10eY-60mi vs. GF/5eY-120mi 51.698 14.305 <0.001 Yes
GF/5eY-15min vs. GF/5eY-120min 51.65 14.292 <0.001 Yes
0min vs. GF/2eY-15min 50.62 14.007 <0.001 Yes
GF/2eY-15min vs. GF/2eY-120min 49.38 13.664 <0.001 Yes
GF/2eY-15min vs. GF/0eY-15min 49.256 13.63 <0.001 Yes
GF/2eY-15min vs. GF-15min 49.231 13.623 <0.001 Yes
GF/10eY-30min vs. GF/2eY-30min 48.141 13.321 <0.001 Yes
GF/10eY-15min vs. GF/2eY-30min 47.733 13.208 <0.001 Yes
GF/2eY-15min vs. GF/2eY-60min 47.693 13.197 <0.001 Yes
GF/10eY-120m vs. GF/5eY-120mi 46.81 12.953 <0.001 Yes
GF/10eY-60min vs. GF/2eY-30min 45.716 12.65 <0.001 Yes
GF/5eY-15min vs. GF/2eY-30min 45.668 12.637 <0.001 Yes
GF/5eY-60min vs. GF/2eY-120min 45.016 12.456 <0.001 Yes
GF/5eY-60min vs. GF/0eY-15min 44.892 12.422 <0.001 Yes
GF/5eY-60min vs. GF-15min 44.866 12.415 <0.001 Yes
GF/5eY-60min vs. GF/2eY-60min 43.328 11.989 <0.001 Yes
GF/5eY-30min vs. GF/5eY-120min 41.477 11.477 <0.001 Yes
GF/10eY-120m vs. GF/2eY-30min 40.828 11.298 <0.001 Yes
GF/5eY-30min vs. GF/2eY-30min 35.495 9.822 <0.001 Yes
0min vs. GF/5eY-30min 34.677 9.595 <0.001 Yes
GF/10eY-30min vs. GF/5eY-60min 32.954 9.119 <0.001 Yes
GF/10eY-15min vs. GF/5eY-60min 32.546 9.006 <0.001 Yes
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GF/10eY-60min vs. GF/5eY-60min 30.528 8.448 <0.001 Yes
GF/5eY-15min vs. GF/5eY-60min 30.481 8.435 <0.001 Yes
GF/2eY-30min vs. GF/2eY-120min 29.828 8.254 <0.001 Yes
GF/2eY-30min vs. GF/0eY-15min 29.704 8.22 <0.001 Yes
GF/2eY-30min vs. GF-15min 29.679 8.213 <0.001 Yes
0min vs. GF/10eY-120min 29.343 8.12 <0.001 Yes
GF/10eY-30min vs. GF/2eY-15min 28.589 7.911 <0.001 Yes
GF/10eY-15min vs. GF/2eY-15min 28.182 7.798 <0.001 Yes
GF/2eY-30min vs. GF/2eY-60min 28.141 7.787 <0.001 Yes
GF/10eY-60min vs. GF/2eY-15min 26.164 7.24 <0.001 Yes
GF/5eY-15min vs. GF/2eY-15min 26.116 7.227 <0.001 Yes
GF/10eY-120m vs. GF/5eY-60min 25.641 7.095 <0.001 Yes
GF/2eY-15min vs. GF/5eY-120min 25.534 7.066 <0.001 Yes
0min vs. GF/5eY-15min 24.503 6.78 <0.001 Yes
0min vs. GF/10eY-60min 24.456 6.767 <0.001 Yes
GF/5eY-120mi vs. GF/2eY-120mi 23.846 6.599 <0.001 Yes
GF/5eY-120min vs. GF/0eY-15min 23.722 6.564 <0.001 Yes
GF/5eY-120min vs. GF-15min 23.697 6.557 <0.001 Yes
0min vs. GF/10eY-15min 22.438 6.209 <0.001 Yes
GF/5eY-120min vs. GF/2eY-60min 22.159 6.132 <0.001 Yes
0min vs. GF/10eY-30min 22.03 6.096 <0.001 Yes
GF/10eY-120m vs. GF/2eY-15min 21.276 5.887 <0.001 Yes
GF/5eY-60min vs. GF/5eY-120min 21.169 5.858 <0.001 Yes
GF/5eY-30min vs. GF/5eY-60min 20.308 5.619 <0.001 Yes
GF/2eY-15min vs. GF/2eY-30min 19.552 5.41 <0.001 Yes
GF/5eY-30min vs. GF/2eY-15min 15.943 4.412 0.001 Yes
GF/5eY-60min vs. GF/2eY-30min 15.187 4.202 0.002 Yes
GF/10eY-30min vs. GF/5eY-30min 12.646 3.499 0.02 Yes
GF/10eY-15min vs. GF/5eY-30min 12.239 3.387 0.027 Yes
GF/10eY-60min vs. GF/5eY-30min 10.221 2.828 0.125 No
GF/5eY-15min vs. GF/5eY-30min 10.173 2.815 0.124 No
GF/10eY-30mi vs. GF/10eY-120m 7.313 2.024 0.603 No
GF/10eY-15mi vs. GF/10eY-120m 6.905 1.911 0.677 No
GF/2eY-30min vs. GF/5eY-120min 5.982 1.655 0.843 No
GF/10eY-120m vs. GF/5eY-30min 5.333 1.476 0.919 No
GF/10eY-60mi vs. GF/10eY-120m 4.887 1.352 0.95 No
GF/5eY-15min vs. GF/10eY-120m 4.84 1.339 0.943 No
GF/2eY-15min vs. GF/5eY-60min 4.365 1.208 0.968 No
GF/10eY-30min vs. GF/5eY-15min 2.473 0.684 1 No
GF/10eY-30mi vs. GF/10eY-60mi 2.425 0.671 1 No
GF/10eY-15min vs. GF/5eY-15min 2.065 0.571 1 No
GF/10eY-15mi vs. GF/10eY-60mi 2.018 0.558 1 No
GF/2eY-60min vs. GF/2eY-120min 1.688 0.467 1 No
GF/2eY-60min vs. GF/0eY-15min 1.564 0.433 1 No
GF/2eY-60min vs. GF-15min 1.538 0.426 0.999 No
GF/10eY-30mi vs. GF/10eY-15mi 0.408 0.113 1 No
GF-15min vs. GF/2eY-120min 0.15 0.0414 1 No
GF/0eY-15min vs. GF/2eY-120min 0.124 0.0343 1 No
GF/10eY-60min vs. GF/5eY-15min 0.0474 0.0131 1 No
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GF-15min vs. GF/0eY-15min 0.0257 0.0071 0.994 No
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Figure 3.5
Thickness (inch)
Passed (P = 0.138)
Failed (P < 0.050)
Group Name N Missing Mean Std Dev SEM
GF 18 0 0.0177 0.00372 0.000877
sIPN GF 12 0 0.0145 0.00166 0.000479
Source of Variation  DF  SS  MS   F   P 
Between Groups 1 7.03E-05 7.03E-05 7.409 0.011
Residual 28 0.000266 9.49E-06
Total 29 0.000336
Comparison Diff of Me t P P<0.050
GF vs. sIPN GF 0.00312 2.722 0.011 Yes
Peak Load (N)
Normality Test (Shapiro-Wilk) Passed (P = 0.954)
Equal Variance Test: Passed (P = 0.936)
Group Name N Missing Mean Std Dev SEM
GF 18 0 2.414 1.23 0.29
sIPN GF 12 0 15.74 1.428 0.412
Source of Variation  DF  SS  MS   F   P 
Between Groups 1 1278.752 1278.752 743.72 <0.001
Residual 28 48.143 1.719
Total 29 1326.896
One Way Analysis of Variance
Data source: Data 1 in Notebook1
Normality Test (Shapiro-Wilk)
Equal Variance Test:
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = 0.011).
Power of performed test with alpha = 0.050: 0.691
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: 
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Comparison Diff of Me t P P<0.050
sIPN GF vs. GF 13.327 27.271 <0.001 Yes
Peak Stress (Mpa)
Normality Test (Shapiro-Wilk) Passed (P = 0.094)
Equal Variance Test: Passed (P = 0.729)
Group Name N Missing Mean Std Dev SEM
GF 18 0 2.037 1.095 0.258
sIPN GF 12 0 16.067 1.474 0.425
Source of Variation  DF  SS  MS   F   P 
Between Groups 1 1417.271 1417.271 896.475 <0.001
Residual 28 44.266 1.581
Total 29 1461.538
Comparison Diff of Me t P P<0.050
sIPN GF vs. GF 14.03 29.941 <0.001 Yes
Modulus (Mpa)
Normality Test (Shapiro-Wilk) Passed (P = 0.073)
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
Overall significance level = 0.05
Comparisons for factor: 
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: 
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Equal Variance Test: Passed (P = 0.443)
Group Name N Missing Mean Std Dev SEM
GF 18 0 135.485 53.042 12.502
sIPN GF 12 0 676.871 74.447 21.491
Source of Variation  DF  SS  MS   F   P 
Between Groups 1 2110312 2110312 543.128 <0.001
Residual 28 108793.4 3885.477
Total 29 2219105
Comparison Diff of Me t P P<0.050
sIPN GF vs. GF 541.386 23.305 <0.001 Yes
Strain At Break (mm/mm)
Normality Test (Shapiro-Wilk) Passed (P = 0.833)
Equal Variance Test: Passed (P = 0.491)
Group Name N Missing Mean Std Dev SEM
GF 18 0 0.0208 0.00772 0.00182
sIPN GF 12 0 0.0497 0.00925 0.00267
Source of Variation  DF  SS  MS   F   P 
Between Groups 1 0.00602 0.00602 86.326 <0.001
Residual 28 0.00195 6.97E-05
Total 29 0.00797
Comparisons for factor: 
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
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Comparison Diff of Me t P P<0.050
sIPN GF vs. GF 0.0289 9.291 <0.001 Yes
Energy To Break (N*mm)
Normality Test (Shapiro-Wilk) Failed (P < 0.050)
Equal Variance Test: Failed (P < 0.050)
Group Name N Missing Mean Std Dev SEM
GF 18 0 0.227 0.17 0.04
sIPN GF 12 0 3.884 1.179 0.34
Source of Variation  DF  SS  MS   F   P 
Between Groups 1 96.258 96.258 170.807 <0.001
Residual 28 15.779 0.564
Total 29 112.037
Comparison Diff of Me t P P<0.050
sIPN GF vs. GF 3.656 13.069 <0.001 Yes
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: 
Comparisons for factor: 
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
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Figure 3.7
One Way Analysis of Variance
Data source: Data 1 in Notebook1
Normality Test (Shapiro-Wilk) Failed (P < 0.050)
Equal Variance Test: Passed (P = 0.473)
Group Name N Missing Mean Std Dev SEM
GF 60 0 3.154 1.244 0.161
sIPN GF 60 0 4.868 1.522 0.197
Source of Variation  DF  SS  MS   F   P 
Between Groups 1 88.121 88.121 45.594 <0.001
Residual 118 228.061 1.933
Total 119 316.182
Comparison Diff of Me t P P<0.050
sIPN GF vs. GF 1.714 6.752 <0.001 Yes
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: 
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Figure 3.9
One Way Analysis of Variance
Data source: Data 1 in Notebook1
Normality Test (Shapiro-Wilk) Passed (P = 0.592)
Equal Variance Test: Passed (P = 0.417)
Group Name N Missing Mean Std Dev SEM
sIPN GIF 15min 3 0 44.792 1.96 1.132
sIPN GIF 30min 3 0 48.371 1.974 1.14
sIPN GIF 60min 3 0 53.276 1.889 1.09
sIPN GIF 90min 3 0 56.532 2.657 1.534
sIPN GIF 120min 3 0 58.556 4.108 2.372
sIPN GIF 240min 3 0 64.451 3.007 1.736
GIF 15min 3 0 56.304 0.827 0.478
GIF 30min 3 0 65.122 0.652 0.376
Source of Variation  DF  SS  MS   F   P 
Between Groups 7 1058.221 151.174 26.642 <0.001
Residual 16 90.79 5.674
Total 23 1149.011
Comparison Diff of Me t P P<0.050
GIF 30min vs. sIPN GIF 15min 20.33 10.453 <0.001 Yes
sIPN GIF 240 vs. sIPN GIF 15m 19.659 10.108 <0.001 Yes
GIF 30min vs. sIPN GIF 30min 16.751 8.612 <0.001 Yes
sIPN GIF 240 vs. sIPN GIF 30m 16.08 8.268 <0.001 Yes
sIPN GIF 120 vs. sIPN GIF 15m 13.764 7.077 <0.001 Yes
GIF 30min vs. sIPN GIF 60min 11.846 6.09 <0.001 Yes
sIPN GIF 90m vs. sIPN GIF 15m 11.74 6.036 <0.001 Yes
GIF 15min vs. sIPN GIF 15min 11.512 5.919 <0.001 Yes
sIPN GIF 240 vs. sIPN GIF 60m 11.175 5.746 <0.001 Yes
sIPN GIF 120 vs. sIPN GIF 30m 10.185 5.237 0.002 Yes
GIF 30min vs. GIF 15min 8.818 4.534 0.006 Yes
GIF 30min vs. sIPN GIF 90min 8.59 4.416 0.007 Yes
sIPN GIF 60m vs. sIPN GIF 15m 8.484 4.362 0.008 Yes
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: 
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sIPN GIF 90m vs. sIPN GIF 30m 8.161 4.196 0.01 Yes
sIPN GIF 240min vs. GIF 15min 8.147 4.189 0.01 Yes
GIF 15min vs. sIPN GIF 30min 7.933 4.079 0.011 Yes
sIPN GIF 240 vs. sIPN GIF 90m 7.919 4.071 0.011 Yes
GIF 30min vs. sIPN GIF 120min 6.566 3.376 0.042 Yes
sIPN GIF 240 vs. sIPN GIF 120 5.895 3.031 0.077 No
sIPN GIF 120 vs. sIPN GIF 60m 5.28 2.715 0.13 No
sIPN GIF 60m vs. sIPN GIF 30m 4.905 2.522 0.167 No
sIPN GIF 30m vs. sIPN GIF 15m 3.579 1.84 0.46 No
sIPN GIF 90m vs. sIPN GIF 60m 3.256 1.674 0.515 No
GIF 15min vs. sIPN GIF 60min 3.028 1.557 0.527 No
sIPN GIF 120min vs. GIF 15min 2.252 1.158 0.707 No
sIPN GIF 120 vs. sIPN GIF 90m 2.024 1.04 0.677 No
GIF 30min vs. sIPN GIF 240min 0.671 0.345 0.93 No
sIPN GIF 90min vs. GIF 15min 0.228 0.117 0.908 No
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Figure 3.11
One Way Analysis of Variance
Data source: Data 1 in Notebook1
p-AKT
Normality Test (Shapiro-Wilk) Passed (P = 0.143)
Equal Variance Test: Failed (P < 0.050)
Group Name N Missing Mean Std Dev SEM
NA 4 0 1 0 0
Insulin 4 0 6.207 0.128 0.0641
GF 4 0 1.855 0.687 0.343
sIPN GF 4 0 1.512 0.647 0.323
GIF 4 0 6.326 0.443 0.222
Source of Variation  DF  SS  MS   F   P 
Between Groups 4 112.608 28.152 127.609 <0.001
Residual 15 3.309 0.221
Total 19 115.917
Comparison Diff of Me t P P<0.050
GIF vs. NA 5.326 16.037 <0.001 Yes
Insulin vs. NA 5.207 15.678 <0.001 Yes
GIF vs. sIPN GF 4.815 14.496 <0.001 Yes
Insulin vs. sIPN GF 4.695 14.137 <0.001 Yes
GIF vs. GF 4.471 13.462 <0.001 Yes
Insulin vs. GF 4.352 13.102 <0.001 Yes
GF vs. NA 0.855 2.576 0.082 No
sIPN GF vs. NA 0.512 1.541 0.373 No
GF vs. sIPN GF 0.344 1.035 0.534 No
GIF vs. Insulin 0.119 0.359 0.724 No
AKT1
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: 
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Normality Test (Shapiro-Wilk) Passed (P = 0.489)
Equal Variance Test: Passed (P = 0.155)
Group Name N Missing Mean Std Dev SEM
NA 4 0 1 0 0
Insulin 4 0 0.889 0.126 0.063
GF 4 0 0.967 0.143 0.0716
sIPN GF 4 0 1.04 0.112 0.0561
GIF 4 0 0.924 0.175 0.0874
Source of Variation  DF  SS  MS   F   P 
Between Groups 4 0.0576 0.0144 0.905 0.486
Residual 15 0.239 0.0159
Total 19 0.296
Power of performed test with alpha = 0.050: 0.050
The power of the performed test (0.050) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. 
Negative results should be interpreted cautiously.
The differences in the mean values among the treatment groups are not great enough to exclude the 
possibility that the difference is due to random sampling variability; there is not a statistically 
significant difference  (P = 0.486).
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Figure 3.12
One Way Analysis of Variance
Data source: Data 1 in Notebook1
p-AKT
Normality Test (Shapiro-Wilk) Failed (P < 0.050)
Equal Variance Test: Passed (P = 1.000)
Group Name N Missing Mean Std Dev SEM
NA 3 0 1 0 0
GIF 30min 3 0 6.052 0.275 0.159
sIPN GIF 15min 3 0 3.218 0.659 0.38
sIPN GIF 30min 3 0 3.712 0.967 0.559
sIPN GIF 60min 3 0 4.386 0.757 0.437
sIPN GIF 120min 3 0 5.838 0.668 0.386
Source of Variation  DF  SS  MS   F   P 
Between Groups 5 52.264 10.453 25.442 <0.001
Residual 12 4.93 0.411
Total 17 57.194
Comparison Diff of Me t P P<0.050
GIF 30min vs. NA 5.052 9.653 <0.001 Yes
sIPN GIF 120min vs. NA 4.838 9.243 <0.001 Yes
sIPN GIF 60min vs. NA 3.386 6.469 <0.001 Yes
GIF 30min vs. sIPN GIF 15min 2.833 5.414 0.002 Yes
sIPN GIF 30min vs. NA 2.712 5.183 0.003 Yes
sIPN GIF 120 vs. sIPN GIF 15m 2.619 5.004 0.003 Yes
GIF 30min vs. sIPN GIF 30min 2.339 4.47 0.007 Yes
sIPN GIF 15min vs. NA 2.218 4.239 0.009 Yes
sIPN GIF 120 vs. sIPN GIF 30m 2.125 4.061 0.011 Yes
GIF 30min vs. sIPN GIF 60min 1.666 3.184 0.046 Yes
sIPN GIF 120 vs. sIPN GIF 60m 1.452 2.775 0.081 No
sIPN GIF 60m vs. sIPN GIF 15m 1.167 2.23 0.17 No
sIPN GIF 60m vs. sIPN GIF 30m 0.673 1.286 0.53 No
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: 
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sIPN GIF 30m vs. sIPN GIF 15m 0.494 0.944 0.595 No
GIF 30min vs. sIPN GIF 120min 0.214 0.409 0.69 No
AKT1
Normality Test (Shapiro-Wilk) Passed (P = 0.168)
Equal Variance Test: Passed (P = 0.064)
Group Name N Missing Mean Std Dev SEM
NA 3 0 1 0 0
GIF 30min 3 0 0.928 0.0657 0.038
sIPN GIF 15min 3 0 1.104 0.109 0.0629
sIPN GIF 30min 3 0 1.156 0.0959 0.0554
sIPN GIF 60min 3 0 1.075 0.144 0.0834
sIPN GIF 120min 3 0 1.033 0.268 0.155
Source of Variation  DF  SS  MS   F   P 
Between Groups 5 0.0976 0.0195 0.99 0.463
Residual 12 0.236 0.0197
Total 17 0.334
Power of performed test with alpha = 0.050: 0.050
The power of the performed test (0.050) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one actually exists. 
Negative results should be interpreted cautiously.
The differences in the mean values among the treatment groups are not great enough to exclude the 
possibility that the difference is due to random sampling variability; there is not a statistically 
significant difference  (P = 0.463).
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Figure 3.14
One Way Analysis of Variance
Data source: Data 1 in Notebook1
Normality Test (Shapiro-Wilk) Passed (P = 0.070)
Equal Variance Test: Failed (P < 0.050)
Group Name N Missing Mean Std Dev SEM
0 min 8 0 100 0 0
15 min 8 0 74.875 2.961 1.047
30 min 8 0 54.625 15.716 5.556
60 min 8 0 39.938 12.339 4.362
120 min 8 0 35.438 17.514 6.192
240 min 8 0 8.813 6.948 2.457
Source of Variation  DF  SS  MS   F   P 
Between Groups 5 40949.3 8189.859 64.401 <0.001
Residual 42 5341.156 127.17
Total 47 46290.45
Comparison Diff of Me t P P<0.050
0 min vs. 240 min 91.188 16.172 <0.001 Yes
15 min vs. 240 min 66.063 11.716 <0.001 Yes
0 min vs. 120 min 64.563 11.45 <0.001 Yes
0 min vs. 60 min 60.063 10.652 <0.001 Yes
30 min vs. 240 min 45.813 8.125 <0.001 Yes
0 min vs. 30 min 45.375 8.047 <0.001 Yes
15 min vs. 120 min 39.438 6.994 <0.001 Yes
15 min vs. 60 min 34.938 6.196 <0.001 Yes
60 min vs. 240 min 31.125 5.52 <0.001 Yes
120 min vs. 240 min 26.625 4.722 <0.001 Yes
0 min vs. 15 min 25.125 4.456 <0.001 Yes
15 min vs. 30 min 20.25 3.591 0.003 Yes
30 min vs. 120 min 19.188 3.403 0.004 Yes
30 min vs. 60 min 14.688 2.605 0.025 Yes
60 min vs. 120 min 4.5 0.798 0.429 No
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: 
139
Figure 3.16
One Way Analysis of Variance
Data source: Data 1 in Notebook1
Normality Test (Shapiro-Wilk) Passed (P = 0.326)
Equal Variance Test: Passed (P = 0.393)
Group Name N Missing Mean Std Dev SEM
sIPN GIF 15min 3 0 0.666 0.0144 0.00829
sIPN GIF 30min 3 0 0.712 0.0066 0.00381
sIPN GIF 60min 3 0 0.868 0.037 0.0213
sIPN GIF 120min 3 0 1.612 0.0551 0.0318
sIPN GIF 240min 3 0 1.798 0.0419 0.0242
Insulin 15min 3 0 0.666 0.0611 0.0353
Insulin 30min 3 0 0.75 0.00287 0.00166
Insulin 60min 3 0 0.879 0.0349 0.0202
Insulin 120min 3 0 1.507 0.0811 0.0468
Insulin 240min 3 0 1.563 0.0743 0.0429
Source of Variation  DF  SS  MS   F   P 
Between Groups 9 5.646 0.627 267.426 <0.001
Residual 20 0.0469 0.00235
Total 29 5.692
Comparison Diff of Me t P P<0.050
sIPN GIF 240 vs. sIPN GIF 15m 1.132 28.624 <0.001 Yes
sIPN GIF 240 vs. Insulin 15mi 1.132 28.624 <0.001 Yes
sIPN GIF 240 vs. sIPN GIF 30m 1.086 27.471 <0.001 Yes
sIPN GIF 240 vs. Insulin 30mi 1.049 26.52 <0.001 Yes
sIPN GIF 120 vs. sIPN GIF 15m 0.945 23.907 <0.001 Yes
sIPN GIF 120 vs. Insulin 15mi 0.945 23.907 <0.001 Yes
sIPN GIF 240 vs. sIPN GIF 60m 0.93 23.514 <0.001 Yes
sIPN GIF 240 vs. Insulin 60mi 0.919 23.245 <0.001 Yes
sIPN GIF 120 vs. sIPN GIF 30m 0.9 22.754 <0.001 Yes
Insulin 240m vs. sIPN GIF 15m 0.897 22.684 <0.001 Yes
Insulin 240m vs. Insulin 15mi 0.897 22.684 <0.001 Yes
The differences in the mean values among the treatment groups are greater than would be expected 
by chance; there is a statistically significant difference  (P = <0.001).
Power of performed test with alpha = 0.050: 1.000
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0.05
Comparisons for factor: 
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sIPN GIF 120 vs. Insulin 30mi 0.862 21.804 <0.001 Yes
Insulin 240m vs. sIPN GIF 30m 0.851 21.531 <0.001 Yes
Insulin 120m vs. sIPN GIF 15m 0.841 21.262 <0.001 Yes
Insulin 120m vs. Insulin 15mi 0.841 21.262 <0.001 Yes
Insulin 240m vs. Insulin 30mi 0.814 20.581 <0.001 Yes
Insulin 120m vs. sIPN GIF 30m 0.795 20.109 <0.001 Yes
Insulin 120m vs. Insulin 30mi 0.758 19.159 <0.001 Yes
sIPN GIF 120 vs. sIPN GIF 60m 0.743 18.797 <0.001 Yes
sIPN GIF 120 vs. Insulin 60mi 0.733 18.528 <0.001 Yes
Insulin 240m vs. sIPN GIF 60m 0.695 17.575 <0.001 Yes
Insulin 240m vs. Insulin 60mi 0.684 17.305 <0.001 Yes
Insulin 120m vs. sIPN GIF 60m 0.639 16.152 <0.001 Yes
Insulin 120m vs. Insulin 60mi 0.628 15.883 <0.001 Yes
sIPN GIF 240 vs. Insulin 120m 0.291 7.362 <0.001 Yes
sIPN GIF 240 vs. Insulin 240m 0.235 5.94 <0.001 Yes
Insulin 60mi vs. sIPN GIF 15m 0.213 5.379 <0.001 Yes
Insulin 60mi vs. Insulin 15mi 0.213 5.379 <0.001 Yes
sIPN GIF 60m vs. sIPN GIF 15m 0.202 5.11 <0.001 Yes
sIPN GIF 60m vs. Insulin 15mi 0.202 5.11 <0.001 Yes
sIPN GIF 240 vs. sIPN GIF 120 0.187 4.717 0.002 Yes
Insulin 60mi vs. sIPN GIF 30m 0.167 4.226 0.006 Yes
sIPN GIF 60m vs. sIPN GIF 30m 0.156 3.957 0.01 Yes
Insulin 60mi vs. Insulin 30mi 0.13 3.275 0.044 Yes
sIPN GIF 60m vs. Insulin 30mi 0.119 3.006 0.074 No
sIPN GIF 120 vs. Insulin 120m 0.105 2.645 0.145 No
Insulin 30mi vs. sIPN GIF 15m 0.0832 2.103 0.359 No
Insulin 30mi vs. Insulin 15mi 0.0832 2.103 0.327 No
Insulin 240m vs. Insulin 120m 0.0562 1.422 0.729 No
sIPN GIF 120 vs. Insulin 240m 0.0484 1.223 0.801 No
sIPN GIF 30m vs. sIPN GIF 15m 0.0456 1.153 0.782 No
sIPN GIF 30m vs. Insulin 15mi 0.0456 1.153 0.704 No
Insulin 30mi vs. sIPN GIF 30m 0.0376 0.95 0.73 No
Insulin 60mi vs. sIPN GIF 60m 0.0106 0.269 0.956 No
Insulin 15mi vs. sIPN GIF 15m 3.33E-16 8.42E-15 1 No
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